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CTGTCATTAAAGCAACGGTGTTTGTAAGTTCATCTGTCATTTTTCATTTATTCACTTTT 
ATTTTGAGGAGCAGACATGTTAATAATAATTTGGAGCAACTGTAAAGTTATCTATGTGT 
ACAGGTTCGAGCCTCAGGTGCAACCACTAATGCTTGTATTAGATTATGTTGTCTGCAT 
CATACCCCTAATTGGAGTGTGGCTCTTCCCGAACCCTGCAATGCTGGATGCTGGATGC 
TTTATGTATCAGACTGACCTTTTTGTTAAACTATCTAAATACTAAGGATGATTTAATAA 
AAATATAGAATGGTAAACAGAAAAAGATGAGATTATTTTTGGGGCTATATGGATTCGC 
CCGGGCTTTGGGAGGTAAAACGGTATCTACCAGTTGAGACTTTACTCCAGAACTTTAT 
CTCGAGAGCTCTGAATAAAAATGAAATAGTATTTACCACTCCAAAATCTTTGATGGTAA 
AAAGATGAGATATAACCTCTTATAATTGATTGAACCACGTTGATAGAATAAAACTTCTT 
TACTCCCATTCAGCATAAGAAAAATGAAACCAAACGGAATTCTTCTCTTTTTTAGGGGG 
AAATTCCTTAATTGCTTGTTGAATATAGATTCATGTCGTTATTCTATTTTTAATAATGAT 
GAAAATCAATATAGTCAAAGTTAATACTTATGTCATTTGGTTTGCGGACAAGTTATATT 
GGAACTATATAATACGTCTATTATAGAATAGTGATTATTTAGAGGATATACATTTTTTT 
TGGATAAATATTTGATTTATTGGATTAAAAATAGAATATACAGGTAAGGTCTAAAACGT 
GTGTTTGCTTTTACACTAAATAAACTTGACCTCGTACAATTCTAAGAAAATATTTGAAA 
TAAATGAATTATTTTATTGTTAATCAATTAAAAAAATCATAGTATAGATGAGATGTGTG 
CATACTTGGCAATAACTATACTAACTAAAACAAGGTATGTGAATAATTGATATTCCTTT 
TTTAATTATTCTTTTTTCCAGAGTTTGGTCTTGGATGCAGCAGACACAGTTGCTCTTCA 
CATAAATTGGGGAATGGCATTATTGATAAACAATCAAAAGGCCTTGACGAAAGCAC 
AAG 
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ALTERATION OF TOBACCO ALKALOID 
CONTENT THROUGH MODIFICATION OF 
SPECIFIC CYTOCHROME P450 GENES 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a continuation application of U.S. 
patent application Ser. No. 12/971,801 filed Dec. 17, 2010 
(allowed), which is a continuation of U.S. application Ser. 
No. 11/580,765, filed Oct. 13, 2006 (now U.S. Pat. No. 
7,884,263), which is a continuation-in-part of International 
Application No. PCT/US2005/005665, filed Feb. 23, 2005, 
the contents of which are herein incorporated by reference in 
their entirety. 
FIELD OF THE INVENTION 
The invention relates to compositions and methods for 
reducing the level of nornicotine and its metabolite, N'-ni-
trosonornicotine, in a plant that is a member of the genus 
Nicotiana, particularly compositions and methods for inhib-
iting expression or function of a cytochrome P450 polypep-
tide involved in the metabolic conversion of nicotine to 
nornicotine. 
BACKGROUND OF THE INVENTION 
The predominant alkaloid found in commercial tobacco 
varieties is nicotine, typically accounting for 90-95% of the 
total alkaloid pool. The remaining alkaloid fraction is com-
prised primarily of three additional pyridine alkaloids: nor-
nicotine, anabasine, and anatabine. Nornicotine is generated 
directly from nicotine through the activity of the enzyme 
nicotine N-demethylase (FIG. 1). Nornicotine usually rep-
resents less than 5% of the total pyridine alkaloid pool, but 
through a process termed "conversion," tobacco plants that 
initially produce very low amounts of nornicotine give rise 
to progeny that metabolically "convert" a large percentage 
of leaf nicotine to nornicotine. In tobacco plants that have 
genetically converted (termed "converters"), the great 
majority of nornicotine production occurs during the senes-
cence and curing of the mature leaf (Wernsman and Matz-
inger (1968) Tab. Sci. 12:226-228). Burley tobaccos are 
particularly prone to genetic conversion, with rates as high 
as 20% per generation observed in some cultivars. 
During the curing and processing of the tobacco leaf, a 
portion of the nornicotine is metabolized to the compound 
N'-nitrosonornicotine (NNN; FIG. 1), a tobacco-specific 
nitrosamine (TSNA) that has been shown to be carcinogenic 
in laboratory animals (Hecht and Hoffmann (1990) Cancer 
Surveys 8:273-294; Hoffmarm et al. (1994) J. Toxicol. Envi-
ron. Health 41:1-52; Hecht (1998) Chem. Res. Toxicol. 
11:559-603). In flue-cured tobaccos, TSNAs were found to 
be predominantly formed through the reaction of alkaloids 
with the minute amounts of nitrogen oxides present in 
combustion gases formed by the direct-fired heating systems 
found in traditional curing barns (Peele and Gentry (1999) 
"Formation of Tobacco-specific Nitrosamines in Flue-cured 
Tobacco," CORESTA Meeting, Agro-Phyto Groups, 
Suzhou, China). Retrofitting these curing barns with heat-
exchangers virtually eliminated the mixing of combustion 
gases with the curing air and dramatically reduced the 
formation of TSNAs in tobaccos cured in this manner 
(Boyette and Hannn (2001) Rec. Adv. Tab. Sci. 27:17-22.). 
In contrast, in the air-cured Burley tobaccos, TSNA forma-
tion proceeds primarily through reaction of tobacco alka-
2 
loids with nitrite, a process catalyzed by leaf-borne microbes 
(Bush et al. (2001) Rec. Adv. Tab. Sci. 27:23-46). Thus far, 
attempts to reduce TNSAs through modification of curing 
conditions while maintaining acceptable quality standards 
5 have not proven to be successful for the air-cured tobaccos. 
In Burley tobaccos, a positive correlation has been found 
between the nornicotine content of the leaf and the amount 
of NNN that accumulates in the cured product (Bush et al. 
(2001) Rec. Adv. Tab. Sci. 27:23-46; Shi et al. (2000) Tab. 
1° Chem. Res. Conj 54:Abstract 27). However, keeping nor-
nicotine levels at a minimum has been difficult because of 
the conversion phenomenon that results in a continual 
introduction of high nornicotine-producing plants within 
15 commercially grown Burley populations. Minimizing the 
number of Burley plants that accumulate high levels of 
nornicotine has traditionally been the responsibility of plant 
breeders and seed producers. Though the percentage of 
converter plants that are ultimately grown in farmers' fields 
20 can be reduced through the roguing of converter plants 
during the propagation of seed stocks, this process is costly, 
time-consuming, and imperfect. 
Previous studies have shown that once a plant has con-
verted, the high nornicotine trait is inherited as a single 
25 dominant gene (Griffith et al. (1955) Science 121:343-344; 
Burk and Jeffrey (1958) Tab. Sci. 2:139-141; Mann et al. 
(1964) Crop Sci. 4:349-353). The nature of this gene, 
however, is currently unknown. In the most simple of 
scenarios, the conversion locus may represent a nonfunc-
30 tional nicotine N-demethylase gene that regains its function 
in converter plants, possibly through the mobilization of a 
mutation-inducing transposable element. Alternatively, the 
converter locus may encode a protein that initiates a cascade 
of events that ultimately enables the plant to metabolize 
35 nicotine to nornicotine, which would mean that multiple 
genes may be involved. 
Regardless of whether there are one or many genes 
associated with the conversion process, it is clear that the 
gene(s) encoding polypeptides having nicotine demethylase 
40 activity play a pivotal role in this process. Although the 
inability to purify active nicotine N-demethylase from crude 
extracts has impeded the isolation and identification of this 
enzyme, there is some evidence that a member of the 
cytochrome P450 superfamily of monooxygenases may be 
45 involved (Hao and Yeoman (1996) Phytochem. 41:477-482; 
Hao and Yeoman (1996) Phytochem. 42:325-329; Chelva-
rajan et al. (1993) J. Agric. Food Chem. 41:858-862; Hao 
and Yeoman (1998) J. Plant Physiol. 152:420-426). How-
ever, these studies are not conclusive, as the classic P450 
50 inhibitors carbon monoxide and tetcylasis have failed to 
lower enzyme activity at rates comparable to other reported 
P450-mediated reactions (Chelvarajan et al. (1993) J. Agric. 
Food Chem. 41:858-862). 
Furthermore, the cytochrome P450s are ubiquitous, trans-
55 membrane proteins that participate in the metabolism of a 
wide range of compounds (reviewed by Schuler (1996) Crit. 
Rev. Plant Sci. 15:235-284; Schuler and Werck-Reichhart 
(2003) Annu. Rev. Plant Biol. 54:629-667). Examples of 
biochemical reactions mediated by cytochrome P450s 
60 include hydroxylations, demethylations, and epoxidations. 
In plants, the cytochrome P450 gene families are very large. 
For example, total genome sequence examination has 
revealed 272 predicted cytochrome P450 genes in Arabi-
dopsis and at least 455 unique cytochrome P450 genes in 
65 rice (see, for example, Nelson et al. (2004) Plant Physiol. 
135(2):756-772). Even though cytochrome P450 has been 
implicated as having a role in the metabolic conversion of 
US 9,913,451 B2 
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nicotine to nornicotine, identification of key participating 
members of this protein family remains a challenge. 
Aside from serving as a precursor for NNN, recent studies 
suggest that the nornicotine found in tobacco products may 
have additional undesirable health consequences. Dickerson 
and Janda demonstrated that nornicotine causes aberrant 
protein glycation within the cell (Dickerson and Janda 
(2002) Proc. Natl. Acad. Sci. USA 99:15084-15088). Con-
centrations of nornicotine-modified proteins were found to 
4 
expression or function of a cytochrome P450 polypeptide of 
the invention. In one such embodiment, the inhibitory 
sequence comprises a sequence set forth in SEQ ID NO: 1, 
3, 5, 7, 9, 11, 13, 14, 15, or 16, or a complement or fragment 
thereof. 
The methods of the invention find use in the production of 
Nicotiana plants that have decreased levels of nornicotine 
and its metabolite, the nitrosamine N'-nitrosonornicotine, 
within the leaf and stem tissues. When harvested, the leaf 
and stem tissues of these plants can be utilized to produce 
tobacco products having reduced levels of nornicotine and 
this tobacco-specific nitrosamine, and thus reduced carcino-
genic potential for individuals consuming these products or 
be much higher in the plasma of smokers compared to 10 
nonsmokers. Furthermore, this same study showed that 
nornicotine can covalently modify commonly prescribed 
steroid drugs such as prednisone. Such modifications have 
the potential of altering both the efficacy and toxicity of 
these drugs. 15 exposed to secondar y  smoke derived from these products. 
Also provided are transgenic Nicotiana plants having a 
nicotine to nornicotine conversion rate of less than about 
2%, where the plants comprise a heterologous nucleic acid 
construct comprising a promoter capable of functioning in a 
In view of the difficulties associated with conversion and 
the undesirable health effects of nornicotine accumulation, 
improved methods for reducing the nornicotine content in 
tobacco varieties, particularly Burley tobacco, are therefore 
desirable. Such methods would not only help ameliorate the 
potential negative health consequences of the nornicotine 
per se as described above, but should also concomitantly 
reduce NNN levels. 
20 plant cell operably linked to a nucleic acid sequence having 
a first nucleotide sequence comprising a fragment of 
between about 100 nucleotides and about 400 nucleotides of 
a Nicotiana nicotine demethylase polynucleotide and a 
second nucleotide sequence capable of forming a double-
SUMMARY OF THE INVENTION 25 stranded RNA with the first nucleotide sequence, where the 
transgenic Nicotiana plants are transgenic converter lines of 
Nicotiana. In some embodiments, the Nicotiana nicotine 
demethylase polynucleotide is a tobacco nicotine demeth-
Compositions and methods for reducing the nornicotine 
content in plants that are members of the genus Nicotiana 
are provided. Compositions include isolated cytochrome 
P450 polynucleotides and polypeptides that are involved in 30 
the metabolic conversion of nicotine to nornicotine in plants, 
particularly Nicotiana species. The isolated polynucleotides 
comprise the nucleotide sequence set forth in SEQ ID NO: 1, 
3, 5, 7, 9, or 11, a nucleotide sequence encoding a polypep-
tide as set forth in SEQ ID N0:2, 4, 6, 8, 10, or 12, and 35 
fragments and variants thereof. Isolated polypeptides of the 
invention comprise an amino acid sequence set forth in SEQ 
ID N0:2, 4, 6, 8, 10, or 12, an amino acid sequence encoded 
ylase polynucleotide. 
The present invention also provides a recombinant nucleic 
acid construct comprising a promoter capable of functioning 
in a plant cell operably linked to a nucleic acid sequence 
having a first nucleotide sequence comprising a fragment of 
between about 100 nucleotides and about 400 nucleotides of 
a tobacco nicotine demethylase polynucleotide and a second 
nucleotide sequence capable of forming a double-stranded 
RNA with the first nucleotide sequence. 
Also provided are methods of reducing the conversion of 
nicotine to nornicotine in a Nicotiana plant comprising by the nucleotide sequence set forth in SEQ ID N0:1, 3, 5, 
7, 9, or 11, and fragments and variants thereof. 40 transforming a Nicotiana plant with a recombinant nucleic 
acid construct comprising a promoter capable of functioning 
in a plant cell operably linked to a nucleic acid sequence 
having a first nucleotide sequence comprising a fragment of 
between about 100 nucleotides and about 400 nucleotides of 
The polynucleotides of the invention find use in suppress-
ing expression of a cytochrome P450 that is involved in the 
metabolic conversion of nicotine to nornicotine in a plant, 
including the cytochrome P450s of the present invention. In 
this marmer, compositions further include expression cas- 45 
settes comprising an inhibitory sequence that is capable of 
inhibiting expression or function of a cytochrome P450 
polypeptide of the invention, where the inhibitory sequence 
is operably linked to a promoter that is functional in a plant 
cell. In some embodiments, the inhibitory sequence com- 50 
prises the sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 
13, 14, 15, or 16, or a complement or fragment thereof. 
Compositions also include transformed plants and plant 
parts that comprise an expression cassette of the present 
invention, optionally stably incorporated into the genome of 55 
the plant. Further provided are tobacco products, including 
chewing tobacco, snuff, cigarettes, pipe tobacco, and cigars, 
having a reduced level of nornicotine, and its related nitro-
samine, N'-nitrosonornicotine. 
The methods of the invention comprise inhibiting the 60 
expression or function of a cytochrome P450 polypeptide of 
the present invention. In some embodiments, an expression 
cassette comprising an inhibitory sequence that targets 
expression or function of a cytochrome P450 polypeptide of 
the present invention is introduced into the plant or plant part 65 
of interest, wherein expression of the inhibitory sequence 
produces a polynucleotide or polypeptide that inhibits 
a Nicotiana nicotine demethylase polynucleotide and a 
second nucleotide sequence capable of forming a double-
stranded RNA with the first nucleotide sequence; and regen-
erating a transgenic Nicotiana plant. In some embodiments, 
the Nicotiana nicotine demethylase polynucleotide is a 
tobacco nicotine demethylase polynucleotide. 
The present invention also provides seed obtained from 
the transgenic Nicotiana plant having a nicotine to norni-
cotine conversion rate of less than about 2%, where the seed 
comprises a heterologous nucleic acid construct comprising 
a promoter capable of functioning in a plant cell operably 
linked to a nucleic acid sequence having a first nucleotide 
sequence comprising a fragment of between about 100 
nucleotides and about 400 nucleotides of a Nicotiana nico-
tine demethylase polynucleotide and a second nucleotide 
sequence capable of forming a double-stranded RNA with 
the first nucleotide sequence, where the transgenic Nicotiana 
plants are transgenic converter lines of Nicotiana. In some 
embodiments, the Nicotiana nicotine demethylase poly-
nucleotide is a tobacco nicotine demethylase polynucleotide. 
The present invention also provides transgenic plant cells 
compnsmg a nucleic acid molecule having a promoter 
functional in a plant cell and a nucleic acid sequence 
US 9,913,451 B2 
5 
encoding a nicotine demethylase having an isoleucine resi-
due at position 274 and a tryptophan residue at position 330. 
The present invention also provides methods of screening 
for a nicotine demethylase sequence comprising: obtaining 
a nucleic acid sequence that has greater than about 90% 5 
sequence identity with SEQ ID N0:5 and identifying a 
codon sequence encoding for a tryptophan residue at posi-
tion 330 of the encoded polypeptide. 
Further provided are methods for screening for a nicotine 
demethylase having an isoleucine at position 274 or a 10 
tryptophan at position 330 comprising obtaining a nucleic 
acid sequence that has greater than about 90% sequence 
identity with SEQ ID N0:5 and identifying a first codon 
sequence encoding for an isoleucine residue at position 274 
or a second codon sequence encoding a tryptophan residue 15 
at position 330 of the encoded polypeptide. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the structures of nicotine, nornicotine, and 20 
N'-nitrosonornicotine (NNN). 
6 
7D_A06 constructs and a vector-only control (control 8). 
Estimated size of hybridizing band is indicated in kilobases 
(kb). (B) Ethidium bromide staining of the portion of the gel 
used in (A) that contains the 28S ribosomal RNA to show the 
relative equivalence of RNA loading among the lanes. 
FIG. 7 shows a genomic sequence of a fragment of the 
3D_Cl2-10 gene possessing an intron. Intron sequences are 
indicated in bold, italicized type. Exon sequences are shown 
in plain type. The sequences corresponding to the PCR 
primers used to amplify the fragment from the tobacco 
genomic DNA are underlined. 
FIG. 8 shows a diagram of the RNAi constructs used to 
silence expression of of members of the 3D_CD12 gene 
family. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Background and Definitions 
Before describing the present invention in detail, it is to 
be understood that many modifications and other embodi-
ments of the inventions set forth herein will come to mind 
to one skilled in the art to which this invention pertains 
having the benefit of the teachings presented in the forego-
FIG. 2 shows Northern blot analysis of converter and 
nonconverter RNAs using 7D_A06 as a hybridization probe. 
Lanes 1 and 2 show RNAs isolated from sodium bicarbon-
ate-treated leaves of genotypes DH 98-325-5 (nonconverter) 
and DH 98-325-6 (converter), respectively. Lanes 3 and 4 
show RNAs isolated from ethephon-treated leaves of geno-
types DH 98-326-3 (nonconverter) and DH 98-326-1 (con-
verter), respectively. Estimated size of the hybridizing band 
is indicated in kilobases (kb). 
25 ing descriptions and the associated drawings. Therefore, it is 
to be understood that the invention is not to be limited to the 
specific embodiments disclosed and that modifications and 
other embodiments are intended to be included within the 
scope of the appended claims. Rather, these embodiments 
30 are provided so that this disclosure will satisfy applicable 
legal requirements. FIG. 3A-3G shows a nucleotide sequence alignment of 
members of the 3D_C12 gene family. Asterisks denote 
positions where sequence identity is conserved among all 
sequences compared. Positions where differences are found 
are indicated with dashes and the corresponding residues are 35 
shaded grey. The nucleotide sequences present in the align-
ment include 3D_C12 (SEQ ID N0:1), 3D_Cl2-10 (SEQ 
ID N0:3); 3D_Cl2-7 (SEQ ID N0:5); 7D_A06 (SEQ ID 
N0:7); 3D_Cl2-15 (SEQ ID N0:9); and 131A_A02 (SEQ 
ID N0:11). The 3D_Cl2-15 and 131A_A02 entries are 40 
partial-length cDNA sequences. The 99 bp region of 
3D_C12 that was used to make the RNAi-based construct is 
underlined. 
FIG. 4 shows an alignment of predicted amino acid 
sequences for full-length members of the 3D_C12 family of 45 
P450 genes. The amino acid sequences present in the 
alig r i ment include 3D_C12 (SEQ ID N0:2), 3D_Cl2-10 
(SEQ ID N0:4); 3D_Cl2-7 (SEQ ID N0:6); and 7D_A06 
(SEQ ID NO: 8). Asterisks denote positions conserved 
among all four sequences. Residues that differ among the 50 
members are shaded in grey. 
FIG. 5 shows a Northern blot analysis of transgenic plants 
possessing the 3D_C12/RNAi construct. (A) Hybridization 
of the 3D_Cl2-7 probe to RNAs isolated from ethephon-
treated, cured leaves of transgenic plants displaying low 55 
nornicotine phenotypes (3D_C12/RNAi-1, 3, and 4) and 
high nornicotine phenotypes (3D_C12/RNAi-6, 7, and vec-
tor-only control plant 11 ). Estimated size of hybridizing 
band is indicated in kilo bases (kb). (B) Ethidium bromide 
staining of the portion of the gel used in (A) that contains the 60 
28S ribosomal RNA to show the relative equivalence of 
RNA loading among the lanes. 
FIG. 6 shows a Northern blot analysis of transgenic plants 
possessing sense-orientation constructs of members of the 
3D_C12 gene family. (A) Hybridization of the 3D_Cl2-7 65 
probe to RNAs isolated from nontreated leaves of indepen-
dent transgenic lines expressing 3D_Cl2-7, 3D_C12, and 
Although specific terms are employed herein, they are 
used in a generic and descriptive sense only and not for 
purposes of limitation. Like numbers refer to like elements 
throughout. Further, the article "a" and "an" are used herein 
to refer to one or more than one (i.e., to at least one) of the 
grammatical object of the article. By way of example, "an 
element" means one or more element. Throughout the 
specification the word "comprising," or variations such as 
"comprises" or "comprising," will be understood to imply 
the inclusion of a stated element, integer or step, or group of 
elements, integers or steps, but not the exclusion of any other 
element, integer or step, or group of elements, integers or 
steps. 
The present invention is drawn to compositions and 
methods for inhibiting the expression or function of 
cytochrome P450 polypeptides that are involved in the 
metabolic conversion of nicotine to nornicotine in a plant, 
particularly plants of the Nicotiana genus, including tobacco 
plants of the various commercial varieties. As used herein, 
the terms "inhibit," "inhibition," and "inhibiting" are defined 
as any method known in the art or described herein that 
decreases the expression or function of a gene product of 
interest (i.e., the target gene product). "Inhibition" can be in 
the context of a comparison between two plants, for 
example, a genetically altered plant versus a wild-type plant. 
Alternatively, inhibition of expression or function of a target 
gene product can be in the context of a comparison between 
plant cells, organelles, organs, tissues, or plant parts within 
the same plant or between different plants, and includes 
comparisons between developmental or temporal stages 
within the same plant or plant part or between plants or plant 
parts. "Inhibition" includes any relative decrement of func-
tion or production of a gene product of interest, up to and 
including complete elimination of function or production of 
that gene product. The term "inhibition" encompasses any 
method or composition that down-regulates translation and/ 
US 9,913,451 B2 
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or transcription of the target gene product or functional 
activity o f  the target gene product. 
8 
polynucleotide or a portion o f  an amino acid sequence and 
hence protein encoded thereby. 
As used herein, the term "plant part" includes plant cells, 
plant protoplasts, plant cell tissue cultures from which a 
whole plant can be regenerated, plant calli, plant clumps, 
and plant cells that are intact in plants or parts of plants such 
as embr yos, pollen, anthers, ovules, seeds, leaves, flowers, 
stems, branches, fruit, roots, root tips, and the like. Progeny, 
variants, and mutants o f  regenerated plants are also included 
The term "inhibitory sequence" encompasses any poly-
nucleotide or polypeptide sequence capable of inhibiting the 
expression or function of a cytochrome P450 polypeptide 
involved in the metabolic conversion o f  nicotine to norni-
cotine in a plant, such as full-length polynucleotide or 
polypeptide sequences, truncated polynucleotide or poly-
peptide sequences, fragments of polynucleotide or polypep-
tide sequences, variants o f  polynucleotide or polypeptide 
sequences, sense-oriented nucleotide sequences, antisense-
oriented nucleotide sequences, the complement o f  a sense-
10 within the scope o f  the invention, provided that these 
comprise the introduced nucleic acid sequences o f  the 
or antisense-oriented nucleotide sequence, inverted regions 
invention. 
By "phenotypic change" is intended a measurable change 
in one or more cell functions. For example, plants having a 
genetic modification at the genomic locus encoding a 
cytochrome P450 polypeptide o f  the invention can show 
reduced or eliminated expression or activity o f  that 
cytochrome P450 polypeptide. 
o f  nucleotide sequences, hair pins o f  nucleotide sequences, 15 
double-stranded nucleotide sequences, single-stranded 
nucleotide sequences, combinations thereof, and the like. 
The term "polynucleotide sequence" includes sequences o f  
RNA,  DNA,  chemically modified nucleic acids, nucleic acid 
analogs, combinations thereof, and the like. 
Inhibitory sequences are designated herein by the name o f  
the target gene product. Thus, a "cytochrome P450 inhibi-
tor y  sequence" refers to an inhibitory sequence that is 
capable o f  inhibiting the expression o f  a cytochrome P450 
polypeptide that is involved in the metabolic conversion o f  25 
nicotine to nomicotine in a plant, for example, at the level 
The term "introducing" is intended to mean presenting to 
20 the plant the polynucleotide or polypeptide in such a manner 
that the sequence gains access to the interior o f  a cell o f  the 
plant. 
o f  transcription and/or translation, or which is capable o f
inhibiting the function of such a cytochrome P450 polypep-
tide. When the phrase "capable of inhibiting" is used in the 
context of a polynucleotide inhibitory sequence, it is 30 
intended to mean that the inhibitor y  sequence itself exerts 
the inhibitory effect; or, where the inhibitor y  sequence 
encodes an inhibitory nucleotide molecule (for example, 
hair pin RNA,  miRNA, or double-stranded R N A  polynucle-
otides ), or encodes an inhibitory polypeptide (i.e., a poly- 35 
peptide that inhibits expression or function o f  the target gene 
product), following its transcription (for example, in the case 
o f  an inhibitory sequence encoding a hair pin RNA,  miRNA,
or double-stranded R N A  polynucleotide) or its transcription 
and translation (in the case o f  an inhibitor y  sequence encod- 40 
ing an inhibitory polypeptide), the transcribed or translated 
product, respectively, exerts the inhibitory effect on the 
target gene product (i.e., inhibits expression or function o f
the target gene product). 
By "host cell" is meant a cell that comprises a heterolo- 45 
gous nucleic acid sequence of the invention. Though the 
nucleic acid sequences o f  the invention, and fragments and 
variants thereof, can be introduced into any cell of interest, 
o f  particular interest are plant cells, more particularly cells 
o f  a Nicotiana plant species, for example, the tobacco plant 50 
species and varieties described herein below. 
The use o f  the term "polynucleotide" is not intended to 
limit the present invention to polynucleotides comprising 
DNA.  Those o f  ordinary skill in the art will recognize that 
polynucleotides can comprise ribonucleotides and combina- 55 
tions of ribonucleotides and deoxyribonucleotides. Such 
deoxyribonucleotides and ribonucleotides include both natu-
rally occurring molecules and synthetic analogues. The 
polynucleotides o f  the invention also encompass all forms o f  
sequences including, but not limited to, single-stranded 60 
forms, double-stranded forms, hair pins, stem-and-loop 
structures, and the like. 
The term "variant" as used herein is intended to mean a 
substantially similar sequence, and the term "native" poly-
nucleotide or polypeptide is intended to mean a naturally 65 
occurring nucleotide sequence or amino acid sequence, 
respectively. By "fragment" is intended a portion o f  a 
The term "operably linked" is intended to mean a func-
tional linkage between two or more elements. For example, 
an operable linkage between a polynucleotide of interest and 
a regulatory sequence (i.e., a promoter) is a functional link 
that allows for expression o f  the polynucleotide o f  interest. 
Operably linked elements may be contiguous or non-con-
ti g u ous. When used to refer to the joining o f  two protein 
coding regions, by operably linked is intended that the 
coding regions are in the same reading frame. 
The term "heterologous" according to the present inven-
tion when used in reference to a sequence is intended to 
mean a sequence that originates from a foreig n  species, or, 
i f  from the same species, is substantially modified from its 
native form in composition and/or genomic locus by delib-
erate human intervention. The term also is applicable to 
nucleic acid constructs, also referred to herein as "poly-
nucleotide constructs" or "nucleotide constructs." In this 
manner, a "heterologous" nucleic acid construct is intended 
to mean a construct that originates from a foreign species, or, 
i f  from the same species, is substantially modified from its 
native form in composition and/or genomic locus by delib-
erate human intervention. Heterologous nucleic acid con-
structs include, but are not limited to, recombinant nucleo-
tide constructs that have been introduced into a plant or plant 
part thereof, for example, via transformation methods or 
subsequent breeding o f  a transgenic plant with another plant 
o f  interest. 
For example, a promoter operably linked to a heterolo-
gous polynucleotide is from a species different from the 
species from which the polynucleotide was derived, or, i f  
from the same/analogous species, one or both are substan-
tially modified from their original form and/or genomic 
locus, or the promoter is not the native promoter for the 
operably linked polynucleotide. Furthermore, as used herein 
a chimeric gene comprises a coding sequence operably 
linked to a transcription initiation region that is heterologous 
to the coding sequence. 
The term "expression" as used herein refers to the bio-
synthesis of a gene product, including the transcription 
and/or translation of said gene product. For example, for the 
purposes of the present invention, an expression cassette, as 
described elsewhere herein, capable o f  expressing a poly-
nucleotide that inhibits the expression o f  at least one 
cytochrome P450 polypeptide o f  the invention is an expres-
sion cassette capable of producing an R N A  molecule that 
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nicotine levels, and levels of its carcinogenic metabolite, 
NNN, within leaves and stems of these plants. 
The cytochrome P450 genes of the invention were iso-
lated from tobacco lines of a Burley variety. The first of 
these cytochrome P450 genes, designated 3D_C12, encodes 
an mRNA transcript corresponding to nucleotides (nt) 
1-1551 of the cDNA sequence set forth in SEQ ID N0:1, 
which codes for the full-length 517-residue polypeptide set 
forth in SEQ ID N0:2. The second member of this novel 
inhibits the transcription and/or translation of at least one 
cytochrome P450 polypeptide. The "expression" or "pro-
duction" of a protein or polypeptide from a DNA molecule 
refers to the transcription and translation of the coding 
sequence to produce the protein or polypeptide, while the 
"expression" or "production" of a protein or polypeptide 
from an RNA molecule refers to the translation of the RNA 
coding sequence to produce the protein or polypeptide. 
Cytochrome 450 Polynucleotides and Polypeptides, and 
Variants and Fragments Thereof 
Compositions of the present invention include isolated 
cytochrome P450 polynucleotides and polypeptides that are 
involved in the metabolic conversion of nicotine to norni-
cotine in plants, including commercial varieties of tobacco 
plants. In particular, compositions of the invention include 
isolated polypeptides comprising the amino acid sequences 
10 cytochrome P450 family, designated 3D_Cl2-10, encodes 
an mRNA transcript corresponding to nt 1-1551 of the 
cDNA sequence set forth in SEQ ID N0:3, which codes for 
the full-length 517-residue polypeptide set forth in SEQ ID 
N0:4. The third of these cytochrome P450 genes, designated 
as shown in SEQ ID NOS:2, 4, 6, 8, 10, and 12, and isolated 
polynucleotides comprising the nucleotide sequences as 
shown in SEQ ID NOS: 1, 3, 5, 7, 9, and 11. The polynucle-
otides of the invention find use in inhibiting expression of 
these cytochrome P450 polypeptides or variants thereof that 
are involved in the metabolic conversion of nicotine to 
nomicotine in plants, particularly tobacco plants. 
15 3D_Cl2-7, encodes anmRNA transcript corresponding to nt 
1-1551 of the cDNA sequence set forth in SEQ ID N0:5, 
which codes for the full-length 517 residue polypeptide set 
forth in SEQ ID N0:6. The fourth member of the novel 
cytochrome P450 family, designated 7D_A06, encodes an 
20 mRNA transcript corresponding to nt 1-1554 of the cDNA 
sequence set forth in SEQ ID N0:7, which codes for the 
full-length 518-residue polypeptide set forth in SEQ ID 
N0:8. 
In this manner, the invention further provides expression 25 
cassettes comprising all or a portion of the polynucleotide 
sequence set forth in SEQ ID N0:1, 3, 5, 7, 9, or 11, a 
complement or fragment thereof, or a sequence having 
substantial sequence identity to SEQ ID N0:1, 3, 5, 7, 9, or 
11, or a complement or fragment thereof, operably linked to 30 
a promoter that is functional in a plant cell for use in 
expressing an inhibitory RNA transcript that interferes with 
expression (i.e., transcription and/or translation) of 
cytochrome P450 polypeptides described herein. In some 
embodiments, the expression cassettes comprise the nucleo- 35 
tide sequence as shown in SEQ ID N0:13, 14, 15, or 16, a 
complement or fragment thereof, or a sequence having 
substantial sequence identity to SEQ ID N0:13, 14, 15, or 
16, or a complement or fragment thereof. Introduction of 
these expression cassettes into a Nicotiana plant of interest, 40 
particularly a tobacco plant of varieties commonly known as 
flue or bright varieties, Burley varieties, dark varieties, and 
oriental/Turkish varieties, results in the production of 
tobacco plants having reduced amounts of nornicotine and 
the nitrosamine, N'-nitrosonomicotine (NNN). Leaf and 45 
stem material from these transgenic plants can be used to 
produce a variety of tobacco products having reduced levels 
of nornicotine, and a concomitant reduction in this carcino-
genic nitrosamine metabolite. 
The cytochrome P450 polynucleotides and encoded poly- 50 
peptides of the present invention represent a novel 
cytochrome P450 gene family, designated the 3D_C12 
cytochrome 450 gene family, that is newly identified as 
having a role in the metabolic conversion of nicotine to 
nomicotine in tobacco plants. Suppression of the expression 55 
of their encoded gene products in transgenic tobacco plants 
results in a sig n if icant reduction in the accumulation of 
nomicotine in the leaves of these transgenic plants. While 
not being bound by theory, the metabolic role of these 
polypeptides may be a direct one, i.e., directly catalyzing the 60 
N-demethylation reaction, or an indirect one, i.e., in the form 
of production of a product that leads to the up-regulation of 
the nicotine demethylase activity of the leaf. Regardless of 
the mechanism, any means by which expression and/or 
function of the polypeptides encoded by members of this 65 
cytochrome P450 gene family are targeted for inhibition 
within a Nicotiana plant will be effective in reducing nor-
Two partial-length P450 gene sequences sharing high 
sequence identity to the full-length members of the 3D_C12 
cytochrome P450 gene family were also isolated from these 
Burley tobacco lines. The first of these, desig nated 3D_Cl2-
15, encodes an mRNA transcript corresponding to the cDNA 
sequence set forth in SEQ ID N0:9, which encodes the 
partial-length polypeptide set forth in SEQ ID N0:10. The 
second partial-length P450 gene sequence, designated 
131A_A02, encodes an mRNA transcript corresponding to 
the cDNA sequence set forth in SEQ ID NO: 11, which 
encodes the partial-length polypeptide set forth in SEQ ID 
N0:12. 
In one aspect, the cytochrome P450 genes of the present 
invention are involved in the conversion of nicotine to 
nornicotine in a plant. In one aspect, the cytochrome P450 
genes of the present invention have nicotine demethylase 
activity. 
An alignment of the members of the 3D_C12 cytochrome 
P450 gene family is shown in FIG. 3A-3G. The predicted 
amino acid sequences for the four full-length clones are 
aligned in FIG. 4. These sequences share high sequence 
identity with each other (at least 90% at both the nucleotide 
and amino acid level (see Tables 2 and 3, Example 4 herein 
below). 
The invention encompasses isolated or substantially puri-
fied polynucleotide or protein compositions. An "isolated" 
or "purified" polynucleotide or protein, or biologically 
active portion thereof, is substantially or essentially free 
from components that normally accompany or interact with 
the polynucleotide or protein as found in its naturally 
occurring environment. Thus, an isolated or purified poly-
nucleotide or protein is substantially free of other cellular 
material, or culture medium when produced by recombinant 
techniques, or substantially free of chemical precursors or 
other chemicals when chemically synthesized. Optimally, an 
"isolated" polynucleotide is free of sequences ( optimally 
protein encoding sequences) that naturally flank the poly-
nucleotide (i.e., sequences located at the 5' and 3' ends of the 
polynucleotide) in the genomic DNA of the organism from 
which the polynucleotide is derived. For example, in various 
embodiments, the isolated polynucleotide can contain less 
than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of 
nucleotide sequence that naturally flank the polynucleotide 
in genomic DNA of the cell from which the polynucleotide 
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is derived. A protein that is substantially free of cellular 
material includes preparations of protein having less than 
about 30%, 20%, 10%, 5%, or 1 % (by dry weight) of 
contaminating protein. When the protein of the invention or 
biologically active portion thereof is recombinantly pro- 5 
duced, optimally culture medium represents less than about 
30%, 20%, 10%, 5%, or 1 % (by dry weight) of chemical 
precursors or non-protein-of-interest chemicals. 
Fragments of the disclosed cytochrome P450 polynucle-
otides and polypeptides encoded thereby are also encom- 10 
passed by the present invention. Fragments of a polynucle-
otide may encode protein fragments that retain the biological 
activity of the native protein and hence are involved in the 
metabolic conversion of nicotine to nomicotine in a plant. 
Alternatively, fragments of a polynucleotide that are useful 15 
as hybridization probes or PCR primers using methods 
described below generally do not encode fragment proteins 
retaining biological activity. Furthermore, fragments of the 
disclosed nucleotide sequences include those that can be 
assembled within recombinant constructs for use in gene 20 
silencing with any method known in the art, including, but 
not limited to, sense suppression/cosuppression, antisense 
suppression, double-stranded RNA (dsRNA) interference, 
hair pin RNA interference and intron-containing hair pin 
RNA interference, amplicon-mediated interference, 25 
ribozymes, and small interfering RNA or micro RNA, as 
described herein below. Thus, fragments of a cytochrome 
P450 polynucleotide sequence may range from at least about 
20 nucleotides, about 50 nucleotides, about 70 nucleotides, 
about 100 nucleotides, about 150 nucleotides, about 200 30 
nucleotides, about 250 nucleotides, about 300 nucleotides, 
about 350 nucleotides, about 400 nucleotides, and up to the 
full-length polynucleotide encoding the proteins of the 
invention, depending upon the desired outcome. In one 
aspect, the fragments of a cytochrome P450 polynucleotide 35 
sequence can be a fragment of between about 50 and about 
400 nucleotides, between about 70 and about 350 nucleo-
tides, between about 90 and about 325 nucleotides, between 
about 90 and about 300 nucleotides, between about 90 and 
about 275 nucleotides, between about 100 and about 400 40 
nucleotides, between about 100 and about 350 nucleotides, 
between about 100 and about 325 nucleotides, between 
about 100 and about 300 nucleotides, between about 125 and 
about 300 nucleotides, or between about 125 and about 275 
nucleotides in length. In some embodiments, a fragment of 45 
a cytochrome P450 polynucleotide is about 50, about 60, 
about 70, about 80, about 90, about 100, about 125, about 
150, about 175, about 200, about 225, about 250, about 275, 
about 300, about 325, about 350, about 400 nucleotides in 
length, and other such values between about 70 and about 50 
400 nucleotides. In one such embodiment, a fragment of a 
cytochrome P450 polynucleotide of the invention is about 
90 bp to about 110 bp in length, including 90, 91, 92, 93, 94, 
95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 
108, 109, and 110 bp in length. In another such embodiment, 55 
a fragment of a cytochrome P450 polynucleotide of the 
invention is about 290 to about 310 bp in length, including 
290, 291,292,293, 294, 295,296, 297, 298,299, 300, 301, 
302, 303, 304, 305, 306, 307, 308, 309, and 310 bp in length. 
A fragment of a cytochrome P450 polynucleotide of the 60 
present invention that encodes a biologically active portion 
of a cytochrome P450 polypeptide of the present invention 
will encode at least 15, 25, 30, 50, 75, 100, 125, 150, 175, 
200, 250, 300, 350, 400, 450, or 500 contiguous amino 
acids, or up to the total number of amino acids present in a 65 
full-length cytochrome P450 polypeptide of the invention 
(e.g., 517 for SEQ ID NOS: 2, 4, and 6; and 518 for SEQ ID 
12 
N0:8), or will encode at least 15, 25, 30, 50, 75, 100, 125, 
150, or up to the total number of amino acids present in a 
partial-length cytochrome P450 polypeptide of the invention 
(e.g., 173 for SEQ ID N0:10; and 222 for SEQ ID N0:12). 
In one aspect, a fragment of a cytochrome P450 polynucle-
otide of the invention encodes a polypeptide that comprises 
position 330 of the encoded polypeptide sequence. In 
another aspect, the polynucleotide fragment encodes a frag-
ment of a cytochrome P450 polypeptide, where the poly-
peptide fragment comprises the amino acids from position 
225 through the amino acid at about position 600 of SEQ ID 
N0:6. In in one such embodiment, the polynucleotide frag-
ment encodes a fragment of a cytochrome P450 polypeptide, 
where the polypeptide fragment comprises the amino acids 
from about position 239 through the amino acid at about 
position 402 of SEQ ID NO: 6. A biologically active portion 
of a cytochrome P450 polypeptide can be prepared by 
isolating a portion of one of the cytochrome P450 poly-
nucleotides of the present invention, expressing the encoded 
portion of the cytochrome P450 polypeptide ( e.g., by recom-
binant expression in vitro), and assessing the activity of the 
encoded portion of the cytochrome P450 polypeptide, i.e., 
the ability to promote conversion of nicotine to nomicotine, 
using assays known in the art and those provided herein 
below. 
Polynucleotides that are fragments of a cytochrome P450 
nucleotide sequence of the present invention comprise at 
least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 
500, 550, 600, 650, 700, 800, 900, 950, 1000, 1050, 1100, 
1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 
1600, 1650, or 1700 contig uous nucleotides, or up to the 
number of nucleotides present in a full-length cytochrome 
P450 polynucleotide as disclosed herein (e.g., 539 for SEQ 
ID N0:9; 666 for SEQ ID NO: 11; 1733 for SEQ ID NOS: 1, 
3, and 5; and 1727 for SEQ ID N0:7). Polynucleotides that 
are fragments of a cytochrome P450 nucleotide sequence of 
the present invention comprise fragments from about 20 to 
about 1700 contiguous nucleotides, from about 50 to about 
1600 contiguous nucleotides, from about 75 to about 1500 
contig uous nucleotides, from about 100 to about 1400 
nucleotides, from about 150 to about 1300 contig uous 
nucleotides, from about 150 to about 1200 contig uous 
nucleotides, from about 17 5 to about 1100 contig uous 
nucleotides, or from about 200 to about 1000 contig uous 
nucleotides from a cytochrome P450 polynucleotide as 
disclosed herein. 
In one aspect, fragments of a cytochrome P450 polynucle-
otide comprise a polynucleotide sequence containing the 
nucleotides from about position 700 to about position 1250 
of a cytochrome P450 coding sequence. In another aspect, 
fragments of a cytochrome P450 polynucleotide comprise a 
polynucleotide sequence containing the nucleotides from 
about position 715 to about position 1210, or from about 
position 717 to about position 1207 of a cytochrome P450 
coding sequence disclosed herein. 
In other embodiments of the invention, fragments of a 
cytochrome P450 polynucleotide comprise a polynucleotide 
sequence containing the nucleotides from about position 265 
to about position 625 of a cytochrome P450 coding sequence 
disclosed herein, or a complement thereof. In some of these 
embodiments, the fragments of a cytochrome P450 coding 
sequence disclosed herein comprise the nucleotides corre-
sponding to about position 297 to about position 594 of the 
P450 coding sequence set forth in SEQ ID N0:3 or SEQ ID 
N0:5, or a complement thereof. 
In yet other embodiments of the invention, fragments of 
a cytochrome P450 polynucleotide comprise a polynucle-
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otide sequence containing the nucleotides from about posi-
tion 1420 to about position 1580 of a cytochrome P450 
coding sequence disclosed herein, or a complement thereof. 
In some of these embodiments, the fragments of a 
cytochrome P450 coding sequence disclosed herein com-
prise the nucleotides corresponding to about position 1453 
to about position 1551 of the P450 coding sequence set forth 
in SEQ ID NO: 1, or a complement thereof. 
Variants of the disclosed polynucleotides and polypep-
tides encoded thereby are also encompassed by the present 10 
invention. Such naturally occurring variants include those 
variants that share substantial sequence identity to the dis-
closed cytochrome P450 polynucleotides and polypeptides 
disclosed herein as defined herein below. The compositions 
and methods of the invention can be used to target expres- 15 
sion or function of any naturally occurring cytochrome P450 
that shares substantial sequence identity to the disclosed 
cytochrome P450 polypeptides and which possesses the 
relevant cytochrome P450 activity, i.e., involvement in the 
metabolic conversion of nicotine to nomicotine in plants. 20 
Such variants may result from, for example, genetic poly-
morphism or from human manipulation as occurs with 
breeding and selection. Biologically active variants of a 
cytochrome P450 protein of the invention, for example, 
variants of the polypeptide set forth in SEQ ID N0:2, 4, 6, 25 
8, 10, or 12, will have at least about 40%, 45%, 50%, 55%, 
60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 
94%, 95%, 96%, 97%, 98%, 99% or more sequence identity 
to the amino acid sequence for the native protein as deter-
mined by sequence alignment programs and parameters 30 
described elsewhere herein, and are characterized by their 
functional involvement in the metabolic conversion of nico-
tine to nornicotine in plants. A biologically active variant of 
a protein of the invention may differ from that protein by as 
few as 1-15 amino acid residues, as few as 10, as few as 9, 35 
as few as 8, as few as 7, as few as 6, as few as 5, as few as 
4, as few as 3, as few as 2, or as few as 1 amino acid residue. 
Variants of a particular polynucleotide of the present 
invention include those naturally occurring polynucleotides 
that encode a cytochrome P450 polypeptide that is involved 40 
in the metabolic conversion of nicotine to nomicotine in 
plants. Such polynucleotide variants can comprise a deletion 
and/or addition of one or more nucleotides at one or more 
sites within the native polynucleotide disclosed herein and/ 
or a substitution of one or more nucleotides at one or more 45 
sites in the native polynucleotide. Because of the degeneracy 
of the genetic code, conservative variants for polynucle-
otides include those sequences that encode the amino acid 
sequence of one of the cytochrome P450 polypeptides of the 
invention. Naturally occurring variants such as these can be 50 
identified with the use of well-known molecular biology 
techniques, as, for example, with polymerase chain reaction 
(PCR) and hybridization techniques as outlined below. Vari-
ant polynucleotides also include synthetically derived poly-
nucleotides, such as those generated, for example, by using 55 
site-directed mutagenesis but which still share substantial 
sequence identity to the naturally occurring sequences dis-
closed herein, and thus can be used in the methods of the 
invention to inhibit the expression or function of a 
cytochrome P450 that is involved in the metabolic conver- 60 
sion of nicotine to nornicotine, including the cytochrome 
P450 polypeptides set forth in SEQ ID NOS:2, 4, 6, and 8, 
and polypeptides comprising the sequence set forth in SEQ 
ID N0:10 or 12. Generally, variants of a particular poly-
nucleotide of the invention, for example, the sequence set 65 
forth in SEQ ID N0:1, 3, 5, 7, 9, or 11, will have at least 
about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 
14 
85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 
99% or more sequence identity to that particular polynucle-
otide as determined by sequence alig n m ent programs and 
parameters described elsewhere herein. 
Variants of a particular polynucleotide of the present 
invention (also referred to as the reference polynucleotide) 
can also be evaluated by comparison of the percent sequence 
identity between the polypeptide encoded by the reference 
polynucleotide and the polypeptide encoded by a variant 
polynucleotide. For example, isolated polynucleotides 
encoding a polypeptide with a particular percent sequence 
identity to the full-length polypeptide of SEQ ID N0:2, 4, 6, 
or 8, or the partial-length polypeptide encoded by SEQ ID 
N0:9 or 11 are disclosed. Such polynucleotides can be used 
in the methods of the present invention to target expression 
of cytochrome P450 polypeptides involved in the metabolic 
conversion of nicotine to nornicotine in plants, particularly 
tobacco plants, thereby inhibiting accumulation of nomico-
tine and its metabolite N'-nitrosonornicotine in the stems and 
leaves of the genetically modified plant. Percent sequence 
identity between any two polypeptides can be calculated 
using sequence alignment programs and parameters 
described elsewhere herein. Where any given pair of poly-
nucleotides of the invention is evaluated by comparison of 
the percent sequence identity shared by the two polypeptides 
they encode, the percent sequence identity between the two 
encoded polypeptides is at least about 40%, 45%, 50%, 
55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 
93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence 
identity. In one aspect, a variant polypeptide of the present 
invention includes a polypeptide having a tryptophan at 
position 330 or an isoleucine at position 274 of the 
cytochrome P450 polypeptide, or both a tryptophan at 
position 330 and an isoleucine at position 274. 
Furthermore, the polynucleotides of the invention can be 
used to isolate corresponding cytochrome P450 sequences 
from other organisms, particularly other plants, more par-
ticularly other members of the Nicotiana genus. PCR, 
hybridization, and other like methods can be used to identify 
such sequences based on their sequence homology to the 
sequences set forth herein. Sequences isolated based on their 
sequence identity to the nucleotide sequences set forth 
herein or to variants and fragments thereof are encompassed 
by the present invention. Such sequences include sequences 
that are orthologs of the disclosed sequences. 
According to the present invention, "orthologs" are genes 
derived from a common ancestral gene and which are found 
in different species as a result of speciation. Genes found in 
different species are considered orthologs when their nucleo-
tide sequences and/or their encoded protein sequences share 
at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 
94%, 95%, 96%, 97%, 98%, 99%, or greater sequence 
identity. Functions of orthologs are often highly conserved 
among species. Thus, isolated polynucleotides that encode 
for a cytochrome P450 polypeptide that is involved in the 
nicotine-to-nomicotine metabolic conversion and which 
hybridize under stringent conditions to the cytochrome P450 
sequences disclosed herein, or to variants or fragments 
thereof, are encompassed by the present invention. Such 
sequences can be used in the methods of the present inven-
tion to inhibit expression of cytochrome P450 polypeptides 
that are involved in the metabolic conversion of nicotine to 
nornicotine in plants. 
Using PCR, oligonucleotide primers can be designed for 
use in PCR reactions to amplify corresponding DNA 
sequences from cDNA or genomic DNA extracted from any 
plant of interest. Methods for designing PCR primers and 
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PCR cloning are generally known in the art and are disclosed 
in Sambrook et al. (1989) Molecular Cloning: A Laboratory 
Manual (2d ed., Cold Spring Harbor Laboratory Press, 
Plainview, N.Y.). Innis et al., eds. (1990) PCR Protocols: A 
Guide to Methods and Applications (Academic Press, New 5 
York); Innis and Gelfand, eds. (1995) PCR Strategies (Aca-
demic Press, New York); and Innis and Gelfand, eds. (1999) 
PCR Methods Manual (Academic Press, New York). Known 
methods of PCR include, but are not limited to, methods 
using paired primers, nested primers, single specific primers, 10 
degenerate primers, gene-specific primers, vector-specific 
primers, partially mismatched primers, and the like. 
GC is the percentage of guanosine and cytosine nucleotides 
in the DNA, % form is the percentage of formamide in the 
hybridization solution, and L is the length of the hybrid in 
base pairs. The Tm is the temperature (under defined ionic 
strength and pH) at which 50% of a complementary target 
sequence hybridizes to a perfectly matched probe. Tm is 
reduced by about 1 ° C. for each 1 % of mismatching; thus, 
Tm, hybridization, and/or wash conditions can be adjusted to 
hybridize to sequences of the desired identity. For example, 
if sequences with >90% identity are sought, the Tm can be 
decreased 10 ° C. Generally, stringent conditions are selected 
to be about 5° C. lower than the thermal melting point (Tm) 
for the specific sequence and its complement at a defined 
ionic strength and pH. However, severely stringent condi-
tions can utilize a hybridization and/or wash at 1, 2, 3, or 4° 
C. lower than the thermal melting point (Tm); moderately
Hybridization techniques involve the use of all or part of 
a known polynucleotide as a probe that selectively hybrid-
izes to other corresponding polynucleotides present in a 15 
population of cloned genomic DNA fragments or cDNA 
fragments (i.e., genomic or cDNA libraries) from a chosen 
organism. 
stringent conditions can utilize a hybridization and/or wash
at 6, 7, 8, 9, or 10° C. lower than the thermal melting point
(Tm); low stringency conditions can utilize a hybridizationHybridization may be carried out under stringent condi-
tions. By "stringent conditions" or "stringent hybridization 
conditions" is intended conditions under which a probe will 
hybridize to its target sequence to a detectably greater degree 
than to other sequences (e.g., at least 2-fold over back-
ground). Stringent conditions are sequence-dependent and 
will be different in different circumstances. By controlling 
the stringency of the hybridization and/or washing condi-
tions, target sequences that are 100% complementary to the 
probe can be identified (homologous probing). Alternatively, 
stringency conditions can be adjusted to allow some mis-
matching in sequences so that lower degrees of similarity are 
detected (heterologous probing). Generally, a probe is less 
than about 1000 nucleotides in length, optimally less than 
500 nucleotides in length. 
Typically, stringent conditions will be those in which the 
salt concentration is less than about 1.5 M Na ion, typically 
about 0.01 to 1.0 M Na ion concentration (or other salts) at 
pH 7.0 to 8.3 and the temperature is at least about 30 ° C. 
Stringent conditions may also be achieved with the addition 
of destabilizing agents such as formamide. Exemplary low 
stringency conditions include hybridization with a buffer 
solution of 30 to 35% formamide, 1 M NaCl, 1 % SDS 
(sodium dodecyl sulphate) at 37 ° C., and a wash in l x  to 
2xSSC (20xSSC= 3.0 M NaCl/0.3 M trisodium citrate) at 50 
to 55 ° C. Exempl a r y  moderate stringency conditions include 
hybridization in 40 to 45% formamide, 1.0 M NaCl, 1 % 
SDS at 37 ° C., and a wash in 0.5x to lxSSC at 55 to 60 ° C. 
Exemplary high stringency conditions include hybridization 
in 50% formamide, 1 M NaCl, 1 % SDS at 37 ° C., and a wash 
20 and/or wash at 11, 12, 13, 14, 15, or 20° C. lower than the 
thermal melting point (Tm). Using the equation, hybridiza-
tion and wash compositions, and desired Tm, those of 
ordinary skill will understand that variations in the strin-
gency of hybridization and/or wash solutions are inherently 
25 described. If the desired degree of mismatching results in a 
Tm of less than 45 ° C. (aqueous solution) or 32 ° C. (forma-
mide solution), it is optimal to increase the SSC concentra-
tion so that a higher temperature can be used. An extensive 
guide to the hybridization of nucleic acids is found in Tij ssen 
30 (1993) Laboratory Techniques in Biochemistry and Molecu-
lar Biology-Hybridization with Nucleic Acid Probes, Part I, 
Chapter 2 (Elsevier, New York); and Ausubel et al., eds. 
(1995) Current Protocols in Molecular Biology, Chapter 2 
(Greene Publishing and Wiley-Interscience, New York). See 
35 Sambrook et al. (1989) Molecular Cloning: A Laboratory 
Manual (2d ed., Cold Spring Harbor Laboratory Press, 
Plainview, N.Y.). 
Hybridization probes may be genomic DNA fragments, 
cDNA fragments, RNA fragments, or other oligonucle-
40 otides, and may be labeled with a detectable group such as 
32P, or any other detectable marker. For example, probes for
hybridization can be made by labeling synthetic oligonucle-
otides based on the cytochrome P450 polynucleotides 
sequences of the present invention. Methods for preparation 
45 of probes for hybridization and for construction of cDNA 
and genomic libraries are generally known in the art and are 
disclosed in Sambrook et al. (1989) Molecular Cloning: A 
Laboratory Manual (2d ed., Cold Spring Harbor Laboratory 
in O.lxSSC at 60 to 65 ° C. Optionally, wash buffers may 
comprise about 0.1 % to about 1 % SDS. Duration of hybrid- 50 
ization is generally less than about 24 hours, usually about 
Press, Plainview, N.Y.). 
For example, the cytochrome P450 polynucleotide 
sequences disclosed herein, or one or more portions thereof, 
may be used as probes capable of specifically hybridizing to 
corresponding cytochrome P450 polynucleotides and mes-
senger RNAs. To achieve specific hybridization under a 
4 to about 12 hours. The duration of the wash time will be 
at least a length of time sufficient to reach equilibrium. 
In a specific embodiment, stringency conditions include 
hybridization in a solution containing 5xSSC, 0.5% SDS, 
5xDenhardt's, 0.45 µg/µl Poly A RNA, 0.45 µg/µl calf 
thymus DNA and 50% formamide at 42 ° C., and at least one 
post-hybridization wash in a solution comprising from about 
O.OlxSSC to about lxSSC. The duration of hybridization is 
from about 14 to about 16 hours. 
Specificity is typically the function of post-hybridization 
washes, the critical factors being the ionic strength and 
temperature of the final wash solution. For DNA-DNA 
hybrids, the Tm can be approximated from the equation of 
Meinkoth and Wahl (1984) Anal. Biochem. 138:267-284: 
Tm= 81.5° C.+16.6 (log M)+0.41 (% GC)-0.61 (% form)-
500/L; where M is the molarity of monovalent cations, % 
55 variety of conditions, such probes include sequences that are 
unique among cytochrome P450 polynucleotide sequences, 
including upstream regions 5' to the coding sequence and 
downstream regions 3' to the coding sequence, and are 
optimally at least about 10 nucleotides in length, and most 
60 optimally at least about 20 nucleotides in length. Such 
probes may be used to amplify corresponding cytochrome 
P450 polynucleotides. This technique may be used to isolate 
additional coding sequences from a desired plant or as a 
diagnostic assay to determine the presence of coding 
65 sequences in a plant. Hybridization techniques include 
hybridization screening of plated DNA libraries ( either 
plaques or colonies; see, for example, Sambrook et al. 
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(1989) Molecular Cloning: A Laboratory Manual (2d ed., 
Cold Spring Harbor Laboratory Press, Plainview, N.Y.). 
As used herein, with respect to the sequence relationships 
between two or more polynucleotides or polypeptides, the 
term "reference sequence" is a defined sequence used as a 
basis for sequence comparison. A reference sequence may be 
a subset or the entirety o f  a specified sequence; for example, 
as a segment of a full-length c D N A  or gene sequence, or the 
complete cDNA or gene sequence. 
18 
residue matches and an identical percent sequence identity 
when compared to the corresponding alignment generated 
by BLASTX,  Clustal W, or GAP. 
For purposes of the foregoing discussion o f  variant 
nucleotide and polypeptide sequences encompassed by the 
present invention, the term "sequence identity" or "identity" 
in the context of two polynucleotides or polypeptide 
sequences makes reference to the residues in the two 
As used herein, the term "comparison window" makes 10 
reference to a contig u ous and specified segment o f  a poly-
nucleotide sequence, wherein the polynucleotide sequence 
sequences that are the same when aligned for maximum 
correspondence over a specified comparison window. When 
percentage o f  sequence identity is used in reference to 
proteins it is recognized that residue positions which are not 
identical often differ by conservative amino acid substitu-
tions, where amino acid residues are substituted for other 
amino acid residues with similar chemical properties (e.g., 
charge or hydrophobicity) and therefore do not change the 
in the comparison window may comprise additions or dele-
tions (i.e., gaps) compared to the reference sequence (which 
does not comprise additions or deletions) for optimal align- 15 
ment o f  the two polynucleotides. Generally, the comparison 
window is at least 20 contiguous nucleotides in length, and 
optionally can be 30, 40, 50, 100, or longer. Those o f  skill 
functional properties o f  the molecule. When sequences differ 
in conservative substitutions, the percent sequence identity 
may be adjusted upwards to correct for the conservative 
nature o f  the substitution. Sequences that differ by such 
conservative substitutions are said to have "sequence simi-
in the art understand that to avoid a high similarity to a 
reference sequence due to inclusion o f  gaps in the poly- 20 
nucleotide sequence a gap penalty is typically introduced 
and is subtracted from the number o f  matches. larity" or "similarity." Means for making this adjustment are 
well known to those of skill in the art. Typically this involves 
scoring a conservative substitution as a partial rather than a 
Methods o f  alignment o f  sequences for comparison are 
well known in the art. Thus, the determination of percent 
sequence identity between any two sequences can be accom-
plished using a mathematical algorithm. Non-limiting 
examples o f  such mathematical algorithms are the algorithm 
o f  Myers and Miller (1988) CABIOS 4:11-17; the local 
ali g n m ent algorithm of Smith et al. (1981) Adv. Appl. Math. 
2:482; the global ali g n m ent algorithm of Needleman and 
Wunsch (1970) J. Mal. Biol. 48:443-453; the search-for-
local alignment method o f  Pearson and Lipman (1988) Proc. 
Natl. Acad. Sci. 85:2444-2448; the algorithm of Karlin and 
Altschul (1990) Proc. Natl. Acad. Sci. USA 872264, modi-
fied as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. 
USA 90:5873-5877. 
The B L A S T  programs of Altschul et al. (1990) J. Mal. 
Biol. 215:403 are based on the algorithm o f  Karlin and 
Altschul (1990) supra. B L A S T  nucleotide searches can be 
performed with the BLASTN program, score= l OO, word-
length= 12, to obtain nucleotide sequences homologous to a 
nucleotide sequence encoding a protein o f  the invention. 
B L A S T  protein searches can be performed with the 
B L A S T X  program, score= 50, wordlength=3, to obtain 
amino acid sequences homologous to a protein or polypep-
tide o f  the invention. To obtain gapped alignments for 
comparison purposes, Gapped B L A S T  (in B L A S T  2.0) can 
be utilized as described in Altschul et al. (1997) Nucleic 
Acids Res. 25:3389. Alternatively, PSI-BLAST (in BLAST 
2.0) can be used to perform an iterated search that detects 
distant relationships between molecules. See Altschul et al. 
(1997) supra. When utilizing BLAST, Gapped BLAST, 
PSI-BLAST, the default parameters of the respective pro-
grams ( e.g., B L A S  T N  for nucleotide sequences, B L A S  T X  
for proteins) can be used (See www.ncbi.nlm.nih.gov). 
Alignment may also be performed manually by inspection. 
The sequence identity/similarity values provided herein 
were calculated using the B L A S T X  (Altschul et al. (1997) 
supra), Clustal W (Higgins et al. (1994) Nucleic Acids Res. 
25 full mismatch, thereby increasing the percentage sequence 
identity. Thus, for example, where an identical amino acid is 
given a score o f  1 and a non-conservative substitution is 
given a score o f  zero, a conservative substitution is given a 
score between zero and 1. The scoring o f  conservative 
30 substitutions is calculated, e.g., as implemented in the pro-
gram PC/GENE (Intelligenetics, Mountain View, Calif.). 
The term "percentage o f  sequence identity" as used herein 
means the value determined by comparing two optimally 
aligned sequences over a comparison window, wherein the 
35 portion o f  the polynucleotide sequence in the comparison 
window may comprise additions or deletions (i.e., gaps) as 
compared to the reference sequence (which does not com-
prise additions or deletions) for optimal alignment o f  the two 
sequences. The percentage is calculated by determining the 
40 number o f  positions at which the identical nucleic acid base 
or amino acid residue occurs in both sequences to yield the 
number o f  matched positions, dividing the number o f  
matched positions by the total number o f  positions in the 
window of comparison, and multiplying the result by 100 to 
45 yield the percentage o f  sequence identity. 
When any two polypeptide sequences are optimally 
aligned for comparison, it is recognized that residues appear-
ing opposite o f  one another within the alignment occupy 
positions within their respective polypeptides that corre-
50 spond to one another. Such positions are referred to herein 
as "corresponding positions" and the residues residing at 
corresponding positions are referred to as "corresponding 
residues" or residues that "correspond" to one another. Thus, 
for example, where a polypeptide o f  interest is optimally 
55 aligned to a reference polypeptide sequence having, for 
example, 10 residues, the residue within the polypeptide o f  
interest appearing opposite residue 5 o f  the reference 
sequence is referred to as the "residue at the position 
corresponding to residue 5" o f  the reference sequence. 
In like manner, when any two polynucleotide sequences 
are optimally aligned for comparison, it is recognized that 
the nucleotides appearing opposite o f  one another within the 
alignment occupy positions within their respective poly-
nucleotide positions that correspond to one another. Such 
22: 4673-4680), and G A P  (University o f  Wisconsin Genetic 60 
Computing Group software package) algorithms using 
default parameters. The present invention also encompasses 
the use o f  any equivalent program thereof for the analysis 
and comparison of nucleic acid and protein sequences. By 
"equivalent program" is intended any sequence comparison 
program that, for any two sequences in question, generates 
65 positions are referred to herein as "corresponding positions" 
and the nucleotides residing at corresponding positions are 
referred to as "corresponding nucleotides" or nucleotides an ali g n m ent having identical nucleotide or amino acid 
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that "correspond" to one another. Thus, for example, where 
a polynucleotide of interest is optimally aligned to a refer-
ence polynucleotide sequence having, for example, 300 
nucleotides, the nucleotide within the polynucleotide of 
interest appearing opposite nucleotide 275 of the reference 
sequence is referred to as the "nucleotide at the position 
corresponding to nucleotide 275" of the reference sequence. 
Where a region of nucleotides is being compared between 
a polynucleotide of interest and a reference polynucleotide, 
the nucleotides within these regions are said to "correspond" 10 
to one another. Thus, for example, where a region of a 
reference polynucleotide sequence, for example, the poly-
nucleotide sequence set forth in SEQ ID N0:5, resides from 
nucleotide position 265 to nucleotide position 625 of the 
reference polynucleotide, and this region of nucleotides is 15 
being compared to the corresponding region of nucleotides 
within an optimally aligned polynucleotide sequence of 
interest, the nucleotides within the corresponding region of 
the polynucleotide of interest are referred to herein as "a 
region" of the polynucleotide of interest that "corresponds to 20 
nucleotide position 265 to nucleotide position 625" of the 
reference sequence, in this case, SEQ ID N0:5. 
Cytochrome P450 polynucleotide and polypeptide 
sequences can be identified using the sequences provided 
herein. Such methods include obtaining a polynucleotide or 25 
polypeptide sequence at least 80%, 85%, 90%, 95%, 98%, 
99% sequence identity with the polynucleotide sequence of 
SEQ ID NO 1, 3, 5, 7, 9, or 11 or a complement or fragment 
thereof, or a polypeptide sequence of SEQ ID N0:2, 4, 6, 7, 
10, or 12. In one embodiment, the identified sequence 30 
contains or encodes for a tryptophan residue at position 330 
and an isoleucine residue at position 274. 
In this mamier, one aspect of the present invention is 
directed to a method of screening for a nicotine demethylase 
sequence. This method comprises obtaining a nucleic acid 35 
sequence that has greater than about 90% sequence identity 
with SEQ ID N0:3 or SEQ ID N0:5; and identifying within 
this nucleic acid sequence a codon sequence encoding for a 
tryptophan residue at position 330 of the polypeptide 
encoded by the nucleic acid sequence. In some embodi- 40 
ments, this nucleic acid sequence also encodes an isoleucine 
at position 274 of the encoded polypeptide. Any suitable 
method known in the art can be used to identify the codon 
sequence encoding the tryptophan or isoleucine residue. In 
one embodiment, the codon sequence is identified by a 45 
method selected from the group consisting of identifying a 
single nucleotide polymorphism and RT-PCR. In some 
embodiments of this aspect of the invention, the screening 
method identifies a nicotine demethylase that converts nico-
tine to nomicotine at a rate that is at least about 5-fold 50 
20 
the encoded polypeptide. As noted above, any suitable 
method known to those of skill in the art can be used to 
identify these codons. In one embodiment, either or both of 
the first and second codons are identified by a method 
selected from the group consisting of identifying a single 
nucleotide polymorphism and RT-PCR. In some embodi-
ments of this aspect of the invention, the screening method 
identifies a nicotine demethylase that converts nicotine to 
nornicotine at a rate that is at least about 5-fold greater than 
the conversion rate of the nicotine demethylase encoded by 
SEQ ID N0:3 (polypeptide set forth in SEQ ID N0:4) or 
SEQ ID N0:5 (polypeptide set forth in SEQ ID N0:6). In 
particular embodiments, the nicotine demethylase identified 
with this screening method has a conversion rate that is at 
least about 8-fold greater than the conversion rate of the 
nicotine demethylase encoded by SEQ ID N0:3 or SEQ ID 
N0:5. 
The present invention also provides transgenic plant cells, 
plants, and seed comprising a nucleic acid molecule having 
a promoter functional in a plant cell and a nucleic acid 
sequence encoding a nicotine demethylase having an iso-
leucine residue at position 274 and a tryptophan residue at 
position 330. In some embodiments, the nucleic acid 
sequence encoding this nicotine demethylase is derived from 
a sequence selected from the group consisting of SEQ ID 
N0:3, SEQ ID N0:5, and SEQ ID N0:7. These transgenic 
plant cells, plants, and seed include, but are not limited to, 
Nicotiana plant cells, Nicotiana plants, and seed of Nicoti-
ana plants. In some embodiments, the Nicotiana plant cells, 
Nicotiana plants, and seed of Nicotiana plants are from 
converter Nicotiana plants. 
Expression Cassettes for Use in the Methods of the Inven-
tion 
Compositions of the present invention further include 
expression cassettes comprising inhibitory sequences 
capable of inhibiting expression or function of a cytochrome 
P450 polypeptide involved in the conversion of nicotine to 
nornicotine in a Nicotiana plant or plant part thereof, where 
the inhibitory sequences are operably linked to a promoter 
that is functional in a plant cell. In this mamier, expression 
cassettes comprising all or part of the sequence set forth in 
SEQ ID N0:1, 3, 5, 7, 9, or 11, a complement or fragment 
thereof, or sequences sharing substantial sequence identity 
to SEQ ID N0:1, 3, 5, 7, 9, 11, or a complement or fragment 
thereof, operably linked to a promoter that is functional in a 
plant cell are constructed for use in the gene-silencing 
methods of the present invention described herein below. 
Such sequences are referred to herein as "inhibitory 
sequences" or "inhibitory polynucleotide sequences" as they 
are capable of being expressed as an RNA molecule that 
inhibits expression (i.e, transcription and/or translation) of 
the target cytochrome P450 polypeptide, for example, the 
polypeptide set forth in SEQ ID N0:2, 4, 6, or 8 and variants 
thereof, or a polypeptide comprising the sequence set forth 
greater than the conversion rate of the nicotine demethylase 
encoded by SEQ ID N0:3 (polypeptide set forth in SEQ ID 
N0:4) or SEQ ID N0:5 (polypeptide set forth in SEQ ID 
N0:6). In particular embodiments, the nicotine demethylase 
identified with this screening method has a conversion rate 
that is at least about 8-fold greater than the conversion rate 
of the nicotine demethylase encoded by SEQ ID N0:3 or 
SEQ ID N0:5. 
55 in SEQ ID N0:10 or 12 and variants thereof, where the 
variant polypeptides have substantial sequence identity to 
these disclosed cytochrome P450 polypeptides and are 
involved in the metabolic conversion of nicotine to norni-
cotine in a plant. 
As noted above, such inhibitory sequences include frag-
ment sequences of the target cytochrome P450 polynucle-
otides. For example, a fragment sequence can include any 
portion of the cytochrome P450 sequence, including coding 
and non-coding sequence (e.g., 5' UTR, intron, and 3' UTR 
In another aspect, the present invention provides a method 
for screening for a nicotine demethylase having an isoleu- 60 
cine at position 274 or a tryptophan at position 329 of the 
polypeptide. This method comprises obtaining a nucleic acid 
sequence that has greater than about 90% sequence identity 
with SEQ ID N0:3 or SEQ ID N0:5; and identifying a first 
codon sequence encoding for an isoleucine residue at posi-
tion 274 of the encoded polypeptide or a second codon 
sequence encoding a tryptophan residue at position 330 of 
65 sequences), and can include fragments of between about 20 
and about 400 nucleotides, between about 50 and about 400 
nucleotides, between about 100 and about 400 nucleotides, 
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between about 125 and about 325 nucleotides, between 
about 125 and about 300 nucleotides, or between about 125 
and about 275 nucleotides. 
22 
In this manner, such inhibitory sequences include, but are 
not limited, sequences that comprise a fragment of a 
cytochrome P450 polynucleotide sequence ranging from at 
least about 20 nucleotides, about 50 nucleotides, about 70 
nucleotides, about 100 nucleotides, about 150 nucleotides, 
about 200 nucleotides, about 250 nucleotides, about 300 
nucleotides, about 350 nucleotides, and up to the full-length 10 
polynucleotide encoding the proteins o f  the invention, 
depending upon the desired outcome. In one aspect, the 
inhibitory sequences comprise a fragment o f  a cytochrome 
P450 polynucleotide sequence that is between about 50 and 
about 400 nucleotides, between about 50 and about 350 15 
nucleotides, between about 70 and about 350 nucleotides, 
between about 90 and about 325 nucleotides, between about 
prises the nucleotides corresponding to about position 1453 
to about position 1551 o f  the P450 coding sequence set forth 
in SEQ ID NO: 1 and a sequence that is fully or partially 
complementary thereto. In preferred embodiments, such 
inhibitory sequences are expressed as a hair pin R N A  as 
described herein below. 
It is recog n ized that expression cassettes o f  the present 
invention encompass constructs in which a desired nucleic 
acid sequence is operably linked to a promoter that is 
functional in a plant cell, particularly in the cell o f  a 
Nicotiana plant. By "promoter" is intended a regulatory 
region o f  D N A  usually comprising a TATA box capable o f  
directing R N A  polymerase II to initiate R N A  synthesis at the 
appropriate transcription initiation site for a particular poly-
nucleotide sequence. A promoter may additionally comprise 
other recog n ition sequences generally positioned upstream 
or 5' to the TATA box, referred to as upstream promoter 
elements, which influence the transcription initiation rate. It 
is also recog n ized that expression cassettes o f  the present 
invention encompass additional domains that modulate the 
level o f  expression, the developmental timing o f  expression, 
90 and about 300 nucleotides, between about 90 and about 
275 nucleotides, between about 100 and about 400 nucleo-
tides, between about 100 and about 350 nucleotides, 20 
between about 100 and about 325 nucleotides, between 
about 100 and about 300 nucleotides, between about 125 and 
about 300 nucleotides, or between about 125 and about 275 
nucleotides in length. In some embodiments, the inhibitory 
sequences comprise a fragment o f  a cytochrome P450 25 
polynucleotide sequence that is about 50, about 60, about 70, 
about 80, about 90, about 100, about 125, about 150, about 
175,about200,about225,about250,about275,about300, 
about 325, about 350, about 400 nucleotides in length, and 
other such values between about 50 and about 400 nucleo- 30 
or tissue type that expression occurs in (e.g., Australian 
Patent No. AU-A-77751/94 and U.S.  Pat. Nos. 5,466,785 
and 5,635,618). By "functional" is intended the promoter, 
when operably linked to an inhibitory sequence encoding an 
inhibitory nucleotide molecule (for example, a hair pin RNA,  
double-stranded RNA,  miRNA polynucleotide, and the 
like), the promoter is capable of initiating transcription o f  
the operably linked inhibitory sequence such that the inhibi-
tory nucleotide molecule is expressed. The promoters can be 
selected based on the desired outcome. The nucleic acids can tides. It is recognized that the inhibitory sequence can also 
comprise a sequence that is complementary to all or a part 
o f  the fragment o f  the cytochrome P450 polynucleotide 
sequence. 
In one such embodiment, the inhibitory sequences com-
prise a fragment o f  a cytochrome P450 polynucleotide o f  the 
invention that is about 90 bp to about 110 bp in length, 
including 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 
102, 103, 104, 105, 106, 107, 108, 109, and l lObp in length, 
and can also comprise a sequence that is complementary to 
all or a part o f  the fragment sequence. In another such 
embodiment, a fragment o f  a cytochrome P450 polynucle-
otide of the invention is about 290 to about 310 bp in length, 
including 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 
300, 301, 302, 303, 304, 305, 306, 307, 308, 309, and310 
bp in length, and can also comprise a sequence that is 
complementary to all or a part o f  the fragment sequence. 
In other embodiments o f  the invention, the inhibitory 
sequence within an expression cassette o f  the invention 
comprises a polynucleotide sequence containing the nucleo-
tides from about position 265 to about position 625 of a 
cytochrome P450 coding sequence disclosed herein and 
sequence that is fully or partially complementary thereto. In 
some o f  these embodiments, the inhibitory sequence com-
prises the nucleotides corresponding to about position 297 to 
about position 594 of the P450 coding sequence set forth in 
SEQ ID N0:3 or SEQ ID N0:5 and a sequence that is fully 
or partially complementary thereto. In preferred embodi-
ments, such inhibitory sequences are expressed as a hair pin 
R N A  as described herein below. 
In yet other embodiments o f  the invention, the inhibitory 
sequence within an expression cassette o f  the invention 
comprises a polynucleotide sequence containing the nucleo-
tides from about position 1420 to about position 1580 o f  a 
cytochrome P450 coding sequence disclosed herein and a 
sequence that is fully or partially complementary thereto. In 
some o f  these embodiments, the inhibitory sequence com-
be combined with constitutive, tissue-preferred, or other 
promoters for expression in plants. 
A n  expression cassette o f  the present invention may also 
35 contain at least one additional gene to be cotransformed into 
the plant. Alternatively, the additional gene(s) can be pro-
vided on multiple expression cassettes. Such an expression 
cassette is provided with a plurality o f  restriction sites and/or 
recombination sites for insertion o f  the cytochrome P450 
40 inhibitory polynucleotide sequence to be under the transcrip-
tional regulation of the regulatory regions. The expression 
cassette may additionally contain selectable marker genes. 
In this manner, an expression cassette of the present 
invention includes a transcriptional and translational initia-
45 tion region (i.e., a promoter) in the 5'-3' direction of tran-
scription, an inhibitory sequence as described elsewhere 
herein, and a transcriptional and translational termination 
region (i.e., termination region) functional in a plant cell. 
The regulatory regions (i.e., promoters, transcriptional regu-
50 latory regions, and translational termination regions) and/or 
the inhibitory sequence o f  the invention may be native/ 
analogous to the host cell or to each other. Alternatively, the 
regulatory regions and/or the inhibitory sequence o f  the 
invention may be heterologous to the host cell or to each 
55 other. While heterologous promoters can be used to express 
the inhibitory sequences of the invention, native promoter 
sequences may also be used. 
The termination region may be native with the transcrip-
tional initiation region, may be native with the operably 
60 linked inhibitory sequence o f  the invention, may be native 
with the plant host, or may be derived from another source 
(i.e., foreig n  or heterologous to the promoter, the inhibitory 
sequence o f  interest, the plant host, or any combination 
thereof). Convenient termination regions are available from 
65 the Ti-plasmid o f  A. tumefaciens, such as the octopine 
synthase and nopaline synthase termination regions. See 
also Guerineau et al. (1991) Mal. Gen. Genet. 262:141-144; 
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Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) 
Genes Dev. 5:141-149; Magen et al. (1990) Plant Cell 
2:1261-1272; Munroe et al. (1990) Gene 91:151-158; Ballas 
et al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et 
al. (1987) Nucleic Acids Res. 15:9627-9639. 
Expression cassettes of the present invention may addi-
tionally contain 5' leader sequences that can act to enhance 
translation. Translation leaders are known in the art and 
include: picornavirus leaders, for example, EMCV leader 
(Encephalomyocarditis 5' noncoding region) (Elroy-Stein et 
al. (1989) Proc. Natl. Acad. Sci. USA 86:6126-6130); poty-
virus leaders, for example, TEV leader (Tobacco Etch Virus) 
(Gallie et al. (1995) Gene 165(2):233-238), MDMV leader 
(Maize Dwarf Mosaic Virus) (Virology 154:9-20), and 
human immunoglobulin heavy-chain binding protein (BiP) 
(Macejak et al. (1991) Nature 353:90-94); untranslated 
leader from the coat protein mRNA of alfalfa mosaic virus 
(AMY RNA 4) (Jobling et al. (1987) Nature 325:622-625); 
tobacco mosaic virus leader (TMV) (Gallie et al. (1989) in 
Molecular Biology o f  RNA, ed. Cech (Liss, New York), pp. 
237-256); and maize chlorotic mottle virus leader (MCMV) 
(Lommel et al. (1991) Virology 81:382-385). See also, 
Della-Cioppa et al. (1987) Plant Physiol. 84:965-968. Other
methods known to enhance translation can also be utilized.
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Acad. Sci. USA 88:5072-5076; Wyborski et al. (1991) 
Nucleic Acids Res. 19:4647-4653; Hillenand-Wissman 
(1989) Topics Mal. Struc. Biol. 10:143-162; Degenkolb et al. 
(1991) Antimicrob. Agents Chemother. 35:1591-1595; 
5 Kleinschnidt et al. (1988) Biochemistry 27:1094-1104; 
Bonin (1993) Ph.D. Thesis, University of Heidelberg; Gos-
sen et al. (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; 
Oliva et al. (1992) Antimicrob. Agents Chemother. 36:913-
919; Hlavka et al. (1985) Handbook o f  Experimental Phar-
10 macology, Vol. 78 (Springer-Verlag, Berlin); Gill et al. 
(1988) Nature 334:721-724. Such disclosures are herein 
incorporated by reference. The above list of selectable 
marker genes is not meant to be limiting. Any selectable 
marker gene can be used in the present invention. 
15 A number of promoters can be used in the practice of the 
invention. Of particular interest are constitutive promoters, 
inducible promoters, particularly chemical-inducible pro-
moters, and tissue-preferred promoters, particularly leaf-
preferred promoters. 
20 Chemical-inducible promoters can be used to inhibit the 
expression of a cytochrome P450 that is involved in the 
metabolic conversion of nicotine to nomicotine in a plant 
through the application of an exogenous chemical regulator. 
Chemical-inducible promoters are known in the art and 
include, but are not limited to, the tobacco PR-la promoter, 
which is activated by salicylic acid. Other chemical-induc-
ible promoters of interest include steroid-responsive pro-
moters (see, for example, the glucocorticoid-inducible pro-
moter in Schena et al. (1991) Proc. Natl. Acad. Sci. USA 
In preparing the expression cassette, DNA fragments of 25 
the invention may be manipulated so as to provide for the 
DNA sequences in the proper orientation and, as appropri-
ate, in the proper reading frame. Adapters or linkers may be 
employed to join the DNA fragments or other manipulations 
may be involved to provide for convenient restriction sites, 
removal of superfluous DNA, removal of restriction sites, or 
the like. For this purpose, in vitro mutagenesis, primer 
repair, restriction, annealing, resubstitutions, e.g., transitions 
and transversions, may be involved. 
30 88:10421-10425 and McNellis et al. (1998) Plant J. 14(2): 
247-257) and tetracycline-inducible promoters (see, for
example, Gatz et al. (1991) Mal. Gen. Genet. 227:229-237,
and U.S. Pat. Nos. 5,814,618 and 5,789,156), herein incor-
porated by reference.
Constitutive promoters include, for example, the core 
promoter of the Rsyn7 promoter and other constitutive 
promoters disclosed in U.S. Pat. No. 6,072,050; the core 
CaMV 35S promoter (Odell et al. (1985) Nature 313:810-
812); ubiquitin (Christensen et al. (1989) Plant Mal. Biol. 
The expression cassettes of the present invention can also 35 
comprise a selectable marker gene for the selection of 
transformed cells. Selectable marker genes are utilized for 
the selection of transformed cells or tissues. Marker genes 
include genes encoding antibiotic resistance, such as those 
encoding neomycin phosphotransferase II (NEO) and 
hygromycin phosphotransferase (HPT), as well as genes 
conferring resistance to herbicidal compounds, such as glu-
fosinate ammonium, bromoxynil, imidazolinones, and 2,4-
dichlorophenoxyacetate (2,4-D). Additional selectable 
markers include phenotypic markers such as  -galactosidase 
and fluorescent proteins such as green fluorescent protein 
(GFP) (Rouwendal et al. (1997) Plant Mo. Biol. 33:989-999; 
40 12:619-632 and Christensen et al. (1992) Plant Mal. Biol. 
18:675-689); pEMU (Last et al. (1991) Theor. Appl. Genet. 
81:581-588); MAS (Velten et al. (1984) EMBO J. 3:2723-
2730); ALS promoter (U.S. Pat. No. 5,659,026), and the 
like. Other constitutive promoters include, for example, U.S. 
45 Pat. Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 
5,466,785; 5,399,680; 5,268,463; 5,608,142; and 6,177,611. 
Tissue-preferred promoters can be utilized to target 
expression of an inhibitory polynucleotide sequence of the 
present invention within a particular plant tissue. Tissue-
Su et al. (2004) Biotechnol Bioeng 85:610-9 and Fetter et al. 
(2004) Plant Cell 16:215-28), cyan florescent protein (CYP) 
(Bolte et al. (2004) J. Cell Science 117:943-54 and Kato et 
al. (2002) Plant Physiol 129:913-42), and yellow fluorescent 
protein (PhiYFP™ from Evrogen, see, Bolte et al. (2004) J. 
Cell Science 117:943-954). For additional selectable mark-
ers, see generally, Yarranton (1992) Curr. Opin. Biotech. 
3:506-511; Christopherson et al. (1992) Proc. Natl. Acad. 
Sci. USA 89:6314-6318; Yao et al. (1992) Cell 71:63-72; 
Reznikoff (1992) Mal. Microbial. 6:2419-2422; Barkley et 
al. (1980) in The Operon, pp. 177-220; Hu et al. (1987) Cell 
48:555-566; Brown et al. (1987) Cell 49:603-612; Figge et 
al. (1988) Cell 52:713-722; Deuschle et al. (1989) Proc. 
Natl. Acad. Aci. USA 86:5400-5404; Fuerst et al. (1989) 
Proc. Natl. Acad. Sci. USA 86:2549-2553; Deuschle et al. 
(1990) Science 248:480-483; Gossen (1993) Ph.D. Thesis, 
University of Heidelberg; Reines et al. (1993) Proc. Natl. 
Acad. Sci. USA 90:1917-1921; Labow et al. (1990) Mal. 
Cell. Biol. 10:3343-3356; Zambretti et al. (1992) Proc. Natl. 
Acad. Sci. USA 89:3952-3956; Baim et al. (1991) Proc. Natl. 
50 preferred promoters include Yamamoto et al. (1997) Plant J. 
12(2):255-265; Kawamata et al. (1997) Plant Cell Physiol. 
38(7):792-803; Hansen et al. (1997) Mal. Gen Genet. 254 
(3):337-343; Russell et al. (1997) Transgenic Res. 6(2):157-
168; Rinehart et al. (1996) Plant Physiol. 112(3): 1331-1341; 
55 Van Camp et al. (1996) Plant Physiol. 112(2):525-535; 
Canevascini et al. (1996) Plant Physiol. 112(2):513-524; 
Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; 
Lam (1994) Results Prob!. Cell Differ. 20:181-196; Orozco 
et al. (1993) Plant Mal Biol. 23(6):1129-1138; Matsuoka et 
60 al. (1993) Proc Natl. Acad. Sci. USA 90(20):9586-9590; and 
Guevara-Garcia et al. (1993) Plant J. 4(3):495-505. 
Of particular interst are leaf-preferred promoters that 
provide for expression predominately in leaf tissues. See, for 
example, Yamamoto et al. (1997) Plant J. 12(2):255-265; 
65 Kwon et al. (1994) Plant Physiol. 105:357-67; Yamamoto et 
al. (1994) Plant Cell Physiol. 35(5):773-778; Gator et al. 
(1993) Plant J. 3:509-18; Orozco et al. (1993) Plant Mal. 
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Biol. 23(6): 1129-1138; Baszczynski et al. (1988) Nucl. Acid 
Res. 16:4732; Mitra et al. (1994) Plant Molecular Biology 
26:35-93; Kayaya et al. (1995) Molecular and General 
Genetics 248:668-674; and Matsuoka et al. (1993) Proc. 
Natl. Acad. Sci. USA 90(20):9586-9590. Senecence-regu- 5 
lated promoters are also of use, such as SAM22 (Crowell et 
sion cassette comprising a polynucleotide encoding a poly-
peptide that inhibits the activity of one or more cytochrome 
P450 polypeptides of the present invention. The activity of 
a cytochrome P450 polypeptide in converting nicotine to 
nornicotine in a Nicotiana plant or plant part is inhibited 
according to the present invention if this conversion activity 
al. (1992) Plant Mal. Biol. 18:459-466); SAG 12 (Lohman et 
al. (1994) Physiol. Plant. 92:322-328; Wingler et al. (1998) 
Plant Physiol. 116:329-335); SAG 13 (Gan and Amasino 
(1997) Plant Physiol. 113:313-319; SAG15 (Gan (1995) 10 
"Molecular Characterization and Genetic Manipulation of 
Plant Senescence," Ph.D. Thesis, University of Wisconsin, 
Madison); SENl (Oh et al. (1996) Plant Mal. Biol. 30:739-
754; promoter of a senescence-specific gene for expression 
ofIPT (Gan andAmasino 91995) Science 270:1986-1988); 15 
and the like (see, for example, Or: et al. (1999) Plant Cell 
11:1073-1080 and McCabe et al. (2001) Plant Physiol. 
127:505-516). 
is statistically lower than conversion activity of the same 
cytochrome P450 polypeptide in a Nicotiana plant or plant 
part that has not been genetically modified to inhibit the 
conversion activity of that cytochrome P450 polypeptide 
and which has been cultured and harvested using the same 
protocols. In particular embodiments, activity of a 
cytochrome P450 polypeptide in converting nicotine to 
nornicotine in a modified Nicotiana plant or plant part 
according to the invention is inhibited if the activity is less 
than 95%, less than 90%, less than 80%, less than 70%, less 
than 60%, less than 50%, less than 40%, less than 30%, less 
than 20%, less than 10%, less than 5%, less than 4%, less 
than 3%, less than 2%, or less than 1 % of the conversion 
activity of the same cytochrome P450 polypeptide in a 
Nicotiana plant that that has not been genetically modified 
Methods for Inhibiting Expression or Function of a 
Cytochrome P450 Involved in the Conversion of Nicotine to 20 
Nornicotine 
Methods of reducing the concentration, content, and/or 
activity of a cytochrome P450 polypeptide of the present 
invention in a Nicotiana plant or plant part, particularly the 
leaf tissue, are provided. Many methods may be used, alone 
or in combination, to reduce or eliminate the activity of a 
cytochrome P450 polypeptide of the present invention. In 
addition, combinations of methods may be employed to 
reduce or eliminate the activity of two or more different 
cytochrome P450 polypeptides. 
In accordance with the present invention, the expression 
of a cytochrome P450 polypeptide of the present invention 
is inhibited if the protein level of the cytochrome P450 
polypeptide is statistically lower than the protein level of the 
same cytochrome P450 polypeptide in a plant that has not 
been genetically modified or mutagenized to inhibit the 
expression of that cytochrome P450 polypeptide, and where 
these plants have been cultured and harvested using the 
same protocols. In particular embodiments of the invention, 
the protein level of the cytochrome P450 polypeptide in a 
modified plant according to the invention is less than 95%, 
less than 90%, less than 80%, less than 70%, less than 60%, 
less than 50%, less than 40%, less than 30%, less than 20%, 
less than 10%, less than 5%, less than 4%, less than 3%, less 
than 2%, or less than 1 % of the protein level of the same 
cytochrome P450 polypeptide in a plant that is not a mutant 
or that has not been genetically modified to inhibit the 
expression of that cytochrome P450 polypeptide and which 
has been cultured and harvested using the same protocols. 
The expression level of the cytochrome P450 polypeptide 
may be measured directly, for example, by assaying for the 
level of the cytochrome P450 transcript or cytochrome P450 
polypeptide expressed in the Nicotiana plant or plant part, or 
indirectly, for example, by measuring the conversion of 
nicotine to nornicotine in the Nicotiana plant or plant part. 
Methods for monitoring the expression level of a protein are 
known in the art, and include, but are not limited to, 
Northern blot analysis as discussed in the examples herein 
below. Methods for determining the activity of the targeted 
cytochrome P450 polypeptide in converting nicotine to 
nornicotine are described elsewhere herein below, and 
include, but are not limited to, alkaloid analysis using gas 
chromatography, for example the procedures described in 
the examples herein below. 
In other embodiments of the invention, the activity of one 
or more cytochrome P450 polypeptides is reduced or elimi-
nated by transforming a plant or plant part with an expres-
to inhibit the expression of that cytochrome P450 polypep-
tide and wich has been cultured and harvested using the 
same protocols. The activity of a cytochrome P450 poly-
25 peptide in converting nicotine to nornicotine in a Nicotiana 
plant or plant part is eliminated according to the invention 
when it is not detectable by the assay methods described 
elsewhere herein. Methods of determining the activity of a 
cytochrome P450 polypeptide in converting nicotine to 
30 nornicotine in a Nicotiana plant or plant part are described 
elsewhere herein, and include the alkaloid analyses using 
gas chromatography disclosed in the examples herein below. 
In specific embodiments, a cytochrome P450 inhibitory 
polynucleotide sequence described herein is introduced into 
35 a Nicotiana plant or plant part. Subsequently, a Nicotiana 
plant or plant part having the introduced inhibitory poly-
nucleotide sequence of the invention is selected using meth-
ods known to those of skill in the art such as, but not limited 
to, Southern blot analysis, DNA sequencing, PCR analysis, 
40 or phenotypic analysis. A plant or plant part altered or 
modified by the foregoing embodiments is grown under 
plant forming conditions for a time sufficient to modulate the 
concentration and/or activity of polypeptides of the present 
invention in the plant. Plant forming conditions are well 
45 known in the art and discussed briefly elsewhere herein. 
In some embodiments, a transformed tobacco plant con-
taining a cytochrome P450 inhibitory polynucleotide 
sequence described herein has a reduced level of conversion 
of nicotine to nornicotine. In particular embodiments, con-
50 version of nicotine to nornicotine in a tranformed tobacco 
plant or plant part according to the invention is less than 
95%, less than 90%, less than 80% less than 70%, less than 
60%, less than 50%, less than 40%, less than 30%, less than 
20% less than 10%, less than 5%, less than 4%, less than 3%, 
55 less than 2%, or less than 1 % of the conversion in a tobacco 
plant that that has not been genetically modified to inhibit 
the expression of that cytochrome P450 polypeptide and 
which has been cultured and harvested using the same 
protocols. In some embodiments, the transformed tobacco 
60 plant is a converter tobacco plant. In some embodiments, the 
transformed tobacco plant has a conversion rate lower than 
the rate observed in commercial nonconverter tobacco 
plants. 
It is also recognized that the level and/or activity of the 
65 polypeptide may be modulated by employing a polynucle-
otide that is not capable of directing, in a transformed plant, 
the expression of a protein or an RNA. For example, the 
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polynucleotides of the invention may be used to design 
polynucleotide constructs that can be employed in methods 
for altering or mutating a genomic nucleotide sequence in an 
organism. Such polynucleotide constructs include, but are 
not limited to, RNA:DNA vectors, RNA:DNA mutational 
vectors, RNA:DNA repair vectors, mixed-duplex oligo-
nucleotides, self-complementary RNA:DNA oligonucle-
otides, and recombinogenic oligonucleobases. Such nucleo-
tide constructs and methods of use are known in the art. See, 
U.S. Pat. Nos. 5,565,350; 5,731,181; 5,756,325; 5,760,012; 10 
5,795,972; and 5,871,984; all of which are herein incor po-
rated by reference. See also, WO 98/49350, WO 99/07865, 
WO 99/25821, and Beetham et al. (1999) Proc. Natl. Acad. 
Sci. USA 96:8774-8778; herein incor porated by reference. 
It is therefore recognized that methods of the present 15 
invention do not depend on the incor poration of the entire 
cytochrome P450 inhibitory polynucleotide into the 
genome, only that the Nicotiana plant or plant part thereof 
is altered as a result of the introduction of this inhibitory 
polynucleotide into a cell. In one embodiment of the inven- 20 
tion, the genome may be altered following the introduction 
of the cytochrome P450 inhibitory polynucleotide into a 
cell. For example, the inhibitory polynucleotide, or any part 
thereof, may incor porate into the genome of the plant. 
Alterations to the genome include, but are not limited to, 25 
additions, deletions, and substitutions of nucleotides into the 
genome. While the methods of the present invention do not 
depend on additions, deletions, and substitutions of any 
particular number of nucleotides, it is recognized that such 
additions, deletions, or substitutions comprise at least one 30 
nucleotide. 
It is further recognized that reducing the level and/or 
activity of a cytochrome P450 sequence of the present 
invention can be performed to elicit the effects of the 
sequence only during certain developmental stages and to 35 
switch the effect off in other stages where expression is no 
longer desirable. Control of cytochrome P450 expression 
can be obtained via the use of inducible or tissue-preferred 
promoters. Alternatively, the gene could be inverted or 
deleted using site-specific recombinases, transposons or 40 
recombination systems, which would also turn on or off 
expression of the cytochrome P450 sequence. 
According to the present invention, changes in levels, 
ratios, activity, or distribution of cytochrome P450 polypep-
tides of the present invention, or changes in Nicotiana plant 45 
or plant part phenotype, particularly reduced accumulation 
of nornicotine and its carcinogenic metabolite, NNN, could 
be measured by comparing a subject plant or plant part to a 
control plant or plant part, where the subject plant or plant 
part and the control plant or plant part have been cultured 50 
and/or harvested using the same protocols. As used herein, 
a subject plant or plant part is one in which genetic altera-
tion, such as transformation, has been affected as to the 
cytochrome P450 polypeptide of interest, or is a Nicotiana 
plant or plant part that is descended from a Nicotiana plant 55 
or plant part so altered and which comprises the alteration. 
A control plant or plant part provides a reference point for 
measuring changes in phenotype of the subject plant or plant 
part. 
The measurement of changes in phenotype can be mea- 60 
sured at any time in a plant or plant part, including during 
plant development, senescence, or after curing. In other 
embodiments, the measurement of changes in phenotype can 
be measured in plants grown under any conditions, includ-
ing from plants grown in a growth chamber, greenhouse, or 65 
in a field. In one embodiment, changes in phenotype can be 
measured by determining the nicotine to nornicotine con-
28 
version rate. In a preferred embodiment, conversion can be 
measured by dividing the percentage of nornicotine (as a 
percentage of the total tissue weight) by the sum of the 
percentage nicotine and nornicotine (as percentages of the 
total tissue weight) and multiplying by 100. 
According to the present invention, a control plant or 
plant part may comprise a wild-type Nicotiana plant or plant 
part, i.e., of the same genotype as the starting material for the 
genetic alteration that resulted in the subject plant or plant 
part. A control plant or plant part may also comprise a 
Nicotiana plant or plant part of the same genotype as the 
starting material but that has been transformed with a null 
construct (i.e., with a construct that has no known effect on 
the trait of interest, such as a construct comprising a select-
able marker gene). Alternatively, a control plant or plant part 
may comprise a Nicotiana plant or plant part that is a 
non-transformed segregant among progeny of a subject plant 
or plant part, or a Nicotiana plant or plant part genetically 
identical to the subject plant or plant part but that is not 
exposed to conditions or stimuli that would induce suppres-
sion of the cytochrome P450 gene of interest. Finally, a 
control plant or plant part may comprise the subject plant or 
plant part itself under conditions in which the cytochrome 
P450 inhibitory sequence is not expressed. In all such cases, 
the subject plant or plant part and the control plant or plant 
part are cultured and harvested using the same protocols. 
As described elsewhere herein, methods are provided to 
reduce or eliminate the activity and/or concentration of a 
cytochrome P450 polypeptide of the present invention by 
introducing into a Nicotiana plant or plant part a cytochrome 
P450 inhibitory polynucleotide sequence that is capable of 
inhibiting expression or function of a cytochrome P450 
polypeptide that is involved in the metabolic conversion of 
nicotine to nornicotine. In some embodiments, the inhibitory 
sequence is introduced by transformation of the plant or 
plant part, such as a plant cell, with an expression cassette 
that expresses a polynucleotide that inhibits the expression 
of the cytochrome P450 polypeptide. The polynucleotide 
may inhibit the expression of a cytochrome P450 polypep-
tide directly, by preventing translation of the cytochrome 
P450 polypeptide messenger RNA, or indirectly, by encod-
ing a polypeptide that inhibits the transcription or translation 
of an cytochrome P450 polypeptide gene encoding a 
cytochrome P450 polypeptide. Methods for inhibiting or 
eliminating the expression of a gene product in a plant are 
well known in the art, and any such method may be used in 
the present invention to inhibit the expression of cytochrome 
P450 polypeptides. 
In other embodiments, the activity of a cytochrome P450 
polypeptide of the present invention may be reduced or 
eliminated by disrupting the gene encoding the cytochrome 
P450 polypeptide. The invention encompasses mutagenized 
plants that carry mutations in cytochrome P450 genes, 
where the mutations reduce expression of the cytochrome 
P450 gene or inhibit the activity of an encoded cytochrome 
P450 polypeptide of the present invention. 
In some embodiments of the present invention, a Nicoti-
ana plant or plant part is transformed with an expression 
cassette that is capable of expressing a polynucleotide that 
inhibits the expression of a cytochrome P450 sequence. 
Such methods may include the use of sense suppression/ 
cosuppression, antisense suppression, double-stranded RNA 
( dsRNA) interference, hair p in RNA interference and intron-
containing hair p in RNA interference, amplicon-mediated 
interference, ribozymes, and small interfering RNA or micro 
RNA. 
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For cosuppression, an expression cassette is desig n ed to complement o f  both the coding sequence and the untrans-
express an R N A  molecule corresponding to all or part of a lated regions o f  a transcript encoding the cytochrome P450 
messenger R N A  encoding a cytochrome P450 polypeptide polypeptide. In addition, the antisense polynucleotide may 
o f  interest (for example, a cytochrome P450 polypeptide be fully complementary (i.e., 100% identical to the comple-
comprising the sequence set forth in SEQ ID N0:2, 4, 6, 8, 5 ment o f  the target sequence) or partially complementary 
10, or 12 or a sequence having substantial sequence identity (i.e., less than 100% identical to the complement of the 
to SEQ ID N0:2, 4, 6, 8, 10, or 12) in the "sense" target sequence) to the target sequence. Antisense suppres-
orientation. Over expression o f  the R N A  molecule can result sion may be used to inhibit the expression o f  multiple 
in reduced expression o f  the native gene. Multiple plant lines proteins in the same plant ( e.g., U.S.  Pat. No. 5,942,657). 
transformed with the cosuppression expression cassette are 10 Furthermore, portions o f  the antisense nucleotides may be 
then screened to identify those that show the greatest inhi- used to disrupt the expression o f  the target gene. Generally, 
bition o f  cytochrome P450 polypeptide expression. sequences o f  at least 50 nucleotides, 100 nucleotides, 200 
The polynucleotide used for co suppression may corre- nucleotides, 300, 400, 450, 500, 550, or greater may be used. 
spond to all or part of the sequence encoding a cytochrome Methods for using anti sense suppression to inhibit the 
P450 polypeptide or the present invention, all or part o f  the 15 expression o f  endogenous genes in plants are described, for 
5' and/or 3' untranslated region o f  a cytochrome P450 example, in Liu et al (2002) Plant Physiol. 129:1732-1743 
polypeptide transcript, or all or part o f  both the coding and U.S.  Pat. Nos. 5,759,829 and 5,942,657, each of which 
sequence and the untranslated regions o f  a transcript encod- is herein incorporated by reference. Efficiency of antisense 
ing a cytochrome P450 polypeptide. In some embodiments suppression may be increased by including a poly-dT region 
where the polynucleotide comprises all or part o f  the coding 20 in the expression cassette at a position 3' to the antisense 
region for a cytochrome P450 polypeptide of the present sequence and 5' o f  the polyadenylation sig n al. See, U.S.  
invention, the expression cassette is designed to eliminate Patent Publication No. 20020048814, herein incorporated 
the start codon of the polynucleotide so that no protein by reference. 
product will be transcribed. For dsRNA interference, a sense R N A  molecule like that 
Cosuppression may be used to inhibit the expression o f  25 described above for cosuppression and an antisense R N A  
plant genes to produce plants having undetectable protein molecule that is fully or partially complementary to the 
levels for the proteins encoded by these genes or may also sense R N A  molecule are expressed in the same cell, result-
be used to inhibit the expression o f  multiple proteins in the ing in inhibition o f  the expression o f  the corresponding 
same plant (e.g., Brain et al. (2002) Plant Cell 14:1417- endogenous messenger RNA.  
1432; U.S.  Pat. No. 5,942,657). Methods for using cosup- 30 Expression o f  the sense and antisense molecules can be 
pression to inhibit the expression o f  endogenous genes in accomplished by desig n ing the expression cassette to com-
plants are described in Flavell et al. (1994) Proc. Natl. Acad. prise both a sense sequence and an antisense sequence for 
Sci. USA 91:3490-3496; Jorgensen et al. (1996) Plant Mal. the target cytochrome P450 sequence. Alternatively, sepa-
Biol. 31:957-973; Johansen and Carrington (2001) Plant rate expression cassettes may be used for the sense and 
Physiol. 126:930-938; Brain et al. (2002) Plant Cell 35 antisense sequences. Multiple plant lines transformed with 
14:1417-1432; Stoutjesdijk et al (2002) Plant Physiol. 129: the dsRNA interference expression cassette or expression 
1723-1731; Yu et al. (2003) Phytochemistry 63:753-763; and cassettes are then screened to identify plant lines that show 
U.S.  Pat. Nos. 5,034,323, 5,283,184, and 5,942,657; each o f  the greatest inhibition o f  expression of the targeted 
which is herein incorporated by reference. The efficiency o f  cytochrome P450 polypeptide. Methods for using dsRNA 
cosuppression may be increased by including a poly-dT 40 interference to inhibit the expression o f  endogenous plant 
region in the expression cassette at a position 3' to the sense genes are described in Waterhouse et al. (1998) Proc. Natl. 
sequence and 5' o f  the polyadenylation signal. See, U.S.  Acad. Sci. USA 95:13959-13964, Liu et al. (2002) Plant 
Patent Publication No. 20020048814, herein incorporated Physiol. 129:1732-1743, and W O  99/49029, W O  99/53050, 
by reference. Typically, such a nucleotide sequence has W O  99/61631, and W O  00/49035; each o f  which is herein 
substantial sequence identity to the sequence o f  the tran- 45 incorporated by reference. 
script o f  the endogenous gene, optimally greater than about Amplicon expression cassettes comprise a plant virus-
65% sequence identity, more optimally greater than about derived sequence that contains all or part o f  the target gene 
85% sequence identity, most optimally greater than about but generally not all o f  the genes o f  the native virus. The 
95% sequence identity (e.g., U.S.  Pat. Nos. 5,283,184 and viral sequences present in the transcription product o f  the 
5,034,323; herein incorporated by reference). 50 expression cassette allow the transcription product to direct 
In some embodiments o f  the invention, inhibition o f  the its own replication. The transcripts produced by the ampli-
expression o f  the cytochrome P450 polypeptide o f  the con may be either sense or antisense relative to the target 
present invention may be obtained by antisense suppression. sequence (i.e., the messenger R N A  for a cytochrome P450 
For antisense suppression, the expression cassette is polypeptide that is involved in the metabolic conversion o f  
designed to express an R N A  molecule complementary to all 55 nicotine to nornicotine ). Methods o f  using amp Ii cons to 
or part o f  a messenger R N A  encoding the cytochrome P450 inhibit the expression o f  endogenous plant genes are 
polypeptide. Over expression of the antisense R N A  mo!- described, for example, in Angell and Baulcombe (1997) 
ecule can result in reduced expression o f  the native gene. EMBO J. 16:3675-3684, Angell and Baulcombe (1999) 
Accordingly, multiple plant lines transformed with the anti- Plant J. 20:357-362, and U.S.  Pat. No. 6,646,805, each o f  
sense suppression expression cassette are screened to iden- 60 which is herein incorporated by reference. 
tify those that show the greatest inhibition o f  cytochrome In additional embodiments o f  the present invention, the 
P450 polypeptide expression. polynucleotide expressed by the expression cassette o f  the 
The polynucleotide for use in antisense suppression may invention is catalytic R N A  or has ribozyme activity specific 
correspond to all or part o f  the complement o f  the sequence for the messenger R N A  o f  a cytochrome P450 polypeptide 
encoding the cytochrome P450 polypeptide, all or part o f  the 65 described herein. Thus, the polynucleotide causes the deg-
complement o f  the 5' and/or 3' untranslated region o f  the radation of the endogenous messenger RNA,  resulting in 
cytochrome P450 polypeptide transcript, or all or part o f  the reduced expression o f  the cytochrome P450 polypeptide. 
US 9,913,451 B2 
31 
This method is described, for example, in U.S. Pat. No. 
4,987,071, herein incor porated by reference. 
In further embodiments of the invention, inhibition of the 
expression of one or more cytochrome P450 polypeptides 
may be obtained by RNA interference (RN Ai) by expression 5 
of a gene encoding a micro RNA (miRNA). miRNAs are 
regulatory agents consisting of about 22 ribonucleotides. 
miRNA are highly efficient at inhibiting the expression of 
endogenous genes. See, for example Javier et al. (2003) 
Nature 425: 257-263, herein inco r porated by reference. 
10 
For miRNA interference, the expression cassette is 
designed to express an RNA molecule that is modeled on an 
endogenous miRNA gene. The miRNA gene encodes an 
RNA that forms a hair pin structure containing a 22-nucleo- 15 
tide sequence that is complementary to another endogenous 
gene (target sequence). For suppression of cytochrome P450 
polypeptide expression, the 22-nucleotide sequence is 
selected from a cytochrome P450 polypeptide transcript 
sequence and contains 22 nucleotides encoding this 20 
cytochrome P450 polypeptide sequence in sense orientation 
and 21 nucleotides of a corresponding antisense sequence 
that is complementary to the sense sequence. miRNA mol-
ecules are highly efficient at inhibiting the expression of 
endogenous genes, and the RNA interference they induce is 25 
inherited by subsequent generations of plants. 
In still other embodiments of the invention, inhibition of 
the expression of one or more cytochrome P450 polypep-
tides by RNAi may be obtained by hair pin RNA (hpRNA) 
interference or intron-containing hair pin RNA (ihpRNA) 30 
interference. These methods are highly efficient at inhibiting 
the expression of endogenous genes. See, Waterhouse and 
Helliwell (2003) Nat. Rev. Genet. 4:29-38 and the references 
cited therein. 
32 
For ihpRNA, the interfering molecules have the same 
general structure as for hpRNA, but the RNA molecule 
additionally comprises an intron that is capable of being 
spliced in the cell in which the ihpRNA is expressed. The use 
of an intron minimizes the size of the loop in the hair pin 
RNA molecule following splicing, and this increases the 
efficiency of interference. See, for example, Smith et al. 
(2000) Nature 407:319-320. In fact, Smith et al. show 100% 
suppression of endogenous gene expression using ihpRNA-
mediated interference. Methods for using ihpRNA interfer-
ence to inhibit the expression of endogenous plant genes are 
described, for example, in Smith et al. (2000) Nature 407: 
319-320; Wesley et al. (2001) Plant J. 27:581-590; Wang 
and Waterhouse (2001) Curr. Opin. Plant Biol. 5:146-150; 
Waterhouse and Helliwell (2003) Nat. Rev. Genet. 4:29-38; 
Helliwell and Waterhouse (2003) Methods 30:289-295, and 
U.S. Patent Publication No. 20030180945, each of which is 
herein incor porated by reference. 
In one such embodiment, RNAi is accomplished by 
expressing an inhibitory sequence that comprises a first 
sequence ofa cytochrome P450 polynucleotide of the inven-
tion that is about 90 bp to about 110 bp in length, including 
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 
104, 105, 106, 107, 108, 109, and 110 bp in length, and a 
second sequence that is complementary to all or a part of the 
first sequence. In another such embodiment, the inhibitory 
sequence comprises a first sequence of a cytochrome P450 
polynucleotide of the invention that is about 290 to about 
310 bp in length, including 290, 291, 292, 293, 294, 295, 
296, 297,298, 299, 300,301, 302, 303,304,305, 306,307, 
308, 309, and 310 bp in length, and a second sequence that 
is complementary to all or a part of the fragment sequence. 
In other embodiments of the invention, RNAi is accom-
plished by expressing an inhibitory sequence that comprises 
For hpRNA interference, the expression cassette is 
designed to express an RNA molecule that hybridizes with 
itself to form a hair pin structure that comprises a single-
stranded loop region and a base-paired stem. The base-
paired stem region comprises a sense sequence correspond-
ing to all or part of the endogenous messenger RNA 
encoding the gene product whose expression is to be inhib-
ited, in this case, a cytochrome P450 polypeptide described 
herein, and an antisense sequence that is fully or partially 
complementary to the sense sequence. Alternatively, the 
base-paired stem region may correspond to a portion of a 
promoter sequence controlling expression of the gene 
encoding the cytochrome P450 polypeptide to be inhibited. 
Thus, the base-paired stem region of the molecule generally 
determines the specificity of the RNA interference. hpRNA 
molecules are highly efficient at inhibiting the expression of 
endogenous genes, and the RNA interference they induce is 
inherited by subsequent generations of plants. See, for 
example, Chuang and Meyerowitz (2000) Proc. Natl. Acad. 
Sci. USA 97:4985-4990; Stoutjesdijk et al. (2002) Plant 
Physiol. 129:1723-1731; and Waterhouse and Helliwell 
(2003) Nat. Rev. Genet. 4:29-38. Methods for using hpRNA 
interference to inhibit or silence the expression of genes are 
described, for example, in Chuang and Meyerowitz (2000) 
Proc. Natl. Acad. Sci. USA 97:4985-4990; Stoutjesdijk et al. 
(2002) Plant Physiol. 129: 1723-1731; Waterhouse and 
Helliwell (2003) Nat. Rev. Genet. 4:29-38; Pandolfini et al. 
BMC Biotechnology 3:7, and U.S. Patent Publication No. 
20030175965; each of which is herein incor porated by 
reference. A transient assay for the efficiency of hpRNA 
constructs to silence gene expression in vivo has been 
described by Panstruga et al. (2003) Mal. Biol. Rep. 30: 135-
140, herein incor porated by reference. 
35 a first polynucleotide sequence containing the nucleotides 
from about position 265 to about position 625 of a 
cytochrome P450 coding sequence disclosed herein and a 
second sequence that is fully or partially complementary 
thereto. In some of these embodiments, the inhibitory 
40 sequence comprises as the first polynucleotide sequence the 
nucleotides corresponding to about position 297 to about 
position 594 of the P450 coding sequence set forth in SEQ 
ID N0:3 or SEQ ID N0:5 and the second sequence is the 
complement (i.e., antisense sequence) of this first sequence. 
45 The inhibitory sequence can optionally comprise an intron 
sequence linked between the first and second sequences. 
Any intron known to those of skill in the art can be used in 
this manner. In some embodiments, the intron is from the 
soybean omega-6 fatty acid desaturase (FAD) (see GenBank 
50 Accession No. DQ672337, and Example 7 herein below). In 
one such embodiment, the intron comprises about 151 
nucleotides that comprise nucleotides 100-247 of the soy-
bean omega-6 fatty acid desaturase polynucleotide shown in 
GenBankk Accession No. DQ672337. Examples of other 
55 intrans include, but are not limited to, the intron nucleotide 
sequences of alcohol dehydrogenase (adhl) genes. Expres-
sion of this inhibitory sequence produces an intron-contain-
ing hair pin RNA that strongly interferes with expression of 
the cytochrome P450 polypeptides disclosed herein. In this 
60 manner, Nicotiana plants that are normally converters of 
nicotine to nomicotine that are transformed with an expres-
sion cassette comprising such an inhibitory sequence advan-
tageously have a nicotine to nornicotine conversion rate that, 
surprisingly, is even lower than that observed for Nicotiana 
65 plants that are nonconverters of nicotine to nomicotine. 
In yet other embodiments of the invention, RNAi is 
accomplished by expressing an inhibitory sequence that 
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comprises a first polynucleotide sequence containing the 
nucleotides from about position 1420 to about position 1580 
of a cytochrome P450 coding sequence disclosed herein and 
a sequence that is fully or partially complementary thereto. 
In some of these embodiments, the inhibitory sequence 5 
comprises as the first polynucleotide sequence the nucleo-
tides corresponding to about position 1453 to about position 
1551 of the P450 coding sequence set forth in SEQ ID NO: 1 
and the second sequence is the complement (i.e., antisense 
sequence) of this first sequence. The inhibitory sequence can 10 
optionally comprise an intron sequence linked between the 
first and second sequences. Any intron known to those of 
skill in the art can be used in this manner, as noted herein 
above. Expression of this inhibitory sequence produces a 
hair pin RNA (or intron-containing hair pin RNA when the 15 
intron is present) that also interferes with expression of the 
cytochrome P450 polypeptides disclosed herein. 
The expression cassette for hpRNA interference may also 
be designed such that the sense sequence and the antisense 
sequence do not correspond to an endogenous RNA. In this 20 
embodiment, the sense and antisense sequence flank a loop 
sequence that comprises a nucleotide sequence correspond-
ing to all or part of the endogenous messenger RNA of the 
target gene. Thus, it is the loop region that determines the 
specificity of the RNA interference. See, for example, WO 25 
02/00904, herein incor porated by reference. 
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plants using random or targeted mutagenesis and selecting 
for plants that have reduced cytochrome P450 activity. 
Transposon tagging may be used to reduce or eliminate 
the activity of one or more cytochrome P450 polypeptides of 
the present invention. Transposon tagging comprises insert-
ing a transposon within an endogenous cytochrome P450 
gene to reduce or eliminate expression of the cytochrome 
P450 polypeptide. 
In this embodiment, the expression of one or more 
cytochrome P450 polypeptides is reduced or eliminated by 
inserting a transposon within a regulatory region or coding 
region of the gene encoding the cytochrome P450 polypep-
tide. A transposon that is within an exon, intron, 5' or 3' 
untranslated sequence, a promoter, or any other regulatory 
sequence of a cytochrome P450 polypeptide gene may be 
used to reduce or eliminate the expression and/or activity of 
the encoded cytochrome P450 polypeptide. 
Methods for the transposon tagging of specific genes in 
plants are well known in the art. See, for example, Maes et 
al. (1999) Trends Plant Sci. 4:90-96; Dharmapuri and Santi 
(1999) FEMS Microbial. Lett. 179:53-59; Meissner et al. 
(2000) Plant J. 22:265-274; Phogat et al. (2000) J. Biosci. 
25:57-63; Walbot (2000) Curr. Opin. Plant Biol. 2:103-107; 
Gai et al. (2000) Nucleic Acids Res. 28:94-96; Fitzmaurice 
et al. (1999) Genetics 153:1919-1928). 
Additional methods for decreasing or eliminating the 
expression of endogenous genes in plants are also known in 
the art and can be similarly applied to the instant invention. 
These methods include other forms of mutagenesis, such as 
ethyl methanesulfonate-induced mutagenesis, deletion 
mutagenesis, and fast neutron deletion mutagenesis used in 
a reverse genetics sense (with PCR) to identify plant lines in 
which the endogenous gene has been deleted. For examples 
of these methods see Ohshima et al. (1998) Virology 243: 
Transcriptional gene silencing (TGS) may be accom-
plished through use of hpRNA constructs wherein the 
inverted repeat of the hair pin shares sequence identity with 
the promoter region of a gene to be silenced. Processing of 30 
the hpRNA into short RNAs that can interact with the 
homologous promoter region may trigger degradation or 
methylation to result in silencing (Aufsatz et al. (2002) Proc. 
Natl. Acad. Sci. 99 (Suppl. 4):16499-16506; Mette et al. 
(2000) EMBO J. 19(19):5194-5201). 
In further embodiments, a polynucleotide may be utilized 
that encodes a zinc finger protein that binds to a gene 
encoding a cytochrome P450 polypeptide, resulting in 
reduced expression of the gene. In particular embodiments, 
the zinc finger protein binds to a regulatory region of a 40 
cytochrome P450 polypeptide gene. In other embodiments, 
the zinc finger protein binds to a messenger RNA encoding 
35 472-481; Okuhara et al. (1994) Genetics 137:867-874; and 
Quesada et al. (2000) Genetics 154:421-436; each of which 
is herein incor porated by reference. In addition, a fast and 
automatable method for screening for chemically induced 
a cytochrome P450 polypeptide and prevents its translation. 
Methods of selecting sites for targeting by zinc finger 
proteins have been described, for example, in U.S. Pat. No. 45 
6,453,242, and methods for using zinc finger proteins to 
inhibit the expression of genes in plants are described, for 
example, in U.S. Patent Publication No. 20030037355; each 
of which is herein incor porated by reference. 
In other embodiments of the invention, the polynucleotide 50 
encodes an antibody that binds to at least one cytochrome 
P450 polypeptide, and reduces the activity of a cytochrome 
P450 polypeptide of the present invention. In another 
embodiment, the binding of the antibody results in increased 
turnover of the antibody-cytochrome P450 polypeptide 55 
complex by cellular quality control mechanisms. The 
expression of antibodies in plant parts and the inhibition of 
molecular pathways by expression and binding of antibodies 
to proteins in plant parts are well known in the art. See, for 
example, Conrad and Sonnewald (2003) Nature Biotech. 60 
21:35-36, incor porated herein by reference. 
In other embodiments, the activity of a cytochrome P450 
polypeptide of the present invention is reduced or eliminated 
by disrupting the gene encoding the cytochrome P450 
polypeptide. The gene encoding the cytochrome P450 poly- 65 
peptide may be disrupted by any method known in the art, 
for example, by transposon tagging or by mutagenizing 
mutations, TILLING (Targeting Induced Local Lesions In 
Genomes), using denaturing HPLC or selective endonu-
clease digestion of selected PCR products is also applicable 
to the instant invention. See McCallum et al. (2000) Nat. 
Biotechnol. 18:455-457, herein incor porated by reference. 
Mutations that impact gene expression or that interfere 
with the function of the encoded cytochrome P450 protein 
can be determined using methods that are well known in the 
art. Insertional mutations in gene exons usually result in 
null-mutants. Mutations in conserved residues can be par-
ticularly effective in inhibiting the metabolic function of the 
encoded protein. Conserved residues of plant cytochrome 
P450 polypeptides suitable for mutagenesis with the goal to 
eliminate activity of a cytochrome P450 polypeptide in 
converting nicotine to nornicotine in a Nicotiana plant or 
plant part have been described (See, for example, FIGS. 3 
and 4). Such mutants can be isolated according to well-
known procedures. 
In another embodiment of this invention, dominant 
mutants can be used to trigger RNA silencing due to gene 
inversion and recombination of a duplicated gene locus. See, 
for example, Kusaba et al. (2003) Plant Cell 15:1455-1467. 
While a number of sequences are recognized in the 
practice of the invention, in particular SEQ ID N0:3 and 
SEQ ID N0:5 find particular use. While not bound by any 
particular mechanisms of action, it is believed that these 
sequences encode a nicotine demethylase that catalyzes the 
oxidative N-demethylation of nicotine to nornicotine. Thus, 
methods to specifically inhibit these coding sequences and 
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not other P450 sequences may be beneficial to the recom-
binant plant. That is, strategies that would lead to inhibition 
of gene function of this individual locus may prove to be 
superior to those that inhibit the entire gene family. The 
P450 enzymes are involved in many mechanisms in the 5 
plant, the inhibition of which may prove deleterious or 
detrimental to the growth and development of the plant or 
may negatively impact factors such as the disease defense 
capabilities of the plant. Likewise, because the Nicotiana 
plant P450 enzymes have been implicated in plant metabo- 10 
lites such as phenylpropanoid, alkaloids, terpenoids, lipids, 
cyanogenic glycosides, glucosinolates, and a host of other 
chemical entities, disruption of p450 activity may alter 
components involved in tobacco flavor, texture, or other 
properties that would impact the commercial usefulness of 15 
the plant. Therefore, the use of the methods discussed above 
to inhibit expression in a manner that specifically targets the 
coding sequence of SEQ ID N0:3 or SEQ ID N0:5 may be 
preferred, including targeted mutational strategies, such as 
chimeraplasty. See, for example, Stewart et al. (2000) Bio- 20 
techniques 29( 4): 838-843; Graham et al. (2002) Biochim 
Biophys Acta 1587(1):1-6, herein incorporated by reference. 
The protein encoded by the cDNAdesig nated 3D_Cl2-10 
(SEQ ID N0:4) differs from 3D_Cl2-7 (SEQ ID N0:6) at 
only two amino acid residues immediately following the 25 
start methionine. The codons corresponding to these amino 
acids were contained within the PCR primer used to gener-
36 
the sequence alig n m ent shown in FIG. 3A-3G was used to 
design PCR primers in regions possessing polymorphisms 
among the members. One primer combination (5' primer 
shown in SEQ ID N0:25 and 3' primer shown in SEQ ID 
N0:26) using sequences specific to 3D_Cl2-10 yields two 
particularly useful results: (1) all PCR products amplified 
from tobacco genomic DNA gave that same unique product 
(as determined by DNA sequence analysis); and (2) the 
presence of a 992 bp intron was revealed that is located 
between the primer sequences (FIG. 7; intron shown in SEQ 
ID N0:24). 
When any cDNA corresponding to a member of the 
3D_C12 family is used as a hybridization probe in a South-
ern blotting assay of tobacco genomic DNA, a complex 
pattern is observed. This is expected, given that there are 
multiple, closely related members of this gene family. 
Because the intron regions of genes are typically less 
conserved than exons, it is predicted that the use of an 
intron-specific probe would reduce this complexity and 
better enable one to distinguish the gene(s) corresponding to 
the 3D_Cl2-7/3D_C12-10 gene from the other members of 
the family. Indeed, the probe corresponding to the sequence 
shown in FIG. 7 resulted in a Southern blotting pattern with 
greatly reduced complexity. The use of a 3D_Cl2-10 intron-
specific probe, and/or the PCR primers used to generate the 
fragment shown in FIG. 7, therefore provide powerful tools 
in assays to determine whether any naturally occurring, or 
mutagenized, tobacco plants possess deletions or rearrange-
ments that may render the gene inactive. Such a plant can 
then be used in breeding programs to create tobacco lines 
that are incapable of converting. 
Transformed Plants, Plant Parts, and Products Having 
Reduced Nornicotine and NNN Content 
The cytochrome P450 polynucleotides of the invention, 
ate the 3D_Cl2-7 cDNA. Thus, the original mRNA template 
from which 3D_Cl2-7 was amplified may be the same as 
that corresponding to the 3D_Cl2-10 gene, with the PCR 30 
primer sequences mediating the changes observed in the 
second and third amino acid sequence. Regardless, the 
encoded protein products would function identically. The 
location of the two amino acids that differ between the 
predicted proteins is in the N-terminal sig nal sequence that 
merely serves to anchor the protein to the endoplasmic 
reticulum membrane and therefore would not be expected to 
influence the catalytic properties of the enzyme. 
35 and variants and fragments thereof, can be used in the 
methods of the present invention to inhibit expression or 
function of cytochrome P450s that are involved in the 
metabolic conversion of nicotine to nornicotine in a plant. In 
this manner, inhibitory sequences that target expression or In another embodiment of the invention, the compositions 
of the invention find use in screening methods to identify 
nonconverter plants for use in breeding programs. In this 
manner, the nucleotide sequences of the invention can be 
used to screen native germplasms for nonconverter plants 
having a stable mutation in one or more p450 genes iden-
tified herein. These nonconverter plants identified by the 
methods of the invention can be used to develop breeding 
lines. 
40 function of a cytochrome P450 polypeptide disclosed herein 
are introduced into a plant or plant cell of interest. In some 
embodiments the expression cassettes described herein are 
introduced into a plant of interest, for example, a Nicotiana 
plant as noted herein below, using any suitable transforma-
45 tion methods known in the art including those described 
herein. 
The methods of the invention do not depend on a par-
ticular method for introducing a sequence into a plant or 
plant part, only that the desired sequence gains access to the 
In addition to the nucleotide sequences encoding P450 
coding sequences, compositions of the invention include an 
intron sequence in the 3D_Cl2-10 sequence that can be used 
in screening methods. While not bound by any mechanism 
50 interior of at least one cell of the plant or plant part. Methods 
for introducing polynucleotide sequences into plants are 
known in the art and include, but are not limited to, stable 
transformation methods, transient transformation methods, 
and virus-mediated methods. 
of action, the 3D_Cl2-7/3D_C12-10 gene(s) may represent 
the only member(s) of the 3D_C12 family involved in the 
metabolic conversion of nicotine to nornicotine (and as 
stated previously there is a good likelihood that the 55 
3D_Cl2-7 and 3D_Cl2-10 cDNAs originated from a single 
unique genetic locus). For certain applications it would be 
useful to have a means of diagnostically differentiating this 
specific member of the 3D_C12 gene family from the rest of 
the closely related sequences within this family. For 60 
example, it is possible that within the naturally existing 
tobacco germplasm (or in mutagenized populations), acces-
sions may exist in which this gene is naturally dysfunctional 
and may therefore may be valuable as a permanently non-
converter resource. A method to specifically assay for such 65 
genotypes (e.g. deletion mutants, rearrangements, and the 
like) could serve as a powerful tool. To obtain such a tool, 
Transformation protocols as well as protocols for intro-
ducing heterologous polynucleotide sequences into plants 
vary depending on the type of plant or plant cell targeted for 
transformation. Suitable methods of introducing polynucle-
otides into plant cells of the present invention include 
microinjection (Crossway et al. (1986) Biotechniques 4:320-
334), electroporation (Shillito et al. (1987) Meth. Enzymol. 
153:313-336; Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 
83:5602-5606), Agrobacterium-mediated transformation 
(U.S. Pat. Nos. 5,104,310, 5,149,645, 5,177,010, 5,231,019, 
5,463,174, 5,464,763, 5,469,976, 4,762,785, 5,004,863, 
5,159,135, 5,563,055, and 5,981,840), direct gene transfer 
(Paszkowski et al. (1984) EMBO J. 3:2717-2722), and 
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ballistic particle acceleration (see, for example, U.S. Pat. 
Nos. 4,945,050, 5,141,131, 5,886,244, 5,879,918, and 
5,932,782; Tomes et al. (1995) in Plant Cell, Tissue, and 
Organ Culture: Fundamental Methods, ed. Gamborg and 
Phillips (Springer-Verlag, Berlin); McCabe et al. (1988) 
Biotechnology 6:923-926). Also see Weissinger et al. (1988) 
Ann. Rev. Genet. 22:421-477; Christou et al. (1988) Plant 
Physiol. 87:671-674 (soybean); McCabe et al. (1988) Biol 
Technology 6:923-926 (soybean); Finer and McMullen 
(1991) In Vitro Cell Dev. Biol. 27P:175-182 (soybean); 10 
Singh et al. (1998) Theor. Appl. Genet. 96:319-324 (soy-
bean); De Wet et al. (1985) in The Experimental Manipu-
lation o f  Ovule Tissues, ed. Chapman et al. (Longman, New 
York), pp. 197-209 (pollen); Kaeppler et al. (1990) Plant 15 
Cell Reports 9:415-418 and Kaeppler et al. (1992) Theor. 
Appl. Genet. 84:560-566 (whisker-mediated transforma-
tion); D'Halluin et al. (1992) Plant Cell 4:1495-1505 (elec-
troporation); all of which are herein incorporated by refer-
38 
785, 5,589,367, 5,316,931, and Porta et al. (1996) Molecular 
Biotechnology 5:209-221; herein incorporated by reference. 
Transformed cells may be grown into Nicotiana plants in 
accordance with conventional methods. See, for example, 
methods disclosed in Vasil and Hildebrandt (1965) Science 
150:889; Negaard and Hoffman (1989) Biotechniques 7(8): 
808-812. These plants may then be grown, and either 
pollinated with the same transformed line or different lines, 
and the resulting progeny having expression of the desired 
phenotypic characteristic identified, i.e., reduced expression 
of one or more cytochrome P450s that are involved in the 
metabolic conversion of nicotine to nornicotine, and thus 
reduced content of nornicotine, and a concomitant reduced 
content of its nitrosamine metabolite, NNN, in the plant, 
particularly in the leaf tissues. Two or more generations may 
be grown to ensure that expression of the desired phenotypic 
characteristic is stably maintained and inherited and then 
seeds harvested to ensure expression of the desired pheno-
ence. 20 typic characteristic has been achieved. In this manner, the 
present invention provides transformed seed ( also referred to 
as "transgenic seed") having a polynucleotide of the inven-
tion, for example, an expression cassette of the invention, 
Any plant tissue that can be subsequently propagated 
using clonal methods, whether by organogenesis or embr yo-
genesis, may be transformed with a recombinant construct 
comprising a cytochrome P450 inhibitory sequence, for 
example, an expression cassette of the present invention. By 25 
"organogenesis" in intended the process by which shoots 
and roots are developed sequentially from meristematic 
centers. By "embr yogenesis" is intended the process by 
which shoots and roots develop together in a concerted 
fashion (not sequentially), whether from somatic cells or 
gametes. Exemplar y  tissues that are suitable for various 
transformation protocols described herein include, but are 
not limited to, callus tissue, existing meristematic tissue 
(e.g., apical meristems, axilla r y  buds, and root meristems) 
and induced meristem tissue (e.g., cotyledon meristem and 
hypocotyl meristem), hypocotyls, cotyledons, leaf disks, 
pollen, embr yos, and the like. 
stably incorporated into their genome. 
The compositions and methods of the invention can be 
used to reduce the nornicotine content, particularly in the 
leaves and stems, of any plant of the genus Nicotiana 
including, but not limited to, the following species: acumi-
nata, ajfinis, alata, attenuate, bigelovii, clevelandii, excel-
30 sior, forgetiana, glauca, glutinosa, langsdorjfii, longiflora, 
obtusifolia, palmeri, paniculata, plumbaginifolia, qudrival-
vis, repanda, rustica, suaveolens, sylvestris, tabacum, 
tomentosa, trigonophylla, and x sanderae. The present 
As used herein, the term "stable transformation" is 
intended to mean that the nucleotide construct of interest 
35 
invention also encompasses the transformation of any vari-
eties of a plant of the genus Nicotiana, including but not 
limited to Nicotiana acuminata multiflora, Nicotiana alata 
grandiflora, Nicotiana bigelovii quadrivalvis, Nicotiana 
introduced into a plant integrates into the genome of the 40 
plant and is capable of being inherited by the progeny 
thereof. "Transient transformation" is intended to mean that 
a sequence is introduced into the plant and is only tempo-
rally expressed or is only transiently present in the plant. 
In specific embodiments, the inhibitory sequences of the 45 
invention can be provided to a plant using a variety of 
transient transformation methods. The inhibitory sequences 
bigelovii wallacei, Nicotiana obtusifolia obtusifolia, Nico-
tiana obtusifolia plameri, Nicotiana quadrivalvis bigelovii, 
Nicotiana quadrivalvis quadrivalvis, Nicotiana quadrivalvis 
wallacei, and Nicotiana trigonophylla palmeri, as well as 
varieties commonly known as flue or bright varieties, Burley 
varieties, dark varieties, and oriental/Turkish varieties. 
The transgenic plants of the genus Nicotiana as described 
herein are suitable for conventional growing and harvesting 
techniques, such as cultivation in manure rich soil or without 
manure, bagging the flowers or no bagging, or topping or no 
topping. The harvested leaves and stems may be used in any 
50 traditional tobacco product including, but not limited to, 
pipe, cigar and cigarette tobacco, and chewing tobacco in 
any form including leaf tobacco, shredded tobacco, or cut 
tobacco. 
of the invention can be transiently transformed into the plant 
using techniques known in the art. Such techniques include 
viral vector systems and the precipitation of the polynucle-
otide in a manner that precludes subsequent release of the 
DNA. Thus, the transcription from the particle-bound DNA 
can occur, but the frequency with which it is released to 
become integrated into the genome is greatly reduced. Such 
methods include the use of particles coated with polyethy- 55 
enlimine (PEI; Sigma #P3143). 
In other embodiments, the inhibitor y  sequence of the 
invention may be introduced into plants by contacting plants 
with a virus or viral nucleic acids. Generally, such methods 
involve incorporating an expression cassette of the invention 60 
within a viral DNA or RNA molecule. It is recognized that 
promoters for use in the expression cassettes of the invention 
also encompass promoters utilized for transcription by viral 
RNA polymerases. Methods for introducing polynucleotides 
into plants and expressing a protein encoded therein, involv- 65 
ing viral DNA or RNA molecules, are known in the art. See, 
for example, U.S. Pat. Nos. 5,889,191, 5,889,190, 5,866, 
Thus the present invention provides a Nicotiana plant, 
particularly leaf tissues of these plants, comprising an 
expression cassette of the invention and a reduced amount of 
nornicotine and N'-nitrosonornicotine. As used herein, the 
term "a reduced amount" or "a reduced level" is intended to 
refer to an amount of nornicotine and/or N'-nitrosonornico-
tine in a treated or transgenic plant of the genus Nicotiana 
or a plant part or tobacco product thereof that is less than 
what would be found in a plant of the genus Nicotiana or a 
plant part or tobacco product from the same variety of 
tobacco, processed (i.e., cultured and harvested) in the same 
manner, that has not been treated or was not made transgenic 
for reduced nornicotine and/or N'-nitrosonornicotine. The 
amount of nornicotine may be reduced by about 10% to 
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greater than about 90%, including greater than about 20%, 
about 30%, about 40%, about 50%, about 60%, about 70%, 
and about 80%. 
40 
entry of the ethephon or sodium bicarbonate solutions 
throughout the transpirational stream. The treated leaves 
were placed in small plastic storage bags after being lightly 
The term "tobacco products" as used herein include, but 
are not limited to, smoking materials ( e.g., cigarettes, cigars, 5 
pipe tobacco), snuff, chewing tobacco, gum, and lozenges. 
The present invention also encompasses a range of tobacco 
product blends that can be made by combining conventional 
tobacco with differing amounts of the low nornicotine and/or 
N'-nitrosonomicotine tobacco described herein. In further 10 
embodiments, the plant or plant part of the genus Nicotiana 
sprayed with water (to maintain high humidity) and cured 
for three days at 30° C. in the dark. To enhance the nicotine 
to nomicotine conversion in the transgenic plants generated 
in this study, detached leaves were dipped into a solution of 
0.2% ethephon, dried, and cured in plastic storage bags for 
seven days at room temperature in the dark. 
cDNA Libraries and Expressed Sequence Tags 
Total cellular RNA was isolated from senescing leaf tissue 
of Burley lines DH 91-1307-46(NC) and DH 91-1307-46 
(Con) using the TRizol® reagent according to the manu-
facturer's protocol (Invitrogen). PolyA+ RNA was isolated 
as described above is cured tobacco. 
In some embodiments of the present invention, the 
tobacco product reduces the carcinogenic potential of 
tobacco smoke that is inhaled directly with consumption of 
a tobacco product such as cigars, cigarettes, or pipe tobacco, 
or inhaled as secondary smoke (i.e., by an individual that 
inhales the tobacco smoke generated by an individual con-
suming a tobacco product such as cigars, cigarettes, or pipe 
tobacco). The cured tobacco described herein can be used to 
prepare a tobacco product, particularly one that undergoes 
chemical changes due to heat, comprising a reduced amount 
15 from total RNA using the MessageMaker system (Invitro-
gen), and cDNA was subsequently synthesized and cloned 
into the lambda ZAP II phage vector using the ZAP-cDNA 
Synthesis and Gigapack III Gold Cloning Kit (Stratagene). 
Aliquots of the phage libraries were converted to pB!ue-
20 script-based plasmid libraries following the mass excision 
protocol outlined by Stratagene. 
Thousands of colonies from both the converter and non-
of nomicotine and/or N'-nitrosonomicotine in the smoke 
stream that is inhaled directly or inhaled as secondary
smoke. In the same manner, the tobacco products of the 25 
invention may be useful in the preparation of smokeless 
tobacco products such as chewing tobacco, snuff, and the 
like. 
converter libraries were grown on selective solid media and 
picked into 384-well plates containing Luria broth (with 
ampicillin) in 10% glycerol to facilitate long term storage of 
the clones at -80° C. Over 11,000 clones from each library 
were transferred from the 384-well plates to 96-well growth 
blocks and grown in selective media. Plasmids were isolated 
in 96-well format using the R.E.A.L. Preparation Kit (Qia-The tobacco products obtained from the transgenic 
tobacco plants of the present invention thus find use in 
methods for reducing the carcinogenic potential of these 
tobacco products, and reducing the exposure of humans to 
the carcinogenic nitrosamine NNN, particularly for indi-
viduals that are users of these tobacco products. 
The following examples are offered by way of illustration 
and not by way of limitation. 
EXPERIMENTAL 
30 gen) with the aid of a BioRobot 3000 Workstation (Qiagen). 
To generate the ESTs, the plasmid clones were sequenced 
using the T3 primer (Qiagen) and BigDye® Terminator 
system (Applied Biosystems) according to the BigDye® 
cycle sequencing protocol. Performa® DTR 96-well plates 
35 (Edge Biosystems) were used to remove the unincorporated 
dye from the sequencing reactions prior to loading the 
samples onto a Perkin Elmer Prism 3700 96-Capillary 
Automated DNA Sequencer. 
Preparation of DNA Chips 
The following materials and protocols were utilized in the 40 
experiments described herein below. 
To obtain DNAs suitable for spotting onto glass slides, the 
M13 forward and reverse sequencing primers (Qiagen) were 
used as PCR primers to amplify cDNA inserts from the 
plasmids containing cDNAs represented in the EST data-
bases. Plasmid clones were subjected to PCR in 96-well 
Plant Materials 
All plant materials utilized in these experiments were 
provided by Dr. Earl Wernsman, Department of Crop Sci-
ence, North Carolina State University. DH 91-1307-46(NC) 
and DH91-1307-46(Con) are near-isogenic doubled haploid 
Burley lines (nonconverter and converter, respectively) 
recovered from the same maternal haploid plant. Burley 
lines DH 98-326-3 (nonconverter) and DH 98-326-1 (con-
verter), and DH 98-325-5 (nonconverter) and DH 98-325-6 
(converter) represent two additional pairs of near-isogenic 
lines. SC58 is a flue-cured tobacco variety, nonconverter 
individuals of which are designated SC58(crer)· SC58 
(CrCr ) is a near-isogenic stable converter line that origi-
nated though the introgression of the single dominant con-
verter locus (C r) found in the tobacco progenitor species N.
tomentosiformis into SC58 (Mann et al. (1964) Crop Sci. 
4:349-353. After eight additional backcrosses to SC58, the 
near-isogenic SC58(CrCr) line was created and subse-
quently maintained via self-fertilization. 
All plants were maintained in growth chambers or green-
houses using standard potting soil and fertilizer. For the 
microarray studies, the metabolism of nicotine to nomico-
tine was accelerated by excising individual leaves and 
inserting their petioles into a solution of 0.1 % ethephon or 
1 % sodium bicarbonate. The leaves were then placed in a 
growth chamber (27° C.) for 5 to 7 hours to facilitate the 
45 format using an Applied Biosystems Gene Amp 9700 model 
thermocycler. The resulting PCR products were processed 
through Millipore Multiscreen™ PCR or Montage™
PCRµ96 purification systems. The resulting products were 
transferred into 384-well plates containing equal volumes of 
50 DSMO. The final DNA concentrations were estimated to be 
equal to or greater than 0.1 mg/ml. The DNAs were subse-
quently spotted onto amino silane-coated slides (Coming® 
GAPS II) using an Affymetrix GMS 417 array printer. DNAs 
were immobilized to the slide surface by UV crosslinking 
55 (-120 mJ/m2), followed by baking at 75 ° C. for two hours. 
Microarray Hybridization and Analysis 
The amino ally! dUTP-based indirect method of dye 
incorporation described by "The Institute of Genome 
Research" (http://pga.tigr.org/protocols.html) was used to 
60 label nonconverter and converter RNAs with Cy3 and Cy3 
fluorescent dyes (Amersham Biosciences). Briefly, 20 µg of 
total RNA was reverse transcribed in a 30 µI volume 
containing 400 units of SuperScript II RT (Invitrogen), 6 ng 
random hexamer primers, 0.5 mM each of dATP, dCTP, and 
65 dGTP, 0.3 mM dTTP, and 0.2 mM amino ally! dUTP 
(Sigma) in first strand synthesis buffer (Invitrogen). Reac-
tions were incubuted for 6 to 14 hours at 42 ° C., followed by 
US 9,913,451 B2 
41 42 
hydrolysis of the RNA with NaOH. The resulting first strand 
cDNA molecules were colunm purified (Qiagen) and 
washed with phosphate buffer. Coupling reactions of the 
NHS-ester Cy3 or Cy5 fluorescent dyes to the cDNA 
occurred during incubation in 0.05 M sodium carbonate 5 
buffer (pH 9.0) and 25% DMSO at room temperature for 1.5 
hours. 
Nucleic Acids Res. 22:4673-4680) and GAP (University of 
Wisconsin Genetic Computing Group software package) 
algorithms. 
The above described strategy was effective in identifying 
full-length sequence information for 3D_C12 and 7D_A06. 
In addition, PCR amplifications using the PCR primer 
internal to the 3D_C12 coding region gave rise to partial-
sequence information for the unique 3D_Cl2-15 cDNA. In 
an attempt to obtain full-length sequence information for Microarray slides were prehybridized in a solution of 
5xSSC, 0.1 % SDS, and 1 % BSA at 42 ° C. for 45 minutes, 
rinsed gently with dH20 and isopropanol, and dried by low 
speed centrifugation. The Cy3- and Cy5-labeled cDNAs 
were colunm purified (Qiagen), combined, and hybridized to 
the DNA slides in a solution containing 5xSSC, 0.5% SDS, 
5xDenhardt's, 0.45 µg/µl Poly A RNA, 0.45 µg/µl calf 
thymus DNA, and 50% formamide. The slides were incu-
bated with the hybridization solution for 14 to 16 hours at 
42 ° C. Post-hybridization washes consisted of sequential 
4-minute incubations with the following solutions: lxSSC,
0.2% SDS; O.lxSSC, 0.2% SDS; O.lxSSC, and a final 10 
second rinse with O.OlxSSC. 
The microarrays were subsequently scanned using Sca-
nArray 2.1 (GSI Lumonics) or ScanArray Express (Perki-
nElmer). Sequential scanning for Cy5 and Cy3 fluorescence 
was performed at a maximal resolution of 10 gm/pixel, and 
laser power and PMT gain adjusted to provide reliable and 
equivalent signal strengths. The acquired array images were 
quantified for signal intensity with QuantArray™ analysis 
software (PerkinElmer), using the histogram-based method. 
Total intensities were used as quantification output fields, 
and the acquired data sets were saved as Unicode, tab-
delimited text files. Importation of the text files into Micro-
soft Excel enabled the subsequent calculation of Cy5/Cy3 
and Cy3/Cy5 ratios, the statistic we employed for the 
identification of candidate genes. 
Cloning Full-Length andAdditional Members of the 3D C12 
Gene Family 
To clone the entire coding region of3D_C12 and 7D_A06 
a modified 5'-RACE strategy was employed using a pB!ue-
script II vector-specific forward primer (BlueSK; 
5'-CGCTCTAGAACTAGTGATC-3'; SEQ ID NO: 17) and a 
set of gene-specific reverse primers. Two 3D_Cl2-specific 
reverse primers were designed, one of which is complemen-
tary to the downstream portion of the 3' untranslated region 
(5'-TTTTTGGGACAATCAGTCAA-3'; SEQ ID N0:18) 
and the other complementary to a sequence within the 
coding region (5'-GTTAGATTTATCGTACTCGAATT-3'; 
SEQ ID N0:19). For the former primer, the first five Ts are 
complementary to the polyA tail of the transcript. A 
7D_A06-specific reverse primer (5'-TTCATTTCAAATT-
ATTTTATGCACCA-3'; SEQ ID N0:20) was also designed, 
and is complementary to a segment in the 3' untranslated 
region of this gene. PCR reactions contained 10 ng of 
converter tobacco leaf cDNA library (within the pB!uescript 
vector) as template, 2 µM concentration of each primer, 350 
µM of each dNTP, and 1.5 mM MgC12 in a final reaction 
volume of 50 µL. Amplification was initiated by the addition 
of 2.5 units of UniPol enzyme mix using conditions 
described by the manufacturer (Roche). After an initial 
denaturation step at 94 ° C. for 4 minutes, the samples were 
subjected to 30 cycles of denaturation at 94 ° C. for 15 
seconds, annealing at 57 ° C. for 30 seconds, and extension 
at 72 ° C. for 90 seconds. A final extension step at 72 ° C. for 
10 minutes was included at the end of the 30 cycles. The 
amplicons were ligated into the pGEM Easy TIA vector 
(Promega), and 10 randomly selected clones from each 
amplification were subjected to DNA sequence analysis. 
Nucleic acid and predicted protein sequences of the various 
members of the 3D_C12 gene family were analyzed and 
compared using the BLAS TX (Altschul et al. (1997) Nucleic 
Acids Res. 25:3389-3402), ClustalW (Higgins et al. (1994) 
10 3D_Cl2-15, a gene-specific primer complementary to the 5' 
terminus of its coding region (5'-ATGGTTTTTCCCATA-
GAAGCC-3'; SEQ ID N0:21) was used in conjunction with 
a pB!uescript-specific reverse primer (5'-TCGAGGTC-
GACGGTATC-3'; SEQ ID N0:22). Although a full-length 
3D_Cl2-15 cDNA was not recovered, this amplification 
15 resulted in the isolation of 3D_Cl2-7, which proved to be 
another unique member of the 3D_C12 gene family. 
Transgenic Plant Analysis 
The RNAi-based gene silencing constructs were 
assembled in a version of the pKYL80 cloning vector 
20 (Schardl et al. (1987) Gene 61:1-11) that was engineered to 
contain a 151-bp fragment of the soybean FAD3 gene intron 
between the Xhol and Sac! restriction sites of the polylinker 
(pKYLX80I). To create a construct in which the FAD3 
intron was flanked by a sense and antisense fragment of 
25 3D_C12, a 99-bp region located immediately upstream of 
the stop codon of the 3D_C12 cDNA (FIG. 3A-3G) was 
cloned between the HindIII-Xhol and Sacl-Xbal restriction 
sites of pKYLX80I in its sense and antisense orientation, 
respectively. The resulting HindIII-Xbal fragment contain-
ing the 3D_C12 sense arm, FAD3 intron, and 3D_C12 
30 antisense arm was subcloned into the pKYLX71 plant 
binary expression vector (Maiti et al. (1993) Proc. Natl. 
Acad. Sci. USA 90:6110-6114) between the 35S CaMV 
promoter and a rubisco small subunit terminator. 
Overexpression constructs were created by replacing the 
35 3-glucuronidase ORF of the plant binary expression vector 
pBI121 (Clontech) with the full-length coding regions of the 
3D_C12, 7D_A06, and 3D_Cl2-7 cDNAs. This placed the 
tobacco P450s under the transcriptional control of the 35S 
CaMV promoter. The pBI121- and pKYLX71-based con-
40 structs were transformed into Agrobacterium tumefaciens 
strain LBA 4404 and introduced into tobacco cul ti vars Petite 
Havana and DH98-325-6 (converter), respectively, using 
established protocols (Horsch et al. (1985) Science 227: 
1229-1231). 
Northern Blot Analysis 45 Total cellular RNAs were isolated from tobacco leaves 
using the TRIZOL® method as described by the manufac-
turer (Invitrogen). Five to ten micrograms of RNA were size 
fractionated on a 1.2% agarose gel prepared in TBE buffer. 
RNA immobilization, probe labeling, and signal detection 
50 were carried out using the DIG nucleic acid labeling and 
detection kits according to the manufacturer's instructions
(Roche). Alternatively, probes were synthesized using 32P-
dCTP according to protocols accompanying the Random 
Primed DNA Labeling kit (Roche). 
55 Alkaloid Analysis 
Tobacco leaves were harvested and air dried in an oven at 
65 ° C. for 2 days. A 100 mg sample of crushed, dried leaf 
was added to 0.5 ml of 2 N NaOH in a 20 mL scintillation 
vial. The sample was mixed and allowed to incubate for 15 
minutes at room temperature. Alkaloids were extracted by 
60 the addition of 5 mL of extraction solution [0.04% quinoline 
( wt/vol) dissolved in methy 1-t-buty 1 ether] and gently rotated 
on a linear shaker for 3 hours. Following phase separation, 
an aliquot of the organic phase was transferred to a sample 
vial. Samples were analyzed using a PerkinElmer Autosys-
65 tern XL gas chromatograph equipped with a flame ionization 
detector, a 4 mm split/splitless glass liner, and a 30 mx0.53 
mm ID DB-5 colunm. Chromatographic conditions were as 
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follows: detector temperature: 250° C.; injector temperature: 
250° C.; helium flow rate at 120° C.: 20 mL/min; injection 
volume: 2 µL; column conditions: 120° C., hold 1 minute, 
120-280 ° C. at 30 ° C./minute ramping rate, hold at 280° C. 
for 2 minutes. Alkaloid composition was determined by the 5 
TotalChrome Navigator software using a calibration curve. 
positives," representing genes that are differentially regu-
lated between a specific genotypic pair and/or uniquely in 
response to a specific treatment, as opposed to differences 
directly associated with the conversion phenomenon. To 
define the set of candidate genes that are most likely to be 
upregulated due to the conversion process, cDNAs were 
identified that met the following criteria: for any set of 
reciprocal experiments (i.e., Exp. 2.1, or Exp. 2.2), the 
hybridization intensity of a given cDNA had to be at least 
Example 1 
Generation of EST Databases 
RNAs isolated from senescing leaves of the converter 
genotype DH 91-1307-46(Con) and its near-isogenic non-
converter counterpart DH 91-1307-46(NC) were used to 
generate cDNA libraries. High-throughput automated DNA 
sequencers were initially used to generate single-run 
sequence information (ESTs) for 11,136 randomly chosen 
cDNAs from the converter library. The local alignment 
search tool BLASTX (Altschul et al. (1990) J. Mal. Biol. 
215:403-410) was used to compare the predicted protein 
sequence of each tobacco cDNA with the nonredundant 
protein database curated by the National Center for Biotech-
nology Information of the National Library of Medicine and 
National Institutes of Health. Subsequently, a similar anno-
tated EST database was generated by conducting sequencing 
runs on 11,904 cDNAs selected from the nonconverter 
library. 
Example 2 
Microarray Analyses of Converter CDNA Library 
Methods 
Upon completion of the EST database generated from the 
converter cDNA library, the inserts from 4992 clones were 
amplified by PCR and spotted onto glass slides. Given the 
possibility that the nicotine demethylase enzyme may be 
catalyzed by an enzyme of the P450 class of oxidative 
enzymes, special attention was given to library entries that 
were predicted by BLASTX analysis to encode P450s. 
From visual inspection of the BLASTX results, it was 
estimated that 31 unique P450 genes were represented in the 
database. When selecting specific 96-well plates to be 
included on the microarray, care was taken to ensure that all 
unique P450 genes would be included among the 4992 
cDNAs selected. 
RNAs isolated from the near-isogenic Burley genotypes 
DH 98-326-3 (nonconverter) and DH 98-326-1 (converter), 
and DH 98-325-5 (nonconverter) and DH 98-325-6 (con-
verter) were used to generate Cy3- and Cy5-labeled cDNAs. 
To maximize the metabolic conversion of nicotine to nor-
nicotine in converter genotypes, detached leaves were 
treated with sodium bicarbonate or ethephon prior to curing, 
treatments that have been shown to accelerate nornicotine 
production in converter plants while having no effect in 
nonconverter individuals (Fannin and Bush (1992) Med. Sci. 
Res. 20:867-868; Shi et al. (2003) J. Agric. Food Chem. 
51:7679-7683). 
10 
2-fold higher with the converter probe than nonconverter
probe in at least one of the hybridizations, and not less than
1.5-fold higher in the reciprocal experiment.
Experiment 2.1-Leaves from near-isogenic lines DH 
98-325-5 and DH 98-325-6 were treated with ethephon and 
cured for 3 days at 30° C. Alkaloid analysis revealed that 
15 virtually all of the nicotine had been metabolized to norni-
cotine in the DH 98-325-6 leaf during this period while 
minimal nomicotine was observed in the DH 98-325-5 leaf. 
RNAs from the DH 98-325-5 nonconverter plant were 
labeled with the Cy3 fluorescent dye, and RNAs extracted 
20 from a DH 98-325-6 (converter) leaf were labeled with Cy5. 
The Cy3- and Cy5-labeled cDNAs were incubated together 
on the same DNA chip and allowed to hybridize overnight. 
Experiment 2 . 2 - A  microarray analysis similar to Exp. 
2.1 was conducted using the DH 98-326-3 (nonconverter) 
25 and DH 98-326-1 (converter) near-isogenic lines. In theseexperiments, leaves from each genotype were treated with 
1 % sodium bicarbonate and cured for 3 days at 30 ° C. At the 
end of the treatment period, nicotine was the predominant 
alkaloid in the DH 98-326-3 leaf, while nearly all of the 
alkaloid in the DH 98-326-1 leaf was nomicotine. As 
30 described for Exp. 2.1, these experiments were reciprocally 
conducted. 
Results 
In both Experiment 2.1 and Experiment 2.2, the great 
majority of the 4992 cDNAs spotted on the glass slides 
35 showed no substantial differences in their hybridization 
intensities to the competing Cy3- and Cy5-labeled probes. 
Of the 4992 cDNAs spotted on the glass slides, only five 
showed at least 2-fold higher expression in one hybridiza-
tion and not less than 1.5-fold in the reciprocal hybridization 
40 for both Exp. 2.1 and Exp. 2.2. These entries were desig-nated 3D_C12, 7D_A06, 27C_C12, 33A_D06, and 
34D_F06. BLASTX analysis of the partial sequence infor-
mation for 3D_C12 and 7D_A06 found in our EST database 
predicted that the cDNAs encode two closely related P450 
enzymes. 27C_C12 and 33A_D06 were predicted to encode 
45 glycine-rich cell wall proteins, displaying over 90% 
sequence identity to small tobacco glycine-rich proteins 
found in GenBank (e.g., Accession No. AAK57546). Clone 
34D_F06 was found to contain a double cDNA insert, one 
insert showing homology to serine/threonine protein 
50 kinases, and the other showing high sequence identity to the 
same glycine-rich cell wall proteins as the 27C_C12 and 
33A D06 cDNAs. 
Example 3 
55 
To minimize the variability inherent with microarray 
experiments, reciprocal experiments were conducted simul-
taneously. In this manner, DH 98-325-5 RNA was labeled 
with Cy5 and DH 98-325-6 RNA was labeled with Cy3, and 
then in a reciprocal experiment DH 98-325-5 RNA was 
labeled with Cy3 and DH 98-325-6 RNA was labeled with 60 
Cy5 (collectively referred to as Exp. 2.1). Similarly, DH 
98-326-3 and DH 98-326-1 RNAs were labeled with Cy3 
and Cy5, respectively, in one experiment, and then the same 
RNAs were labeled with Cy5 and Cy3, respectively, in a 
reciprocal experiment (collectively referred to as Exp. 2.2). 65 
Microarray Analysis of CDNA Non-Converter 
Library 
Upon completion of the EST database from the noncon-
verter library (generated from senescing leaves of genotype 
DH 91-1307-46 (NC)), another set of microarray experi-
ments was initiated. For this next generation of microarrays, 
the goal was to produce glass slides containing the complete 
nonredundant set of genes represented in both libraries. 
To obtain an estimate of the number of unique genes that 
are represented in the database, clustering analysis was 
conducted to identify ESTs predicted to be represented 
multiple times in the database ( contigs) versus those pre-
Even when conducted reciprocally, the results of any 
given microarray experiment are likely to include "false 
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dieted to be represented only once (singletons) (Huang and 
Madan (1999) Genome Res. 9:868-877). Due to the nature of 
the clustering algorithms, sequences showing high, but 
imperfect, sequence identities are clustered into the same 
contig. The total set of predicted unique genes, or uni genes, 
within a database is calculated as the sum of the contigs and 
singletons. Clustering analysis of the combined converter 
and nonconverter databases predicted 2246 contigs and 4 717 
singletons for a total of 6,963 unigenes. Inserts from all 
singletons and an individual from each contig were ampli- 10 
fled by PCR and spotted onto glass slides, resulting in a gene 
chip containing the complete 6,963 unigene set. 
In addition to creating a new DNA chip, the genetic 
materials used to generate hybridization probes also differed 
from those used in Example 2. SC58 is a flue-cured tobacco 
cDNA 
3D C12 
7D_A06 
3D C12 
7D_A06 
131A_A02 
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verter RNAs to cDNAs encoding members of the 
same closely related P450 family was the only result 
shared by all three microarray experiments using the defined 
criteria. 131 A_A02 is the name of the cDNA that was 
spotted onto the 6963-member unigene chip that is repre-
sentative of the closely-related P450 gene family that 
includes 3D_C12 and 7D_A06 (3D_C12 and 7D_A06 them-
selves were not spotted on the unigene slide). No other 
cDNAs on the array in Example 3, which included repre-
sentatives of the contigs containing the glycine-rich protein-
encoding 27C_C12 and 33A_D06 and 34D_F06 cDNAs, 
scored positive by the defined criteria and also scored 
positive in Exp. 2.1 or Exp. 2.2 of Example 2 above, 
regardless of whether the results were compared individu-
ally or collectively. 
TABLE 1 
Microarray results of members of tbe 3D_Cl2 gene family 
Experiment 2.1 Experiment 2.1 (reciprocal) 
Cy3 Cy5 Cy5/Cy3 Cy3 Cy5 Cy5/Cy3 
reading reading ratio reading reading ratio 
15514.14 25928.95 1.67 19355.85 9507.87 2.04 
15238.23 37196.19 2.44 13651.03 8121.04 1.68 
Experiment 2.2 Experiment 2.2 (reciprocal) 
Cy3 Cy5 Cy5/Cy3 Cy3 Cy5 Cy5/Cy3 
reading reading ratio reading reading ratio 
12756.43 28669.28 2.25 32198.81 16166.13 1.99 
7571.06 19180.94 2.53 42408.85 18440.17 2.30 
Example 3 Example 3 (reciprocal) 
Cy3 Cy5 Cy5/Cy3 Cy3 Cy5 Cy5/Cy3 
reading reading ratio reading reading ratio 
11138.96 19638.82 1.76 36963.45 10085.25 3.67 
Combined Results 
The combined results of microarray experiments 
described above defined members of a closely related P450 
gene family, hereafter referred to as the 3D_C12 family, to 
be the best candidates for playing a direct role in the 
metabolic conversion of nicotine to nornicotine in converter 
tobacco plants. The hybridization results of the members of 
this P450 family in each of the three microarray experiments 
are shown in Table 1. The results of the microarrays were 
independently confirmed using Northern blotting assays. As 
shown in FIG. 2, an approximately 2-fold higher signal was 
variety, nonconverter individuals of which are desig nated 
SC58(crer)· SC58(CzCr) is a near-isogenic stable converter 40 
line that originated though the introgression of the single 
dominant converter locus (Cr) found in the tobacco pro-
genitor species N. tomentosiformis into SC58 (Mann et al. 
(1964) Crop Sci. 4:349-353). After eight additional back-
crosses to SC58, the near-isogenic SC58(CzCr) line was 45 
created and subsequently maintained via self-fertilization. 
The conversion phenotype of SC58(CzCr) plants is unique 
with respect to standard converter tobacco lines in that the 
metabolism of nicotine to nomicotine in the leaf does not 
require senescence or curing. Plants possessing the Cr 
converter locus from N. tomentosiformis contain nornicotine 
50 observed in senescing, cured converter leaves compared to 
their nonconverter counterparts when RNA blots were incu-
bated with a radiolabeled 7D_A06 hybridization probe. as the predominant alkaloid even in green leaf tissue (Wer-
nsman and Matzinger (1968) Tab. Sci. 12:226-228). 
Example 4 
Sequence Analysis of the 3D_C12 Gene Family 
Once microarray experiments defined 3D_C12 and 
7D_A06 as potentially being involved in the conversion 
RN As isolated from green leaf tissue of SC58( eye r ) and 
SC58(CzCr) were labeled with Cy3 and Cy5, respectively, 55 
and simultaneously hybridized to a DNA chip containing the 
entire 6,963 unigene set of cDNAs. The fluorescent dyes 
were reversed to produce the probes for a reciprocal experi-
ment as described in Exps. 2.1 and 2.2 of Example 2. 
60 process, obtaining complete DNA sequence information for 
these genes became the next step in their characterization. 
The original 3D_C12 and 7D_A06 clones that were 
sequenced when generating the EST database described 
elsewhere herein (and spotted onto the microarrays) were 
Results 
Results were evaluated using the same criteria as in 
Example 2, i.e., individual cDNAs were identified that 
showed at least 2-fold enhanced hybridization to the labeled 
SC58(CzCr) versus SC58(crer) cDNAs in one experiment 
and at least 1.5-fold enhancement in the reciprocal assay. 
Results were compared to those from Exp. 2.1 and Exp. 
2.2 in Example 2 above. Enhanced hybridization of con-
65 not full-length cDNAs. To obtain a full-length sequence, 
primers were generated corresponding to regions in the 3' 
flanking region and in the interior of the coding regions that 
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were sufficiently polymor phic to distinguish between 
7D_A06 and 3D_C12. These gene-specific primers were 
used in combination with primers specific to the cloning site 
of pB!uescript II to amplify cDNAs from the converter 
cDNA library in an attempt to obtain sequence that would 5
include the complete 5' ends of the 3D_C12 and 7D_A06 
reading frames. 
This strategy led to the determination of the DNA 
sequence corresponding to the complete coding regions of 
3D_C12 (nt 1-1551 of SEQ ID N0:1; predicted amino acid 10 
sequence shown in SEQ ID N0:2) and 7D_A06 (nt 1-1554 
of SEQ ID N0:7; predicted amino acid sequence shown in 
SEQ ID N0:8) (FIGS. 3A-3G and 4). GAP analyses of the 
3D_C12 and 7D_A06 DNA and predicted protein sequences 15 
showed that they share 93.4% DNA sequence identity and 
92.3% identity at the protein level (Tables 2 and 3). Initial 
BLASTX analysis against the nonredundant GenBank data-
base revealed that 3D_C12 and 7D_A06 share greatest 
sequence homology to CYP82El, a tobacco P450 gene of 20 
unknown function that is upregulated in response to fungal 
elicitors (Takemoto et al. (1999) Plant Cell Physiol. 
40:1232-1242). The CYP82El protein is 66.9% and 67.5% 
identical to the predicted amino acid sequences of 3D_C12 
(SEQ ID N0:2) and 7D_A06 (SEQ ID N0:8), respectively, 25 
and the CYP82El DNA sequence is 72.1 % and 73.5% 
identical to the respective coding sequences for 3D_C12 (nt 
1-1551 of SEQ ID N0:1) and 7D_A06 (nt 1-1554 of SEQ 
ID N0:7). 
30 
TABLE 2 
Nucleotide sequence identities between members oftbe 3D_Cl2 gene 
famil. 
3D C12- 3D C12- 3D C12- 35 
3D _Cl2 7D _A06 7 10 15* 
7D _A06 93.4** 
3D C12-7 93.7 94.0 
3D C12-10 93.7 94.4 99.7 
3D C12- 95.5 92.6 93.1 92.8 40 
15* 
131A_A02* 98.0 94.0 93.4 93.1 93.1 
*partial sequences 
**numbers indicate percentages 
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corresponding DNA sequence of 3D_C12 and 92.6% iden-
tical to the same region of 7D_A06 (Table 2). 
Because the 3D_Cl2-15 fragment represented an addi-
tional, distinct member of the 3D_C12 gene family, an 
attempt was made to obtain a full-length cDNA sequence of 
this gene. A PCR primer specific to the first seven codons of 
the 3D_Cl2-15 reading frame was used in combination with 
a pB!uescript II-specific primer in an amplification reaction 
using our converter cDNA library as template. Sequence 
analysis of several independent amplification products failed 
to reveal a full-length 3D_Cl2-15 gene. Instead, a new 
member of this family was recovered, designated 3D_Cl2-7 
(FIG. 3A-3G; coding sequence set forth as nt 1-1551 of SEQ 
ID N0:5). Across the full-length nucleotide sequence shown 
in SEQ ID N0:5, 3D_Cl2-7 shares 93.7% nucleotide 
sequence identity with 3D_C12 (across SEQ ID N0:1), 
94.0% nucleotide sequence identity with 7D_A06 (across 
SEQ ID N0:7), and 93.1% identity over the corresponding 
region of fragment 3D_Cl2-15 (SEQ ID N0:9) (Table 2). 
The predicted amino acid sequence of 3D_Cl2-7 (SEQ ID 
N0:6) is 92.8% identical to the 3D_C12 protein (SEQ ID 
N0:2), and 94.8% identical to the 7D_A06 protein (SEQ ID 
N0:8) (Table 3). 
Two additional members of the 3D_C12 family were also 
identified. A gene designated 3D_Cl2-10 (FIG. 3A-3G; 
coding sequence set forth as nt 1-1551 of SEQ ID N0:3; 
predicted amino acid sequence set forth in SEQ ID N0:4) 
was recovered from an amplification reaction using a PCR 
primer complementary to a sequence in the 3' flanking 
region of 3D_C12 together with a Bluescript II-specific 
primer (and the converter library as template). 3D_Cl2-10 
differs at only five nucleotide positions from the 3D_Cl2-7 
nucleotide sequence (SEQ ID N0:5) (FIG. 3A-3G), and at 
only two amino acids positions from the predicted 
3D_Cl2-7 protein product (SEQ ID N0:6) (FIG. 4). 
With the completion of the nonconverter EST database, 
another member of the 3D_C12 gene family was revealed. 
The partial DNA sequence of 131A_A02 (SEQ ID N0:11; 
predicted amino acid sequence set forth in SEQ ID N0:12) 
that is found in this database is 98.0% identical to the 
corresponding sequence of3D_C12, and 94.0% identical to 
the same region of 7D_A06 (FIG. 3A-3G and Table 2). As 
described in the previous section, 131A_A02 is a member of 
the 3D_C12 gene family that was represented on the com-
45 prehensive unigene chip used in microarray assays as 
described elsewhere herein. 
TABLE 3 
Predicted amino acid sequence identities between full-lengtb members of 
tbe 3D C12 gene family .
3D C12 
7D_A06 
3D C12-7 
3D C12-10 
**numbers indicate percentages 
92.3* 
92.8 
92.5 
7D_A06 
94.8 
94.4 
3D C12-7 
99.6 
In addition to enabling the acqms1t10n of full-length 
sequence information for the 3D_C12 and 7D_A06 cDNAs, 
the above described PCR amplifications yielded additional 
products that were closely related to, yet clearly distinct 
from, the 3D_C12 and 7D_A06 cDNA sequences. Using a 
primer directed against a sequence interior to the 3D_C12 
cDNA, in combination with a primer specific to pB!uescript 
II, a unique sequence designated 3D_Cl2-15 (FIG. 3A-3G; 
SEQ ID N0:9; predicted amino acid sequence shown in 
SEQ ID N0:10) was amplified in addition to the expected 
3D_C12 product. 3D_Cl2-15 is 95.5% identical to the 
50 
Example 5 
Transgenic Plant Analysis of Members of the 
3D_C12 Gene Family 
To determine whether members of the 3D_C12 family of 
cytochrome P450 genes are involved in the metabolic con-
55 version of nicotine to nornicotine, transgenic plants were 
generated using constructs designed to either enhance or 
inhibit gene expression. To test the effects of down-regulat-
ing gene activity, an RNA interference (RNAi) strategy was 
employed. A 99-bp region of 3D_C12 located immediately 
60 upstream of the stop codon (FIG. 3A-3G), was used to create 
a construct that would form a dsRNA hair pin within the 
plant cell. Such dsRNA structures are known to activate an 
RNAi silencing complex that leads to the degradation of 
both transgene RNAs and endogenous RNAs that are iden-
65 tical or highly homologous to the sequence found in the 
dsRNA (Wesley et al. (2001) Plant J. 27: 581-590; Water-
house & Helliwell (2002) Nat. Gen. Rev. 4: 29-38). 
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Given that each member of the 3D_C12 characterized as 
described herein shares over 90% DNA sequence identity, an 
RNAi construct synthesized against one member was 
expected to silence the entire gene family. Specifically, the 
RNAi construct generated against the 3D_C12 sequence 
shares sequence identities of 90/99 and 91/99 with the 
7D_A06 and 3D_Cl2-7 cDNAs, respectively, over this 
region (FIG. 3A-3G). The 3D_C12/RNAi construct (also 
referred to in Example 7 as the 3D_C12Ri99 construct) was 
cloned downstream of the constitutive 35S promoter of 10 
cauliflower mosiac virus (CaMV) and introduced into the 
strong converter Burley tobacco line DH 98-325-6 using 
Agrobacterium-mediated transformation. 
A hallmark of RNAi-mediated silencing is the marked 15 
reduction in steady-state transcript accumulation of the gene 
whose activity has been down-regulated. To confirm that 
gene silencing of the 3D_C12 gene family had occurred in 
50 
required when conducting Agrobacterium-mediated trans-
formation, is known to enhance the frequency of genetic 
conversion and would thus potentially complicate interpre-
tation of results ( e.g., assessing whether a novel phenotype 
was solely attributable to the transgene as opposed to being 
the result of the plant having undergone genetic conversion). 
Results 
Given the high degree of variability typically observed 
among independent transgenic plants transformed with the 
same trans gene construct, 10 independently transformed 
individuals were selected to assess the effects of the 
3D_C12/RNAi construct on the metabolic conversion of 
nicotine to nomicotine. Leaves from each of the 10 3D_C12/ 
RNAi individuals, in addition to two control plants trans-
formed with the pBI121 vector alone, were treated with 
ethephon and cured for seven days. Alkaloid analysis of 
these materials is shown in Table 4. 
TABLE 4 
Alkaloid analysis of DH 98-325-6 plants independently transformed 
with the 3D_Cl2/RNAi construct (and pBI121 vector 
control). Leaves were treated with ethephon and cured for seven days. 
% % % % % 
Sample Nicotine* Nornicotine* Anabasine* Anatabine* Conversion** 
3D_Cl2 RNAi (1) 3.149 0.100 0.012 0.159 2.8 
3D_Cl2 RNAi (2) 2.569 0.193 0.009 0.110 7.0 
3D_Cl2 RNAi (3) 2.175 0.064 0.007 0.080 2.9 
3D_Cl2 RNAi (4) 3.517 0.125 0.012 0.139 3.4 
3D_Cl2 RNAi (5) 1.085 0.868 0.009 0.119 44.4 
3D_Cl2 RNAi (6) 0.025 2.260 0.011 0.122 98.9 
3D_Cl2 RNAi (7) 0.027 1.867 0.011 0.122 98.6 
3D_Cl2 RNAi (8) 2.268 0.128 0.009 0.102 5.3 
3D_Cl2 RNAi (9) 2.197 0.133 0.008 0.099 5.7 
3D _ C l 2  RNAi 2.434 0.112 0.009 0.110 4.4 
(10) 
vector control (3) 1.811 1.1735 O.G18 0.170 48.9 
vector control (11) 0.290 2.090 0.013 0.143 87.8 
*percentage of leaf dry weight 
**[% nornicotine/(% nicotine+ nornicotine)] x 100 
the plants showing low nornicotine phenotypes, a Northern 
blot analysis was conducted using RNAs isolated from three 
40 
Typical of line DH 98-325-6, ethephon treatment and 
curing resulted in substantial nomicotine production in the 
two control plants ( 48.9% and 87.8% conversion of nicotine 
to nomicotine ). In dramatic contrast, seven of the ten 
of the transgenic plants possessing 3D_C12/RNAi con-
structs and displaying low nomicotine phenotypes, two 
individuals transformed with the 3D_C12/RNAi construct 
yet still showing high levels of nornicotine, and one of the 
vector-only control plants. 
45 independent transgenic plants possessing the 3D_C12/RNAi 
construct displayed minimal nicotine to nomicotine conver-
sion, with conversion percentages ranging from 2.8 to 7.0 
percent. The other three 3D_C12/RNAi lines displayed 
alkaloid contents similar to the vector-only control plants. 
To assess the affects of overexpression of gene activity, 
the cDNAs from the three members of the 3D_C12 gene 
family for which we first obtained full-length sequence 
information (3D_C12, 7D_A06, and 3D_Cl2-7) were 
cloned in their sense orientations downstream of the 35S 
CaMV promoter. These constructs were subsequently intro-
duced into N. tabacum cultivar Petite Havana using Agro-
bacterium-mediated transformation. The Petite Havana line 55 
is commonly used by researchers because of its shorter 
stature and abbreviated generation time in relation to com-
mercial tobacco cultivars. The converter/nonconverter status 
of the Petite Havana cultivar is unknown, but the alkaloid 
assays of the present application clearly showed that the 
plants in our possession were strong converters. 
Although the host plants in these experiments were con-
verters, the present strategy was to conduct alkaloid assays 
50 Concentrations of the minor alkaloids anabasine and anat-
abine did not appear to be sig n if icantly influenced by the 
presence or absence of the 3D_C12/RNAi transgene (Table 
4). 
Although the cDNA insert of the 3D_Cl2-7 gene was 
used as the specific hybridization probe, at the hybridization 
and wash conditions used in this experiment, cross-hybrid-
ization to the entire 3D_C12 gene family would be expected. 
As shown in FIG. 5, a strong hybridization signal was 
detected in each plant showing a high nomicotine pheno-
60 type, and minimal hybridization was detected in the plants 
transformed with the 3D_C12/RNAi construct that showed 
on green, non-cured tissue, where minimal nomicotine accu-
mulates in converter and nonconverter plants alike (and the 65 
35S CaMV promoter is very active). In fact, a nonconverter 
line was purposely chosen because tissue culturing, as 
a low nomicotine phenotype. We thus conclude that the 
effective silencing of the 3D_C12 gene family inhibits the 
metabolic conversion of nicotine to nornicotine in tobacco. 
Alkaloid analysis of the Petite Havana transgenic plants is 
shown in Table 5. Four independently transformed plants 
containing the 35S:3D_C12 and 35S:3D_Cl2-7 constructs 
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nicotine in the green, nontreated leaf than any other plant in 
this study. This may be the result of cosuppression of the 
3D_C12 gene family in this specific plant, a phenomenon 
frequently observed in transgenic plants even when a trans-
gene is expressed in its sense orientation (Fagard and 
Vaucheret (2000) Annu. Rev. Plant Physiol. Plant Mal. Biol. 
51: 167-194). 
If plant 35S:3D_C12 (1) was truly displaying a cosup-
pression phenotype, this phenotype would be expected to be 
were tested along with seven independent 35S:7D_A06 
individuals and three plants independently transformed with 
the pBI121 control vector. As expected, the green, non-cured 
leaves of the three vector-only control plants contained 
minimal amounts of nornicotine. Likewise, all plants trans-
formed with the 35S:3D_C12 and 35S:7D_A06 constructs 
showed minimal metabolic conversion of nicotine to norni-
cotine. A very different phenotype, however, was observed 
with plants transformed with 35S:3D_Cl2-7. All four plants 
independently transformed with this construct contained 
nomicotine as the predominant alkaloid in the green, non-
treated leaf; nicotine to nomicotine conversion percentages 
ranged from 94.6 to 98.6. 
10 maintained even upon ethephon treatment and curing of the 
leaves, similar to the low nomicotine phenotypes conferred 
by the 3D_C12/RNAi construct in the converter genotype 
DH 98-325-6 as described above. To test this prediction, 
TABLE 5 
Alkaloid analysis of individual Petite Havana plants transformed with 3D_Cl2, 
3D_Cl2-7, 7D_A06 constructs or the pBI121 vector control. Green 
leaves were harvested and analyzed without treatment or curing. 
% % % % 
Sample Nicotine* Nornicotine* Anabasine* Anatabine* 
vector control (2) 0.673 0.018 0.006 O.G18 
vector control (8) 0.605 0.014 0.005 0.016 
vector control (10) 0.694 0.017 0.004 O.G18 
35S:3D_Cl2 (1) 0.706 0.005 0.006 0.020 
35S:3D_Cl2 (2) 0.814 0.022 0.007 0.017 
35S:3D_Cl2 (3) 0.630 0.010 0.003 0.012 
35S:3D_Cl2 (4) 0.647 0.010 0.004 0.011 
35S:3D_Cl2-7 (1) 0.005 0.347 0.002 0.012 
35S:3D_Cl2-7 (2) 0.006 0.255 0.002 0.009 
35S:3D_Cl2-7 (3) 0.017 0.300 0.002 0.010 
35S:3D_Cl2-7 (4) 0.010 0.384 0.002 O.G15 
35S:7D_A06 (1) 0.761 0.011 0.005 O.G18 
35S:7D_A06 (2) 0.507 0.009 0.003 0.007 
35S:7D_A06 (4) 0.653 0.015 0.006 O.G15 
35S:7D_A06 (5) 0.643 0.013 0.004 O.G18 
35S:7D_A06 (6) 0.521 0.007 0.004 0.014 
35S:7D_A06 (7) 0.716 0.015 0.005 0.020 
35S:7D_A06 (8) 0.701 0.027 0.004 O.G18 
*percentage of leaf dry weight 
**[% nornicotine/(% nicotine+ nornicotine)] x 100 
40 
Example 6 
Cosuppression of the 3D_C12 Gene Family 
45 In addition to the major conclusion that the 3D_Cl2-7 
gene was capable of mediating nicotine to nornicotine 
conversion, one additional observation stood out in the 
alkaloid analyses of the Petite Havana transgenic plants. The 
alkaloid results reported in Table 5 together with additional 
alkaloid assays conducted independently (data not shown) 50 
consistently showed one of the plants transformed with the 
35S:3D_C12 construct (35S:3D_C12(1)) as having less nor-
% 
Conversion** 
2.6 
2.3 
2.4 
0.7 
2.6 
1.6 
1.5 
98.6 
97.4 
94.6 
97.5 
1.4 
1.7 
2.2 
2.0 
1.3 
2.1 
3.7 
alkaloid profiles were determined on ethephon treated, cured 
leaves of 35S:3D_C12 (1) and two vector-only control 
plants. As shown in Table 6, ethephon treatment and curing 
resulted in over 97% nicotine to nornicotine conversion in 
the two control plants whereas similarly treated 35S: 
3D_C12 (1) leaves displayed negligible conversion (0.6%). 
Leaves from five other plants expressing either 35S:3D_C12 
and 35S:7D_A06 transgenes were also subjected to ethep-
hon treatment and curing. In each case a high nornicotine 
phenotype was observed, similar to the vector-only control 
plants (data not shown). 
TABLE 6 
Alkaloid analysis of 35S:3D_Cl2 (1) and pBI121 vector controls plants. Leaves were 
treated with ethephon cured for seven days. 
% % % % % 
Sample Nicotine* Nornicotine* Anabasine* Anatabine* Conversion** 
vector control (8) 0.009 0.425 n.d. 0.011 97.9 
vector control (10) 0.008 0.560 n.d. 0.025 98.6 
35S:3D_Cl2 (1) 1.185 0.007 n.d. 0.020 0.6 
*percentage of leaf dry weight 
**[% nornicotine/(% nicotine+ nornicotine)] x 100 
n.d., not detected 
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Finally, Northern blot assays were conducted on select 
plants representing each of the Petite Havana transgenic 
genotypes (FIG. 6). Using a 3D_Cl2-7 cDNA as a hybrid-
ization probe, minimal signal was detected with RNAs 
isolated from green, nontreated leaves of the vector-only 5 
control plant. In contrast, hybridization was easily detected 
First-Strand Synthesis System (Stratagene, Cedar Creek, 
Tex.). Relative quantitative RT-PCR was employed for 
determining the abundance of the 3D_Cl2-7 cDNA using 
SYBR® Green I fluorescence chemistry Morrison et al. 
(1998) Biotechniques 24:954-962. 
A calibration curve was generated with a serial dilution of 
the 3D _ Cl 2-7 cDNA cloned into the pGEM®-T Easy vector 
(Promega Corporation, Madison, Wis.). The RT-PCR mix-
ture contained 2.5 mM MgC12, 125 µMeach dNTP, 0.5 µM 
each primer, 0.5xSYBR® Green I, 0.5 µg cDNA (or 1 µl 
reference plasmid), and 1.25 U Platinum Taq polymerase 
in RNA samples from all four independent transgenic plants 
possessing the 35S:3D_Cl2-7 construct. A strong hybrid-
ization signal was similarly observed using RNAs from all 
other transgenic plants tested that were transformed with the 10 
35S:3D_C12 and 35S:7D_A06 constructs, with the excep-
tion of the low nornicotine containing plant 35S:3D_C12 (lnvitrogen Life Technologies). The sequences of the allele-
specific 3D_Cl2-7 primers (E4SyFwd and E4SyRev) were 
5'-ACGTGATCCTAAACTCTGGTCTG-3' (E4SyFwd 
(SEQ ID N0:29)) and 5'-GCCTGCACCTTCCTTCATG-3' 
(E4SyRev (SEQ ID N0:30)). RT-PCR was performed in a 
(1 ). 
Overall results of the Northern blotting assays show that 
the 35S CaMV promoter was generally effective in mediat- 15 
ing a high level of gene expression for each of the three 
members of the 3D_C12 gene family tested in this study. 
Failure to detect a hybridization signal in plant 35S:3D_C12 
BioRad iCycler thermocycler (BioRad Laboratories, Hercu-
les, Calif.) set to the following protocol: 95 ° C. for 2 min; 
35 cycles of 95 ° C. for 30 sec, 55 ° C. for 30 sec 72 ° C. for 
50 sec, followed by final extension at 72 ° C. for 5 min. A 
165-bp fragment of the a-tubulin gene was used as an 
(1) is consistent with the interpretation that the 3D_C12 
gene family has been silenced via cosuppression in this 20 
individual. 
Example 7 
Additional Characterization and Suppression of 
Additional 3D_C12 Genes 
A second RNAi construct was prepared using polynucle-
otide sequences from the 3D_Cl2-7 sequence. The assem-
bly of the 3D_Cl2-7/RNAi expression cassette followed the 
same basic steps as those outlined for 3D_C12/RNAi above. 
Briefly, a 298-bp sense and antisense strand of the 
3D_Cl2-7 cDNA (SEQ ID N0:5) corresponding to the 
region between nucleotide positions 297 and 594 of the 
coding sequence (positions 1-1551 of SEQ ID N0:5) were 
ligated into the pKYLX801 vector downstream and 
upstream of the 151-bp soybean omega-6 fatty acid desatu-
rase intron (see GenBank Accession No. DQ672337), 
respectively. The primers (E4SFwd and E4SRev) used for 
the isolation of the 298-bp region by sense and antisense 
arms were 5'-AAGCTTTGACGCCATTTTTTCCAATCG-
3' (SEQ ID N0:27), and 5'-CTCGAGTTTTCCAGCGAT-
CATCTTCAC-3' (SEQ ID N0:28), respectively. The RNAi 
cassette was excised from pKYL801 and placed between a 
strong CaMV35S2 promoter and a rubisco small subunit 
terminator of the binary plant expression vector, pKYLX71 
(see FIG. 8). In the discussions below, this RNAi construct 
is referred to as the 3D_Cl2-7-Ri298 construct. 
Transgenic tobacco plants were generated via Agrobac-
terium-mediated transformation following the procedures 
provided above. Briefly, transformed burley tobacco plants 
were regenerated from calli on Murashige-Skoog (MS) 
medium supplemented with 100 mg/L kanamycin and plant 
hormones in a growth room maintained at 25 ° C. under a 16 
hr/8 hr light/dark cycle. Calli were transferred to fresh 
selection media every 2-3 weeks until shoots appeared. 
Small shoots were transferred to rooting media to allow root 
development for 2 weeks. Fully regenerated plants were 
transferred to a greenhouse and grown under standard con-
ditions. 
SYBR® Green I Chemistry 
Total RNA was isolated from cured leaves of converter 
and nonconverter burley tobacco plants using the TRizol® 
reagent (Invitrogen, Life Technologies, Carlsbad, Calif.). 
Purified RNA was treated with RNase-free DNase (TURBO 
DNA-Free™ , Ambion, Austin, Tex.). First strand cDNA was 
synthesized using 514 of total RNA and the StrataScript® 
internal standard. 3D_Cl2-7 cDNAconcentration was deter-
mined from the transcript-specific calibration curve and 
normalized to the internal standard. Fold-induction was 
25 calculated by dividing the normalized fluorescence values of 
the converter by the nonconverter samples. Melting-curve 
analysis was used to confirm the purity of PCR products as 
described in Ririe et al. (1997) Anal. Biochem. 245:154-160. 
Two plants were sampled per treatment and amplifications 
30 were repeated three times. 
TaqMan® Chemistry 
Total RNA was isolated from tobacco lines using TRizol 
reagent. Purified RNA was treated with RNase-free DNase 
(TURBO DNA-Free™ ). First strand cDNA was synthesized 
35 using 10 µg of total RNA and the High Capacity cDNA 
Archive Kit (Applied Biosystems, Foster City, Calif.). The 
RT-PCR mixture contained lx  TaqMan® Universal PCR 
Master Mix (Applied Biosystems, Foster City, Calif.), 400 
nM of each primer (E4TmFwd and E4TmRev), 250 nM 
40 TaqMan® minor groove binder (MGB) probe (E4MGB), 2 
ng of cDNA, and nuclease-free water (Afonina et al. (2002) 
Biotechniques 32:940-949). The primer and probe 
sequences were 5'-CGGTAATCGGCCATCTTTTC-3' 
(E4TmFwd (SEQ ID N0:31)), 5'-CCGAGTTTTC-
45 GAGCTAATGGA-3' (E4TmRev (SEQ ID N0:32)), and 
5'-CAATGACGAACGGCGACAG-3' (MGB probe (SEQ 
ID N0:33)). RT-PCR was performed in anABI 7500 Real-
Time System (Applied Biosystems, Foster City, Calif.) set to 
the following protocol: 50° C. for 2 min; 95 ° C. for 10 min; 
50 40 cycles of 95 ° C. for 15 sec, 60° C. for 1 min. Glyceral-
dehyde-3-phosphate dehydrogenase (G3PDH) was used as 
the endogenous control to normalize the amount of cDNA 
template in the reactions. Fold-change was determined by 
dividing the normalized fluorescence values of each sample 
55 by those obtained from a nonconverter or uncured control 
sample. For each treatment, RNA was isolated from three 
independent plants and amplifications were repeated 3 times 
per RNA sample. 
Northern and Southern Blot Analyses 
60 Total RNA was isolated from cured tobacco leaves using 
the TRizol reagent according to the manufacturer's instruc-
tions (Invitrogen, Life Technologies). Total RNA samples 
were separated on 1.2% TBE agarose gel, and transferred to 
positively charged nylon membranes by electroblotting with 
65 2xTBE buffer. Membranes were UV crosslinked and washed 
in 2xSSC for 5 min. Northern blot hybridization, washing, 
and detection were carried out using the digoxigenin (DIG) 
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System as described by the manufacturer (Roche Diagnos-
tics Corp., Indianapolis, Ind.). The 1.8 kb full-length ORF of 
the 3D_Cl2-7 cDNA was labeled with DIG and used as a 
probe. 
Genomic DNA was extracted with DNAzol® (Invitro- 5 
gen, Life Technologies) from green tobacco leaves accord-
ing to manufacturer's protocol. After incubation with FcoRl 
or Neal restriction enzymes overnight, 15 µg of the digested 
DNA was separated on 0.7% TBE agarose gel, depurinated 
with 0.25 M HCl for 10 min, and denaturated with 0.5 N 10 
NaOH for 30 minutes. DNA was blotted overnight by 
capillary transfer onto positively charged nylon membranes 
(Roche Diagnostics Corp.) and hybridized at 65 ° C. over-
night with a 515-bp DIG-labeled fragment of the neomycin 
phosphotransferase II (NPT II) gene. Hybridization, wash- 15 
ing, and detection were performed according to the proto-
cols supplied with the DIG System. The primers used for the 
amplifications of the Northern and Southern hybridization 
probes were E4FIFwsd (5'-ATGGTTTTTCCCATA-
GAAGCC-3' (SEQ ID N0:34)), E4FIRev (5'- 20 
TTTTTGGGACAATCAGTCAAT-3' (SEQ ID N0:35)), 
KanFwd (5'-TGAATGAACTGCAGGACGAG-3' (SEQ ID 
N0:36)), and KanRev (5'-AATATCACGGGTAGC-
CAACG-3' (SEQ ID N0:37)). 
56 
was screened by germinating seedlings on MS-agar plates 
containing 100 mg/L kanamycin for 6 weeks. Survivors 
were transplanted to soil and grown in a greenhouse as 
described above. Plants were fertilized with Peter's Profes-
sional All Purpose Plant Food (20-20-20; Spectrum Brands 
Inc., Madison, Wis.) once a week. 
RT-PCR Analysis of3D _ Cl2-7 Expression in Converter and 
Nonconverter Tobacco 
To further characterize the role of3D_Cl2-7 in nicotine 
N-demethylation, experiments were performed to demon-
strate that the regulation of3D_Cl2-7 expression is consis-
tent with the levels of nicotine N-demethylation activity 
observed in converter versus nonconverter tobacco. 
To determine the rate of3D_Cl2-7 mRNA accumulation 
in converter and nonconverter tobacco, an allele-specific 
real-time RT-PCR strategy was employed. Because RT-PCR 
involves the detection and measurement of the amplification 
products of a PCR template, the use of allele-specific 
primers allows the quantification of a single isoform among 
a group of highly homologous sequences. For accurate 
quantification of the 3D_Cl2-7 transcript, two different 
segments of the 3D_Cl2-7 coding region were amplified 
and both SYBR® Green and TaqMan® chemistries were 
Alkaloid Analysis 
Tobacco leaves were harvested and air dried in an oven at 
50 ° C. for 2 days. A 100 mg sample of crushed, dried leaf 
is added to 0.5 ml of 2 N Na OH in a 20 ml scintillation vial. 
The sample was mixed and allowed to incubate for 15 
minutes at room temperature. Alkaloids were extracted by 
the addition of 5 ml of extraction solution[0.04% quinoline 
(wt/vol) dissolved in methyl-t-butyl ether] and gently rotated 
25 used to generate fluorescence signals. RT-PCR analysis 
using the SYBR® Green I chemistry revealed an 80-fold 
increase in the levels of the 3D_Cl2-7 transcript in the cured 
leaves of converter versus nonconverter tobacco. A single 
peak melting curve and gel electrophoretic analyses of the 
30 amplicons confirmed the homogeneity of the PCR products. 
on a linear shaker for 3 hours. Following phase separation, 
In the TaqMan® chemistry-based RT-PCR experiment, 
3D_Cl2-7 transcript levels were quantified in untreated and 
ethephon-treated converter and nonconverter tobacco leaves an aliquot of the organic phase was transferred to a sample 
vial. Samples were analyzed using a PerkinElmer Autosys-
tem XL (PerkinElmer, Boston, Mass.) gas chromatograph 
equipped with a flame ionization detector, a 4 mm split/ 
splitless glass liner and a 30 mx0.53 mm ID DB-5 colunm. 
Chromatographic conditions were as follows: detector tem-
perature: 250° C.; injector temperature: 250° C.; helium flow 
35 that were cured for 0, 1 or 5 days. Low levels of3D_Cl2-7
transcripts were detected in the uncured leaves or following 
a 1-day curing period regardless of conversion type or 
ethephon treatment. Similarly, base line levels of3D_Cl2-7 
transcription were observed in converter or nonconverter 
40 leaves that were cured for 5 days without ethephon treat-
ment. In contrast, a 7.5-fold increase in 3D_Cl2-7 transcript 
accumulation was detected in the cured leaves of converter 
versus nonconverter tobacco, and a 70-fold increase was 
at 120° C.: 20 ml/min; injection volume: 2 µl; column 
conditions: 120° , hold 1 min, 20-280 ° C. at 30° C./min 
ramping rate, hold at 280° C. for 2 min. Alkaloid compo-
sition was determined by the TotalChrome Navigator soft-
ware using a calibration curve. Means of the alkaloid 45 
measurements were separated according to Fisher's Pro-
tected LSD (PROC MIXED). 
Plants Double haploid burley tobacco lines DH 98-325-5 
(325-5; nonconverter) and DH98-325-6 (325-6; converter) 
described above were used in all experiments, except for the 50 
fluorogenic 5' nuclease (TaqMan®) chemistry-based RT-
PCR assays where the isogenic DH 91-1307-46 (noncon-
verter) and DH 91-1307-46 (converter) lines were used. All 
plants were grown in a controlled environment greenhouse 
equipped with supplemental lighting providing, a 14 hr/10 55 
hr light/dark cycle. 
For curing, tobacco leaves were collected from converter 
and nonconverter plants about 1 month before flowering and 
treated by dipping each leaf twice for 10 sec, into 2% 
ethephon and dried for 2 hours. Leaves were cured for up to 60 
two weeks in plastic bags, under dark conditions, until they 
turned yellow. Cured leaves were used for the Northern and 
alkaloid analyses. Samples of cured leaves subjected to GC 
analysis were dried at 50 ° C. for 2 days. For Southern 
analysis, green tobacco leaves of adult plants were used. To 65 
produce T 1 generation transgenic plants, primary transfor-
mants (T 0) were self-pollinated, and the harvested T 1 seed 
observed in the uncured versus cured leaves of a converter 
tobacco variety when ethephon treatment preceded the 5-day 
curing period. While not intending to be limited by any 
particular theory, these results suggest that 3D_Cl2-7 is a 
major contributor to nicotine N-demethylation and is 
strongly inducible by ethylene in senescing tobacco leaves. 
Suppression of Nicotine to Nornicotine Conversion by the 
3D_Cl2-Ri99 and 3D_Cl2-7-Ri298 Constructs 
To compare the extent to which 3D_C12 and 3D_Cl2-7 
mediate the suppression of nomicotine production, con-
verter and nonconverter burley tobacco plants were trans-
formed with the two gene silencing vectors. Ten (10) trans-
genic plants were regenerated per RNAi construct. About 
80% of tobacco plants overexpressing either the 99-bp or 
298-bp inverted repeat showed reduced nornicotine levels 
compared to the empty vector controls (Tables 7 and 8). In 
the nonconverter genotype, 3D_Cl2-Ri99 and 3D_Cl2-7-
Ri298 expression reduced nicotine to nomicotine conver-
sion by about 1.8-fold (2.0%) and 3.0-fold (1.2%), respec-
tively, in comparison to the rate of conversion detected in the 
vector controls (3.6%) (Table 7). Among the silenced non-
converter plants, the lowest conversion level of 0.9% was 
achieved using the 3D_Cl2-7-Ri298 construct (Table 7). 
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TABLE 7 
Alkaloid analysis of nonconvertor burley tobacco plants transformed 
witb tbe 3D C12-Ri99 or 3D C12-7-Ri298 construct. 
Linec % Nicotined % Nornicotined % Conversione 
3D-C12-Ri99 
1.693 0.034 2.0 
2 1.435 0.031 2.1 
2.095 0.043 2.0 
4 2.868 0.053 1.8 
0.947 0.025 2.6 
2.357 0.043 1.8 
7 2.599 0.043 1.6 
0.796 0.020 2.4 
9 2.178 0.039 1.8 
10 3.162 0.061 1.9 
MEAN 2.013 0.039 2.0a 
STE 0.748 0.012 0.3 
3D _Cl2-7-Ri298 
1.806 0.020 1.1 
4 1.948 0.207 1.4 
2.061 0.020 1.0 
2.704 0.040 1.5 
2.652 0.023 0.9 
9 1.074 O.G15 1.3 
MEAN 2.041 0.024 1.2b 
STE 0.550 0.008 0.2 
Vector ControW 
1.206 0.052 4.2 
2 1.265 0.038 2.9 
1.752 0.058 3.2 
4 1.230 0.072 5.6 
1.777 0.060 3.3 
1.536 0.044 2.8 
MEAN 1.461 0.054 3.6c 
STE 0.240 0.011 1.0 
10 
15 
20 
58 
TABLE 8-continued 
Alkaloid analysis of convertor burley tobacco plants transformed witb tbe 
3D C12-Ri99 or 3D C12-7-Ri298 construct. 
3D 
Linec 
4 
9 
10 
MEAN 
S T F  
C12-7-Ri298b 
2 
7 
9 
10 
MEAN 
STE 
% Nicotined 
2.175 
3.517 
2.268 
2.197 
2.434 
2.654 
0.573 
2.043 
3.427 
2.603 
2.427 
2.106 
1.412 
3.328 
1.493 
2.065 
2.323 
0.669 
% Nornicotined % Conversione 
0.064 2.9 
0.125 3.4 
0.128 5.3 
0.133 5.7 
0.112 4.4 
0.122 4.5a 
0.039 1.6 
0.020 1.0 
0.026 0.8 
0.020 0.8 
0.030 1.2 
0.021 1.0 
O.G15 1.1 
0.028 0.8 
O.G15 1.0 
O.G18 0.8 
0.021 0.9b 
0.005 0.1 
25 Vector Controlh.; 
30 
2 
4 
MEAN 
STE 
0.126 
0.330 
0.060 
0.114 
0.119 
0.150 
0.093 
1.550 92.5 
2.604 88.8 
1.419 95.9 
1.267 91.7 
1.303 91.6 
1.628 92.lc 
0.498 2.3 
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25 ° C. 
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25 ° C. 
35 
bOf the plants transformed with an RN Ai construct, only silenced individuals are shown. 
Alkaloid data represent the means o f  2 measurements. 
bOf the plants transformed with an RN Ai construct, only silenced individuals are shown. 
'Numbers represent independently transformed individuals. 
'Numbers represent independently transformed individuals. 
"Percentage o f  leaf dry weight. 
e[% nornicotine/(% nicotine + % nornicotine)] x 100; values followed by different letters 
are significantly different according to Fisher's Protected LSD (0.05). 
fsTE, standard error 
gTobacco plants transformed with only pKYLX71 vector were used as controls. 
"Percentage o f  leaf dry weight. 
e[% nornicotine/(% nicotine+% nornicotine)] x 100; values followed by different letters 
are significantly different according to Fisher's Protected LSD (0.05). 
fsTE, standard error 
4 0  gTobacco plants transformed with only pKYLX71 vector were used as controls. 
Relative to nonconverter tobacco, nomicotine accumula-
tion was suppressed even more dramatically in the silenced 
individuals of the strong converter plants (Table 8). Using 
3D_Cl2-Ri99 constructs, nicotine conversion was reduced 45 
to levels as low as 4.5% in 3D_Cl2-Ri 99-transformed 
To test the heritability of nomicotine suppression in the 
3D_Cl2-7-Ri298-transformed plants, a set of 3D_Cl2-7-
Ri298-transfomed converter and nonconverter lines that 
displayed the lowest levels of nicotine conversion were 
advanced to the T 1 generation (Table 9). Because segrega-
tion of the transgene(s) occurs in the T 1 progeny, transgenic 
individuals were identified by selecting seedlings capable of 
growing on kanamycin-containing media. Nine kanamycin-
325-6 tobacco plants in sharp contrast to the 325-6 control 
plants exhibiting about 98% conversion rates; Table 8). 
However, using the 3D_Cl2-7-Ri298 construct even greater 
reductions in nicotine conversion were obtained (Table 8). 
Four 3D_Cl2-7-Ri298-transformed individuals converted 
as low as 0.8% of their nicotine to nomicotine, and the 
arithmetic mean across the 9 silenced transformants was 
0.9% conversion. All silenced plants were morphologically 
indistinguishable from both the empty vector and wild-type 
controls (data not shown). 
TABLE 8 
Alkaloid analysis of convertor burley tobacco plants transformed witb tbe 
3D C12-Ri99 or 3D C12-7-Ri298 construct. 
3D C12-Ri99 
2 
% Nicotined 
3.419 
2.569 
% Nornicotined 
0.100 
0.193 
% Conversione 
2.8 
7.0 
50 resistant progenies of each selected T0-generation 3D_Cl2-
7-Ri298 transformant and four kanamycin-resistant indi-
viduals from each selected vector control line were analyzed 
for alkaloid content. The rate of nicotine conversion did not 
differ significantly between the primary 3D_Cl2-7-Ri298 
55 transformants and their T 1 progeny, indicating high herita-
bility of the nomicotine suppression trait (see Tables 7, 8, 
and 9). However, advancing the "nonconverter" vector con-
trol line by a single generation increased the nicotine to 
60 nornicotine conversion rate from 4.2% to an average value 
of 11.6%, illustrating the high degree of instability of the 
conversion locus in transgenic plants lacking the 3D_Cl2-
7-Ri298-specific RNAi construct (Tables 7 and 9). Overall, 
these results show that RNAi-mediated silencing of the 
65 3D_C12 gene subfamily is a highly effective means of 
lowering nomicotine production in both nonconverter and 
strong converter tobacco plants. 
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TABLE 9 
Alkaloid analysis o f T1-generat10n 3D C12-7-Ri298 transformants. 
Line % Nicotinec % Nornicotinec % Conversiond 
DH98-325-5 (nonconverter) 
3D C12-7-Ri298#3 
Mean 1.764 0.024 1.4a 
STE 0.456 0.004 0.3 
3D C12-7-Ri298#5 
Mean 1.500 0.020 1.3a 
STE 0.306 0.006 0.3 
3D C12-7-Ri298#8 
Mean 1.772 0.020 1.2a 
STE 0.409 0.003 0.3 
Vector Control#! e 
Mean 1.466 0.203 11.6b 
STE 0.713 0.161 9.7 
DH98-325-6 (converter) 
3D C12-7-Ri298#2 
Mean 1.970 0.019 1.0a 
STE 0.536 0.004 0.3 
3D C12-7-Ri298#8 
Mean 1.623 0.022 1.3a 
STE 0.300 0.002 0.2 
3D C12-7-
Ri298#10 
Mean 1.419 0.017 1.3a 
STE 0.515 0.004 0.3 
Vector Control#2e 
Mean 0.028 1.170 97.6c 
STE 0.006 0.234 0.5 
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C. 
 eans and standard errors (STE) represent 9 and 4 T1 progenies of the 3D_Cl2-7-Ri298 
construct and empty vector-transformed (vector control) lines, respectively. 
"Percentage of leaf dry weight. 
d[% nornicotine/(% nicotine+% nornicotine)] x 100; values followed by different letters 
are significantly different according to Fisher's Protected LSD (0.015). 
eTobacco plants transformed with only pKYLX71 vector were used as controls. 
Furthermore, transforming tobacco with the 3D_Cl2-7-
298 construct conferred a 3.6-fold reduction in nicotine 
conversion relative to typical nonconverter control plants 
without affecting plant growth and development. 
To demonstrate that the down-regulation of nornicotine 
production in 3D _Cl2-7-298-transformed tobacco was con-
comitant with a reduction of the 3D_C12 gene subfamily 
transcripts, a 3D_Cl2-7 cDNAprobe was hybridized to the 
total RNA isolated from cured leaves of nonconverter and 
converter plants. A weak hybridization signal was generated 
by the RNA isolated from 3D_Cl2-7-Ri298 transformants 
displaying low nornicotine content in contrast to the strong 
signal produced by the RNA extracted from plasmid control 
or wild-type plants. These results indicate that the down-
regulation of nicotine conversion was a result of RNAi-
mediated gene silencing of the nicotine N-demethylase 
gene(s). 
10 
15 
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construct using Southern blot analysis of genomic DNA 
digested with the EcoRI restriction enzyme. Transgene copy 
number was confirmed using Neal digested DNA (data not 
shown). These results indicate that the integration of a single 
3D_Cl2-7-Ri298 construct into the genome of a strong 
converter tobacco is sufficient for suppressing nornicotine 
production to very low levels. 
General Conclusions 
The analyses outlined in Examples 1-6 above resulted in 
the discovery of a closely related P450 gene family, desig-
nated the 3D_C12 family, whose collective steady-state 
transcript levels were sig n if icantly elevated in converter 
tobacco plants that were actively metabolizing nicotine to 
nornicotine in comparison to their nonconverter counter-
parts. Transgenic plant analysis demonstrated that the sup-
pression of gene expression of this P450 family in converter 
tobacco lines inhibited the metabolism of nicotine to norni-
cotine to levels similar to that observed in nonconverter 
plants. Furthermore, sense expression of several individuals 
of this closely related gene family identified one member, 
designated 3D_Cl2-7, as playing a direct role in the meta-
bolic conversion of nicotine to nornicotine. Overexpression 
of3D_Cl2-7 using a strong constitutive promoter caused a 
dramatic increase in nornicotine production and accumula-
tion in non-cured green leaves of transgenic tobacco plants, 
a tissue where nicotine is normally the predominant alkaloid 
in converter and nonconverter plants alike. Given that the 
cytochrome P450 family member designated 3D_Cl2-10 
differs from 3D_Cl2-7 at only two amino acid residues 
immediately following the start methionine and within the 
N-terminal signal sequence, it is predicted that these 
encoded products function identically. 
The contrast in alkaloid phenotypes between the 35S: 
3D_C12 (1) plant and vector-only control plants was most 
dramatic in leaves that had been ethephon treated and cured 
(0.6% conversion versus >97% conversion; Table 6). How-
ever, it is noteworthy that the nornicotine content of the 
co-suppressed 35S:3D_C12 (1) plant was reduced even in 
green, nontreated leaves where the high nornicotine pheno-
type is typically not manifest in converter or nonconverter 
tobacco lines. The green, nontreated leaves of line 35S: 
3D_C12 (1) showed only 0.7% nicotine to nornicotine 
conversion, whereas every other plant in this experiment 
showed conversion percentages ranging from 1.3 to 3.7 
45 (Table 5). This result suggests that the inhibition of gene 
expression of the 3D_C12 family may prove to be effective 
in the further lowering of nornicotine levels even in tobacco 
lines where genetic conversion isn't typically a major prob-
lem (such as flue-cured tobaccos) or in the nonconverter 
50 individuals in lines that are prone to genetic conversion 
(such as Burley tobaccos). 
Southern blotting assays using members of the 3D_C12 
gene family as hybridization probes gives very complex 
banding patterns, suggesting that more members of this gene 
55 family may exist even beyond those that have been identi-
fied and characterzed herein (data not shown). The hypoth-
esis that the 3D_C12 gene family is comprised of additional 
members is further supported by the recent publication of75 
full-length tobacco P450 cDNAs of unknown function (U.S. Determination of Transgene Copy Number To determine 
whether the integration of multiple 3D _ Cl2-7-Ri298 copies 
were required for producing transplants displaying very low 
nicotine N-demethylase activity, Southern analysis was per-
formed on selected individuals exhibiting <1.5% nornico-
tine accumulation. The number of transgenes varied widely 
among these plants including individuals containing 1 copy 65 
(325-5, lines 5 & 8; 325-6, lines 2 & 8), 5 copies (325-6, line 
10), and 6 copies (325-5, line 6) of the 3D_Cl2-7-Ri298 
60 Patent Application Publication 20040162420). Within this 
list of P450s are additional cDNAs that would, based on the 
work described herein, be placed within the 3D_C12 family 
in view of their display of over 90% amino acid sequence 
identity to the protein sequences shown in FIG. 4. 
With respect to the specific molecular function of the 
3D_Cl2-7 gene or the nearly identical family member 
3D_Cl2-10, it is possible that it encodes the actual nicotine 
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demethylase enzyme which catalyzes the oxidative N-dem-
ethylation of nicotine to nornicotine (FIG. 1). Alternatively, 
the 3D_Cl2-7 encoded enzyme or nearly identical 3D_Cl2-
10 encoded enzyme may produce a product that leads to the 
up-regulation of the nicotine demethylase activity of the 
leaf, as opposed to directly catalyzing the N-demethylation 
reaction. 
In addition, an allele-specific RT-PCR was employed to 
compare 3D_Cl2-7 expression between converter and non-
converter plants (Example 7). An approximately 80-fold 
increase in 3D-Cl2-7 expression in converter versus non-
converter plants was identified using the SYBR® Green-
chemistry RT-PCR assay. A 7.5-fold up-regulation was iden-
tified by the TaqMan® chemistry-based RT-PCR 
experiment. While the DH 91-1307-46 tobacco variety used 
in the TaqMan® chemistry-based RT-PCR experiment 
exhibits low to moderate levels of nicotine conversion, the 
DH98-325-5 nonconverter plants used in the SYBR® 
Green-based RT-PCR assay consistently convert a very low 
percentage of their nicotine to nomicotine. Expression of the 
3D-Cl2-7 gene was induced at least 7-fold by ethylene in 
senescing leaves of converter tobacco plants. 
An additional RNAi construct, 3D_Cl2-7-Ri298, was 
prepared based on a region of the 3D_Cl2-7 polynucleotide 
that corresponds to nucleotide positions 297 through 594 of 
SEQ ID N0:5. Expression of this RNAi construct allows for 
the suppression of nomicotine production in a strong con-
verter tobacco line below the levels normally found in 
nonconverter plants. The expression cassette of the 
3D_Cl2-7-Ri298 construct encoded an intron-spliced hair-
pin RNA in which the stem region was engineered from this 
298-bp fragment of the 3D_Cl2-7 cDNA inserted as an 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 37 
<210> SEQ ID NO 1
<211> LENGTH, 1733
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE,
<221> NAME/KEY, CDS
<222> LOCATION, (1) ... (1551)
<400> SEQUENCE, 1
62 
inverted repeat. The loop of the hair p in was created by 
placing a 151-bp intron of the FAD gene between the two 
sides of the palindromic sequences. An arm length of298-bp 
was used for the inverted repeats. 
3D_Cl2-7-Ri298-transformed plants accumulated less 
nornicotine than those harboring the 3D_Cl2-Ri99 con-
struct (Tables 7 and 8). No correlation was found between 
the number of copies of the 3D_Cl2-7-Ri298 construct and 
nornicotine production (Tables 7 and 8). The 3D_Cl2-7-
10 Ri298 expression cassette enabled the production of tobacco 
with a conversion rate as low as 0.8%, which is below the 
3-5% rate detected in burley lines used by seed producers. 
Such dramatic reduction in nornicotine production by tar-
geting this particular region of the 3D_Cl2-7 polynucleotide 
15 is an unexpected result. Also, suppression of nornicotine 
production showed a high degree of heritability in the T 1 
progeny of the primary transformants (Table 9). Suppression 
of nornicotine production in these transgenic plants yielded 
no obvious differences in growth and development when 
20 compared to wild-type plants. 
All publications and patent applications mentioned in the 
specification are indicative of the level of those skilled in the 
art to which this invention pertains. All publications and 
patent applications are herein incor porated by reference to 
25 the same extent as if each individual publication or patent 
application was specifically and individually indicated to be 
incor porated by reference. 
Although the foregoing invention has been described in 
some detail by way of illustration and example for pur poses 
30 of clarity of understanding, it will be obvious that certain 
changes and modifications may be practiced within the 
scope of the appended claims. 
atg gtt ttt CCC ata gaa gee ttt gta gga eta gta ace ttc aca ttt 48 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa CCC 96 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttt 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat aac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gat aaa tac ggc CCC gtt ttc act ttt egg eta ggt ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc 336 
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-continued
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac gga 384 
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg cga aaa aat cgt aaa tta gtc att cag gaa gtt etc tct 432 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln 
145 150 155 160 
acg age att aag aat tta tac act cga att aat gga aat tcg agt acg 528 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr 
165 170 175 
ata aat eta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt tta tea atg 672 
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met 
210 215 220 
gaa ttt gta tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggt cat att aag gca atg aaa agg aca ttt aag gat ata 768 
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aac tgg tta gag gaa cat att aat aaa aga gaa 816 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
aaa atg gag gtt ggt gca gaa ggg aat gaa caa gat ttc att gat gtg 864 
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa ttg agt aaa gaa tat ctt gat gaa ggt tac tct cgt 912 
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aaa gca aca gtt ttt agt ttg gtc ttg gat gca gca 960 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg aca tta ttg ata aac 1008 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn 
325 330 335 
aat caa aat gee ttg atg aaa gca caa gaa gag ata gac aca aaa gtt 1056 
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gat aga tgg gta gaa gag agt gat att aag gat tta gta tac 1104 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa aag gtg tta cga tta tat cca cca gga cct 1152 
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
ttg tta gta cca cat gaa aat gta aag gat tgt gtt gtt agt gga tat 1200 
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa gag act aga tta ttc gca aac gtc atg aaa ctg cag 1248 
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
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cgc gat cct aaa etc ttg tea aat cct gat aag ttc gat cca gag aga 1296 
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
ttc ate get ggt gat att gac ttc cgt ggt cac cac tat gag ttt ate 1344 
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile 
435 440 445 
cca ttt ggt tct gga aga cga tct tgt ccg ggg atg act tat gca ttg 1392 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
caa gtg gaa cac eta aca atg gca cat tta ate cag ggt ttc aat tac 1440 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aaa act cca aat gac gag gee ttg gat atg aag gaa ggt gca ggc ata 1488 
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
ace ata cgt aag gta aat cca gtg gaa ttg ata ata acg cct cgc ttg 1536 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu 
500 505 510 
gca cct gag ctt tac taaaacctaa gatctttcat cttggttgat cattgtttaa 1591 
Ala Pro Glu Leu Tyr 
515 
tactcctaga tgggtattca tttacctttt ttcaattaat tgcatgtacg agctttttta 1651 
atttggtata tttgtaacaa taagtaaaga atgattgtgc taatatataa agatttgcag 1711 
aagataattg actgattgtc cc 1733 
<210> SEQ ID NO 2
<211> LENGTH, 517 
<212> TYPE, PRT
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 2
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1 5 10 15 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
US 9,913,451 B2 
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195 200 205
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn 
325 330 335 
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 3
<211> LENGTH, 1733
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE,
<221> NAME/KEY, CDS
<222> LOCATION, (1) ... (1551)
<400> SEQUENCE, 3
atg ctt tct CCC ata gaa gee att gta gga eta gta ace ttc aca ttt 48 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa CCC 96 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
us 9,913,451 B2 
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20 25 30 
tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat gac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac ggc CCC gtt ttc act ttt egg eta ggc ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga 384 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg cga aaa aat cga aaa tta gtt att cag gaa gtt etc tee 432 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
gcg age att aag aat tta tat act cga att gat gga aat tcg agt acg 528 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 672 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 768 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa 816 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg 864 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt 912 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aaa gca acg gtg ttt agt ttg gtc ttg gat gca gca 960 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac 1008 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt 1056 
us 9,913,451 B2 
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Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac 1104 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa gaa gtg tta cga tta tat cca cca gga cct 1152 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat 1200 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa 1248 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga 1296 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate 1344 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
ccg ttt ggt tct gga aga cga tct tgt cca ggg atg act tat gca ttg 1392 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac 1440 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aga act cca aat gac gag CCC ttg gat atg aag gaa ggt gca ggc ata 1488 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg 1536 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa 1591 
Ala Pro Glu Leu Tyr 
515 
tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta 1651 
atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag 1711 
aagataattg actgattgtc cc 1733 
<210> SEQ ID NO 4
<211> LENGTH, 517 
<212> TYPE, PRT
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 4
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
US 9,913,451 B2 
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Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
Ile Asn Leu Thr 
180 
165 170 175 
Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile 
185 190 
Val 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala 
305 310 315 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys 
340 345 350 
Ala 
320 
Asn 
Val 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
74 
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515 
<210> SEQ ID NO 5
<211> LENGTH, 1733
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE,
<221> NAME/KEY, CDS
<222> LOCATION, (1) ... (1551)
<400> SEQUENCE, 5
atg gtt ttt CCC ata gaa gee att gta gga eta gta ace ttc aca ttt 48 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa CCC 96 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat gac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac ggc CCC gtt ttc act ttt egg eta ggc ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga 384 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg cga aaa aat cga aaa tta gtt att cag gaa gtt etc tee 432 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
gcg age att aag aat tta tat act cga att gat gga aat tcg agt acg 528 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 672 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 768 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa 816 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
us 9,913,451 B2 
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260 265 270 
aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg 864 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt 912 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aag gca acg gtg ttt agt ttg gtc ttg gat gca gca 960 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac 1008 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt 1056 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac 1104 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa gaa gtg tta cga tta tat cca cca gga cct 1152 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat 1200 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa 1248 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga 1296 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate 1344 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
ccg ttt ggt tct gga aga cga tct tgt cca ggg atg act tat gca ttg 1392 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac 1440 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aga act cca aat gac gag CCC ttg gac atg aag gaa ggt gca ggc ata 1488 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg 1536 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa 1591 
Ala Pro Glu Leu Tyr 
515 
tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta 1651 
atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag 1711 
aagatgattg actgattgtc cc 1733 
<210> SEQ ID NO 6
<211> LENGTH, 517 
<212> TYPE, PRT
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE,
US 9,913,451 B2 
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Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys 
20 25 30 
Pro 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
Ile Asn Leu Thr 
180 
165 170 175 
Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile 
185 190 
Val 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala 
305 310 315 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys 
340 345 350 
Ala 
320 
Asn 
Val 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
Leu 
Leu 
385 
His 
355 360 365 
Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
390 395 400 
Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
80 
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Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 7
<211> LENGTH, 1727
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE,
<221> NAME/KEY, CDS
<222> LOCATION, (1) ... (1554)
<400> SEQUENCE, 7
atg gtt ttt ccg gta gaa gee att gta ggg eta gtg ace ttc aca ttt 48 
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc ttc tac ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa CCC 96 
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
tta cca ccg aaa ate ccg gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
tac ttc gat gac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac gga CCC gtt ttc act ttt egg eta ggc ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtg tta gtt gta age agt tac gaa get ata aaa gat tgt ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gaa tac ctt ggc tac aaa aat gee atg eta ttt ttg gca aat tac gga 384 
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
tct tac tgg cga aaa aat cgt aaa tta att att cag gaa gtt etc tct 432 
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttc gee aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
acg age att aag aat tta tac act cga att gat gga aat tcg agt acg 528 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
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aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 672 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 768 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aat tgg tta gag gaa cat att aag aaa aga gaa 816 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu 
260 265 270 
aaa ata atg gag gtt ggt aca gaa ggg aat gaa caa gat ttt ata gat 864 
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp 
275 280 285 
gtg gtg ctt tea aaa atg agt aat gaa tat ctt ggc gaa ggt tac tct 912 
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser 
290 295 300 
cgc gat act gtc ata aaa gca aca gta ttt agt ttg gtc ttg gat gca 960 
Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala 
305 310 315 320 
gca gac aca gtt get ctt cac ata aat tgc gga atg gca tta ttg ata 1008 
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile 
325 330 335 
aac aat caa aat gee ttg aag aaa gca caa gaa gag ata gac aca aaa 1056 
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys 
340 345 350 
gtt ggt aag gat aga tgg gta gaa gag agt gat att aag gat ttg gta 1104 
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val 
355 360 365 
tac etc caa get att gtt aaa gaa gtg tta cga tta tat cca ccg gga 1152 
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly 
370 375 380 
cct ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga 1200 
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly 
385 390 395 400 
tat cac att cct aaa gga act aga eta ttc gca aat gta atg aaa eta 1248 
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu 
405 410 415 
caa cgt gat cct aaa etc tgg tea aat cct gat aag ttc aat cca gag 1296 
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu 
420 425 430 
aga ttc ate get cgt gat att gac ttt cat ggt cag cac tat gag tat 1344 
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr 
435 440 445 
ate ccg ttt ggt tct gga aga cgc tct tgt ccg ggg atg act tat gca 1392 
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala 
450 455 460 
ttg caa gtg gaa cac eta aca atg gca cat ttg ate cag ggt ttc aat 1440 
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn 
465 470 475 480 
tac aga act cca act gat gag CCC ttg gat atg aaa gaa ggt gca ggc 1488 
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly 
485 490 495 
ata act ata cgt aag gta aat cct gtg aaa gtg ata att acg cct cgc 1536 
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg 
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500 505 510 
ttg gca cct gag ctt tat taaaatctaa gatgtttcat cttggttgat 
Leu Ala Pro Glu Leu Tyr 
515 
cattgtttaa tactcctaga tgggtattca tctacctttt ttcaattagt tgtcggtacg 
tattttttta atttggtaag tttgtaataa taagtaaaga aggattgtgc taatatataa 
tggtgcataa aataattgaa atg 
<210> SEQ ID NO 8
<211> LENGTH, 518 
<212> TYPE, PRT
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 8
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys 
20 25 30 
Pro
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu 
260 265 270 
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp 
275 280 285 
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser 
290 295 300 
Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala 
305 310 315 320 
86 
1584 
1644 
1704 
1727 
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Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile 
325 330 335 
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys 
340 345 350 
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val 
355 360 365 
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly 
370 375 380 
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly 
385 390 395 400 
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu 
405 410 415 
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu 
420 425 430 
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr 
435 440 445 
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala 
450 455 460 
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn 
465 470 475 480 
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly 
485 490 495 
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg 
500 505 510 
Leu Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 9
<211> LENGTH, 539
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE,
<221> NAME/KEY, CDS
<222> LOCATION, (1) ... (539)
<400> SEQUENCE, 9
atg gtt ttt CCC ata gaa gee ttt gta gga eta gta ace ttc aca ttt 48 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa CCC 96 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttt 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat aac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gat aaa tac ggc CCC gtt ttc act ttt egg eta ggt ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
tct aca aat gat gee att ttc tee aat cgt cca get ttt ctt tat ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
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gaa tac ctt ggc tac agt aat gee atg eta ttt tga caa aat acg gac 384 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Gln Asn Thr Asp 
115 120 125 
ctt act ggc gaa aaa ata gaa aat tag tea ttc agg aag ttc tct gtg 432 
Leu Thr Gly Glu Lys Ile Glu Asn Ser Phe Arg Lys Phe Ser Val 
130 135 140 
eta gtc gtc tcg aaa aat tga age acg tga gat ttg gtg aaa ttc aga 480 
Leu Val Val Ser Lys Asn Ser Thr Asp Leu Val Lys Phe Arg 
145 150 155 
cga gca tta aga att tat aca etc gaa ttg atg gaa att cga gta cga 528 
Arg Ala Leu Arg Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg 
160 165 170 
taa ate taa ca 539 
Ile 
<210> SEQ ID NO 10 
<211> LENGTH, 173 
<212> TYPE, PRT
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 10 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1 5 10 15 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Gln Asn Thr Asp Leu 
115 120 125 
Thr Gly Glu Lys Ile Glu Asn Ser Phe Arg Lys Phe Ser Val Leu Val 
130 135 140 
Val Ser Lys Asn Ser Thr Asp Leu Val Lys Phe Arg Arg Ala Leu Arg 
145 150 155 160 
Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg Ile 
165 170 
<210> SEQ ID NO 11 
<211> LENGTH, 666 
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE,
<221> NAME/KEY, CDS
<222> LOCATION, (1) ... ( 666) 
<400> SEQUENCE, 11 
atg gtt ttt CCC ata gaa gee att gta gga gca gta ace eta att aca 48 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr 
1 5 10 15 
ttt etc tta tac ttc eta tgt aca aaa aaa tct caa aaa cat tea aag 96 
Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys 
20 25 30 
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CCC tta cca acg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt 144 
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu 
35 40 45 
ttc cac ttc aat aac gac ggc gac gac cgt cca ttt get cga aaa etc 192 
Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu 
50 55 60 
gga gac tta get gat aaa tac ggc CCC gtt ttc act ttt egg eta ggt 240 
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly 
65 70 75 80 
ctt CCC ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc 288 
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys 
85 90 95 
ttc tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac 336 
Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr 
100 105 110 
ggc gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac 384 
Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr 
115 120 125 
gga cct tac tgg cga aaa aat cgt aaa tta gtc att cag gaa gtt etc 432 
Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu 
130 135 140 
tct get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att 480 
Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile 
145 150 155 160 
caa acg age att aag aat tta tac act cga att aat gga aat tcg agt 528 
Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser 
165 170 175 
acg ata aat eta agt gat tgg tta gaa gaa ttg aat ttt ggt ctg ate 576 
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile 
180 185 190 
gtg aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa 624 
Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu 
195 200 205 
caa gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt 666 
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val 
210 215 220 
<210> SEQ ID NO 12 
<211> LENGTH, 222 
<212> TYPE, PRT
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 12 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr
1 5 10 15 
Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys
20 25 30 
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu 
35 40 45 
Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu 
50 55 60 
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly 
65 70 75 80 
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys 
85 90 95 
Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr 
100 105 110 
Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr 
115 120 125 
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Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu 
130 135 140 
Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile 
145 150 155 160 
Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn 
165 170 
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly 
180 185 190 
Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly 
195 200 205 
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val 
210 215 220 
<210> SEQ ID NO 13 
<211> LENGTH, 99 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
Ser Ser 
175 
Leu Ile 
Asp Glu 
<223> OTHER INFORMATION, Partial coding sequence selected from SEQ ID 
N0,1
<400> SEQUENCE, 13 
gacgaggcct tggatatgaa ggaaggtgca ggcataacca tacgtaaggt aaatccagtg 60 
gaattgataa taacgcctcg cttggcacct gagctttac 99 
<210> SEQ ID NO 14 
<211> LENGTH, 99 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Partial coding sequence selected from SEQ ID 
N0,3 
<400> SEQUENCE, 14 
gacgagccct tggatatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg 60 
gaactgataa tagcgcctcg cctggcacct gagctttat 99 
<210> SEQ ID NO 15 
<211> LENGTH, 99 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Partial coding sequence selected from SEQ ID 
N0,5 
<400> SEQUENCE, 15 
gacgagccct tggacatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg 60 
gaactgataa tagcgcctcg cctggcacct gagctttat 99 
<210> SEQ ID NO 16 
<211> LENGTH, 99 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Partial coding sequence selected from SEQ ID 
N0,7
<400> SEQUENCE, 16 
gatgagccct tggatatgaa agaaggtgca ggcataacta tacgtaaggt aaatcctgtg 60 
aaagtgataa ttacgcctcg cttggcacct gagctttat 99 
94 
<210> SEQ ID NO 17 
<211> LENGTH, 19 
<212> TYPE, DNA
95 
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer
<400> SEQUENCE, 17 
cgctctagaa ctagtgatc
<210> SEQ ID NO 18 
<211> LENGTH, 20 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer
<400> SEQUENCE, 18 
tttttgggac aatcagtcaa
<210> SEQ ID NO 19 
<211> LENGTH, 23 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer
<400> SEQUENCE, 19 
gttagattta tcgtactcga att
<210> SEQ ID NO 20
<211> LENGTH, 26 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer
<400> SEQUENCE, 20
ttcatttcaa attattttat gcacca
<210> SEQ ID NO 21
<211> LENGTH, 21 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer
<400> SEQUENCE, 21
atggtttttc ccatagaagc c
<210> SEQ ID NO 22 
<211> LENGTH, 17 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer
<400> SEQUENCE, 22 
tcgaggtcga cggtatc
<210> SEQ ID NO 23 
<211> LENGTH, 1118
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 23 
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19 
20 
23 
26 
21 
17 
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ctgtcattaa agcaacggtg tttgtaagtt catctgtcat ttttcattta ttcactttta 
ttttgaggag cagacatgtt aataataatt tggagcaact gtaaagttat ctatgtgtac 
aggttcgagc ctcaggtgca accactaatg cttgtattag attatgttgt ctgcatcata 
cccctaattg gagtgtggct cttcccgaac cctgcaatgc tggatgctgg atgctttatg 
tatcagactg acctttttgt taaactatct aaatactaag gatgatttaa taaaaatata 
gaatggtaaa cagaaaaaga tgagattatt tttggggcta tatggattcg cccgggcttt 
gggaggtaaa acggtatcta ccagttgaga ctttactcca gaactttatc tcgagagctc 
tgaataaaaa tgaaatagta tttaccactc caaaatcttt gatggtaaaa agatgagata 
taacctctta taattgattg aaccacgttg atagaataaa acttctttac tcccattcag 
cataagaaaa atgaaaccaa acggaattct tctctttttt agggggaaat tccttaattg 
cttgttgaat atagattcat gtcgttattc tatttttaat aatgatgaaa atcaatatag 
tcaaagttaa tacttatgtc atttggtttg cggacaagtt atattggaac tatataatac 
gtctattata gaatagtgat tatttagagg atatacattt tttttggata aatatttgat 
ttattggatt aaaaatagaa tatacaggta aggtctaaaa cgtgtgtttg cttttacact 
aaataaactt gacctcgtac aattctaaga aaatatttga aataaatgaa ttattttatt 
gttaatcaat taaaaaaatc atagtataga tgagatgtgt gcatacttgg caataactat 
actaactaaa acaaggtatg tgaataattg atattccttt tttaattatt cttttttcca 
gagtttggtc ttggatgcag cagacacagt tgctcttcac ataaattggg gaatggcatt 
attgataaac aatcaaaagg ccttgacgaa agcacaag 
<210> SEQ ID NO 24 
<211> LENGTH, 998 
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 24 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1118 
gtaagttcat ctgtcatttt tcatttattc acttttattt tgaggagcag acatgttaat 60 
aataatttgg agcaactgta aagttatcta tgtgtacagg ttcgagcctc aggtgcaacc 120 
actaatgctt gtattagatt atgttgtctg catcataccc ctaattggag tgtggctctt 180 
cccgaaccct gcaatgctgg atgctggatg ctttatgtat cagactgacc tttttgttaa 240 
actatctaaa tactaaggat gatttaataa aaatatagaa tggtaaacag aaaaagatga 300 
gattattttt ggggctatat ggattcgccc gggctttggg aggtaaaacg gtatctacca 360 
gttgagactt tactccagaa ctttatctcg agagctctga ataaaaatga aatagtattt 420 
accactccaa aatctttgat ggtaaaaaga tgagatataa cctcttataa ttgattgaac 480 
cacgttgata gaataaaact tctttactcc cattcagcat aagaaaaatg aaaccaaacg 540 
gaattcttct cttttttagg gggaaattcc ttaattgctt gttgaatata gattcatgtc 600 
gttattctat ttttaataat gatgaaaatc aatatagtca aagttaatac ttatgtcatt 660 
tggtttgcgg acaagttata ttggaactat ataatacgtc tattatagaa tagtgattat 720 
ttagaggata tacatttttt ttggataaat atttgattta ttggattaaa aatagaatat 780 
acaggtaagg tctaaaacgt gtgtttgctt ttacactaaa taaacttgac ctcgtacaat 840 
tctaagaaaa tatttgaaat aaatgaatta ttttattgtt aatcaattaa aaaaatcata 900 
gtatagatga gatgtgtgca tacttggcaa taactatact aactaaaaca aggtatgtga 960 
98 
99 
ataattgata ttcctttttt aattattctt ttttccag 
<210> SEQ ID NO 25 
<211> LENGTH, 20 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, PCR Primer
<400> SEQUENCE, 25 
ctgtcattaa agcaacggtg
<210> SEQ ID NO 26 
<211> LENGTH, 20 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, PCR Primer
<400> SEQUENCE, 26 
ggccttgacg aaagcacaag
<210> SEQ ID NO 27 
<211> LENGTH, 27 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
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<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 27 
aagctttgac gccatttttt ccaatcg
<210> SEQ ID NO 28 
<211> LENGTH, 27 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 28 
ctcgagtttt ccagcgatca tcttcac
<210> SEQ ID NO 29 
<211> LENGTH, 23 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 29 
acgtgatcct aaactctggt ctg
<210> SEQ ID NO 30 
<211> LENGTH, 19 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 30 
gcctgcacct tccttcatg
<210> SEQ ID NO 31 
<211> LENGTH, 20 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
100 
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-continued
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 31
cggtaatcgg ccatcttttc
<210> SEQ ID NO 32 
<211> LENGTH, 21 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 32 
ccgagttttc gagctaatgg a
<210> SEQ ID NO 33 
<211> LENGTH, 19 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 33 
caatgacgaa cggcgacag
<210> SEQ ID NO 34 
<211> LENGTH, 21 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 34 
atggtttttc ccatagaagc c
<210> SEQ ID NO 35
<211> LENGTH, 21 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 35
tttttgggac aatcagtcaa t
<210> SEQ ID NO 36 
<211> LENGTH, 20 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 36 
tgaatgaact gcaggacgag
<210> SEQ ID NO 37
<211> LENGTH, 20 
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 37
aatatcacgg gtagccaacg
102 
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What is claimed is: 
1. A tobacco seed or a tobacco plant grown therefrom,
wherein said tobacco seed or tobacco plant comprises a 
stable mutation in a wild type allele encoding a nicotine 
demethylase comprising an amino acid sequence having at 
least 98% identity to SEQ ID NO: 4, wherein said mutation 
reduces or eliminates the expression or activity of said 
nicotine demethylase, wherein the amount of nornicotine or 
N'-nitrosonomicotine in said tobacco plant is reduced by 
greater than about 10% compared to a control tobacco plant 10 
comprising said wild type allele, wherein said tobacco plant 
is a Nicotiana tabacum plant. 
2. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said tobacco seed or tobacco 
plant grown therefrom is homozygous for said mutation. 
3. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said tobacco plant has a 
non-converter phenotype and reduced nicotine demethylase 
activity from said nicotine demethylase. 
15 
4. The tobacco seed or tobacco plant grown therefrom 20 
according to claim 1, wherein said tobacco plant has a 
non-converter phenotype and comprises less than 5% nico-
tine demethylation. 
5. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said tobacco seed or plant 25 
grown therefrom is selected from the group consisting of a 
Burley type, a dark type, a flue-cured type, and an Oriental 
type. 
6. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said mutation is selected from 30 
the group consisting of a point mutation, a deletion, and an 
insertion. 
7. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said wild type allele encodes 
SEQ ID NO: 4. 35 
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N'-nitrosonomicotine in said tobacco plant is reduced by 
greater than about 90% compared to a control tobacco plant 
comprising said wild type allele. 
_11. A method comprising preparing a tobacco productusmg a cured tobacco leaf from the tobacco plant of claim 
1. 
12. The method of claim 11, wherein said tobacco product
is_ selected from the group consisting of a cigarette, a cigar, 
pipe tobacco, snuff, chewing tobacco, gum, and a lozenge. 
13. A tobacco product comprising cured tobacco from the
tobacco plant of claim 1, wherein said tobacco product is 
s lected from the group consisting of a cigarette, a cigar, 
pipe tobacco, snuff, chewing tobacco, gum, and a lozenge. 
14. A method comprising:
a. detecting a mutation in a tobacco plant or plant part
thereof, wherein said mutation is at a locus encoding a
polypeptide having at least 96% sequence identity to 
SEQ ID NO: 4, and wherein said mutation is in a
sequence corresponding to the codon sequence encod-
ing the tr yptophan residue at position 329 of SEQ ID 
NO: 4; and
b. producing a tobacco product from said tobacco plant or
plant part thereof comprising said mutation detected in
step a. 
15. The method of claim 14, wherein said method further
comprises isolating a nucleic acid molecule from said 
tobacco plant, said plant part thereof, or said tobacco prod-
uct; and 
detecting said mutation in said nucleic acid molecule. 
16. The method of claim 14, wherein said tobacco plant
is a Nicotiana tabacum plant. 
. 17. The method of claim 14, wherein said tobacco plant1s selected from the group consisting of a Burley type, a dark 
type, a flue-cured type, and an Oriental type. 
18. The method of claim 14, wherein said plant part is 
selected from the group consisting of a cell, a protoplast, a 
cell tissue culture from which a whole plant can be regen-
erated, a callus, an embr yo, pollen, an anther, an ovule, a 
seed, a leaf, a flower, a stem, a branch, a fruit, a root, and a 
8. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein the amount of nornicotine or 
N'-nitrosonomicotine in said tobacco plant is reduced by 
greater than about 20% compared to a control tobacco plant 
comprising said wild type allele. 40 root tip. 
9. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein the amount of nornicotine or 
N'-nitrosonomicotine in said tobacco plant is reduced by 
greater than about 60% compared to a control tobacco plant 
comprising said wild type allele. 
10. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein the amount of nornicotine or 
19. The method of claim 14, wherein said tobacco product
is selected from the group consisting of a cigarette, a cigar, 
pipe tobacco, snuff, chewing tobacco, gum, and a lozenge. 
20. The method of claim 14, wherein said mutation
45 reduces or eliminates the expression or activity of said 
polypeptide. 
* * * * *
